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Adequate and efficient treatment of tumors in patients requires a detailed 
understanding of tumor biology and pathogenesis Treatment outcome depends highly on 
tumor properties some tumors tend to develop a more malignant phenotype leading to 
more invasive growth pattern (both local and distant), while others do not Tumors also 
differ in their response to radiation therapy or chemotherapy, reinforcing the need for 
parameters that can predict tumor response or identify more aggressive tumors 
Knowledge of tumor characteristics and behaviour would help to tailor treatment and 
select patients who will benefit from aggressive therapy It can also provide new insights 
into how to direct new strategies to more specifically target tumor cells 
During the last decades it has become progressively clearer that the tumor 
microenvironment plays an important role in the pathogenesis and progression of human 
cancer and in the response of a tumor to anti-cancer treatment Hypoxia is one of the 
major components of the tumor microenvironment and is the subject of this thesis Studies 
in patients with different types of tumors showed that hypoxia is a prognostic factor for 
bad outcome in patients treated with either radiotherapy, chemotherapy or surgery (1,2,3) 
There are different explanations for this detrimental effect of hypoxia on patient outcome 
Firstly, it is well documented that low oxygen tension confers resistance of tumors to 
ionizing radiation and chemotherapy (1,4,5,6) Secondly, hypoxia can push cells into a 
more aggressive phenotype through transcriptional activation of genes that alter cellular 
metabolism and promote neoangiogenesis and invasion Since tumor cells in hypoxic 
areas are under a strong selection, only the most well adapted (and thus phenotypically 
more aggressive) cells will survive (7) 
At the start of this research, all the studies showing a correlation between hypoxia 
and outcome made use of the Polarographie Eppendorf electrodes After insertion of a 
needle into the tumor oxygen tensions can be registered in various positions usually by 
stepwise movement along a track This method is an invasive procedure and has several 
disadvantages, among them the difficult application in deep-seated lesions and possible 
disturbances of blood flow and tissue architecture In addition this method is not able to 
differentiate between chronic or acute hypoxia 
The aim of the first part of our study was to develop easily applicable and 
reproducible methods to measure tumor hypoxia and perfusion in routine clinical practice 
The ultimate goal is to use these methods to select patients who can benefit from hypoxia 
modulating therapies In addition, they can provide valuable information on the role of 
hypoxia in determining patient outcome 
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Chapter 1 
1. Acute versus chronic hypoxia 
We can broadly distinguish two different types of hypoxia: "chronic" or 'diffusion 
limited" hypoxia and acute or transient hypoxia, which results from local fluctuations in 
blood perfusion and oxygen supply. Chronic hypoxia is often caused by diffusion 
limitations, since tumor cells grow faster than the formation of new blood vessels and 
cells are gradually pushed away from the vessels. Oxygen levels decrease as a function of 
distance from the nearest blood vessel. Cells that are more than 200 microns away usually 
die and form necrosis. Prolonged or chronically hypoxic cells are probably less viable but 
better adapted to low oxygen levels than acute hypoxic cells. Acute hypoxia occurs when 
perfusion is suddenly limited, e.g. by shut down of blood vessels, or by slowed or even 
reversed blood flow. High intratumoral pressure and weakly formed blood vessels are 
responsible for these sudden blood flow variations in tumor tissue. Such flow changes are 
readily seen in animal tumor models and also implicated in human tumors (8,9,10,11,12). 
This acute type of hypoxia is typically more abrupt and shorter in duration. Rapid 
reoxygenation after restoration of flow can have biological consequences, since 
reperfusion can lead to release of free radicals, with mutagenic consequences. Acute 
hypoxia may be at least as dangerous as chronic hypoxia, due to the shorter time hypoxic, 
resulting in less decrease in viability while retaining full resistance to radiation and 
probably partial resistance to drugs. 
Blood vessel closure can initially cause acute hypoxia, but when prolonged can result in 
chronic exposure to low oxygen levels. The difference between acute and chronic hypoxia 
could be clinically significant and methods to distinguish between both types of hypoxia 
are not currently routinely available for human use. Few data are available on the relative 
importance of acute versus chronic hypoxia on treatment outcome. Chronically hypoxic 
cells are energy deficient for a longer time, resulting in an adapted energy metabolism 
and, depending on the severity of hypoxia, reduced DNA repair (13,14). This could 
reduce their impact in determining the outcome of therapy. Acutely hypoxic cells, on the 
other hand, have not been adapted yet to a low-energy situation, and thus may well be 
capable of repair and resistant to therapy. In our study we attempted to simultaneously 
measure diffusion and perfusion limited hypoxia. 
2. Measurements of hypoxia 
More recent methods to measure hypoxia include the use of bioreductive oxygen-
dependent drugs, endogenous hypoxia markers (genes or proteins upregulated under 
hypoxia), vascular parameters, and radiologic and spectroscopic evaluations. Techniques 
to measure tumor perfusion are dynamic NMR imaging, double labeling techniques with 
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Introduction 
hypoxia probes separated in time or use of perfusion markers such as labeled dextrans, 
albumins, and fluorescent dyes (studied in animals but not m patients for toxicity reasons) 
All of these methods are reviewed in chapter 2 in more detail Here, we briefly summarize 
the methods used in this thesis 
Bioreductive oxygen dependent markers 
Bioreductive markers are exogenous compounds that become reduced specifically under 
hypoxic conditions Examples are 2-nitroimidazole derivatives like pimomdazole, EF5 
and misomdazole that are currently used in patient studies (15,16,17) (One of the first 
pilot studies using pimomdazole in head and neck cancer patients is included in this 
thesis) After administration to the patients, the reduced product, formed under hypoxic 
conditions, binds covalently to cellular macromolecules and can subsequently be 
visualized immunohistochemically by using an antibody against the reduced product 
Bioreductive markers can also be radiolabeled and subsequently detected by nuclear 
scanning techniques Information obtained from SPECT (single photon emission 
computed tomography) and PET (positron emission tomography) images can provide a 
sensitive, non-invasive assay to measure hypoxia The advantage of this approach is that 
no is that no biopsy material is necessary and that measurements can easily be repeated 
during treatment 
Endogenous hypoxia markers 
Recently, proteins involved in the hypoxic response of tumor cells have received attention 
as endogenous markers of tumor hypoxia Cells undergo significant changes in their 
mRNA and protein profile upon induction of hypoxia (18,19,20) Proteins or mRNA that 
are upregulated or expressed in hypoxic conditions can be used as endogenous markers of 
hypoxia This is attractive, since no drug needs to be administered and analysis can be 
done on retrospective series One candidate is hypoxia-inducible factor-la (HIF-la), a 
transcription factor subumt which is stabilized in the nucleus under hypoxic conditions 
and regulates the activation of many hypoxia-responsive genes by forming the dimer HIF-
1 and binding to hypoxia-responsive elements (HREs) in their promoter regions Under 
normoxic conditions, HIF-1 α is rapidly degraded by the proteosome after being targeted 
for ubiquitmation, a process that is dependent on pVHL (21) Under hypoxic conditions, 
degradation of HIF-la is suppressed, resulting in the transcription of hypoxically 
responsive genes, such as vascular endothelial growth factor (VEGF), erythropoietin 
(EPO), glucose transporters (GLUTs) and carbonic anhydrase 9 (CA9) (22,23,24,25,26) 
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Chapter I 
Measurements of perfusion 
Several markers are available for measuring perfusion in animal tumors, including labeled 
dextrans, albumins, and fluorescent dyes such as Hoechst 33342 and DiOC7 (8) 
Typically, the marker is injected intravenously and a tumor sample is taken within 
minutes, or visualized directly in the undisturbed tumor using the "sandwich tumor" 
technique (10) Hoechst dyes diffuse quickly out of vessels and bind to DNA of cells 
surrounding a vessel, thereby delineating areas of perfusion Unfortunately, most of these 
markers are not suitable for human use for toxicity reasons and so other markers have and 
are being sought which are suitable for clinical application 
3. Hypoxic radioresistance 
In the second part of this thesis (chapter 6) we studied the role of DNA repair genes in 
determining hypoxic radiosensitivity with the ultimate goal to find possible targets that 
can overcome hypoxic radioresistance that often leads to treatment failure 
Oxygen enhancenment ratio (OER) 
Hypoxic cells are about three times more resistant to ionizing radiation than well 
oxygenated cells This is expressed as the Oxygen Enhancement Ratio (OER), which is 
the ratio of the doses required to obtain the same amount of cell kill under hypoxic 
compared to oxic circumstances Radiochemical mechanisms have been known for many 
years to play an important role in determining resistance Oxygen can modify the 
induction of DNA damage since it is capable of reacting with electrons ejected from 
macromolecules by the irradiating photons (ionizations) It prevents return and 
recombination on the ionized macromolecule, thereby fixing the damage radiochemically 
Hydrogen donation by thiols, particularly glutathione, can repair lesions, but thiols 
compete inefficiently with the counteracting effects of oxygen (27,28,29,30) Oxygen thus 
acts as a radiosensitizer by "fixing" the DNA damage, while in the absence of oxygen, 
damaged ionized macromolecules become more easily restituted resulting in less DNA 
damage 
DNA damage after irradiation under hypoxic circumstances 
In this perspective, it has been shown that for a given dose of irradiation more base 
damages, DNA single-strand breaks and double-strand breaks are formed in the presence 
of oxygen, resulting in a greater radiosensitivity In addition to these lesions, ionizing 
radiation also induces DNA-protein cross-links (31) and DNA-interstrand crosslinks 
(32,33) DNA-protein crosslinks have been shown to be formed at a higher rate under 
hypoxia than under normoxic irradiation conditions, showing thus an inverse oxygen 
14 
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effect (31) This can be explained by the fact that oxygen, by reacting with radical 
intermediates and by fixing DNA damage, prevents crosslink formation (34) as for 
example has been shown for cyclopunne lesions, involving a covalent bond between 
DNA base and sugar. DNA interstrand cross-links (between nucleotides rather than within 
a nucleotide) are likely to be formed by the same mechanism, although this has not yet 
been shown. 
DNA repair pathways after irradiation under hypoxia 
The fact that different types of DNA damage are formed in the presence or absence of 
oxygen implies that different repair pathways might be involved in determining radiation 
sensitivity in oxic versus hypoxic conditions Not only radiochemical, but also 
biochemical mechanisms (for example the repair of DNA crosslinks) could play a role in 
radioresistance of hypoxic cells To study the role of DNA repair pathways in repairing a 
specific type of DNA damage, cell lines deficient in a DNA repair protein can be used. If 
the mutant cell line is more sensitive than its wild-type counterpart to induced damage, the 
mutated or deficient repair protein is probably involved in repairing the damage Murray 
and colleagues (35,36) studied different hamster mutant cell lines, deficient in NER 
(nucleotide excision repair), for their role in irradiation under hypoxia He showed a 
correlation between hypoxic radioresistance and the sensitivity of the cells to DNA 
interstrand cross-linking agents. From all the cell lines he studied, only cells deficient in 
ERCC1 and XPF showed reduced OER's. The ERCC1 and XPF mutants are also the only 
NER deficient cell lines that are extremely sensitive to crosslinking agents This implies 
that the ability to repair cross-links is important for radioresistance under hypoxia, but less 
so for normoxic irradiation, because fewer cross-links are formed 
Not too much is known about repair pathways involved in the removal of DNA-protein 
crosslinks Repair pathways involved in removal of interstrand crosslinks are somewhat 
better elucidated The repair of these lesions is a complex process involving several 
different pathways because both strands of the DNA are simultaneously affected and thus 
no undamaged strand is available as template. Sensitivity studies in rodent cells have 
shown that ERCC1 and XPF, proteins central to nucleotide excision repair (NER), play a 
role These proteins form a dimer that is capable of incising DNA, 5' of a lesion such as a 
bulky adduci or thymine dimer (37,38). In addition, homologous recombination (HR) 
appears to play a central role in cross-link repair, because cells lacking one of several 
genes central to HR also exhibit enhanced sensitivity to crosslinking agents (39,40,41,42) 
Given the link between cross-link repair and hypoxic resistance, we studied a potential 




This thesis deals with two different aspects of tumor hypoxia In the first part 
(chapter 3-6) we studied non-invasive methods to measure tumor hypoxia In the second 
part (chapter 7) we studied the role of DNA repair genes in determining hypoxic 
radiosensitivity 
Given the limitations of the Eppendorf electrode, we focused on methods to study 
hypoxia and perfusion at a microregional level in relation to vasculature and areas of 
necrosis, with the aim of developing markers which could distinguish acute and 
chronically hypoxic cells By correlating parameters with outcome we could then 
determine the relative importance of acute versus chronic hypoxia The study concentrated 
primarily on immunohistochemical methods, using both endogenous and exogenous 
markers As exogenous marker, we used pimomdazole, a bioreductive drug, one of the 
only such hypoxia markers available at the outset of the study In addition, we tested 
whether the cell proliferation marker lododeoxyundine (IdUrd) could also indicate 
vascular perfusion As study group, we used patients with a head and neck tumor treated 
primarily by surgery, with or without subsequent radiotherapy Hypoxia has been shown 
in previous studies to play an important role in determining outcome for both these 
treatment modalities Resection specimens provided us with considerable material for 
study Patients were injected the evening before operation with two study drugs 
pimomdazole and IdUrd 
The aim of the second part of the study was to further identify genes involved in 
radiation response specifically under hypoxic conditions We hypothesized that repair 
proteins responsible for repair of crosslink lesions formed under hypoxia, could be 
involved in determining this sensitivity From rodent data we already know that cells 
deficient in ERCC1 and XPF show reduced oxygen enhancement ratios Since 
homologous recombination appears to play a central role in crosslink repair, we 
investigated the role of homologous recombination in hypoxic radiosensitivity by using 
hamster and human cell lines deficient in homologous recombination To show relevance 
of the results to humans, we also studied human fibroblast including crosslink-sensitive 
mutant lines from Fanconi Anemia patients The ultimate goal of studying repair proteins 
involved in hypoxic irradiation damage is to find possible targets that can overcome 
hypoxic radioresitance that often leads to treatment failure 
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Outline of study 
OUTLINE OF STUDY 
The second chapter gives a detailed overview of the prevalence and importance of 
hypoxia in head and neck tumors 
In the third chapter we describe our initial experiments with immunohistochemical 
methods to measure hypoxia and perfusion Pimonidazole is a bioreductive drug that 
becomes reduced under hypoxic conditions only By using an antibody against the 
reduced product, it is possible to visualize tumor areas where this drug becomes reduced 
Image analysis software was developed to quantify these hypoxic areas Secondly we 
developed a vascular parameter called the diffusion limited fraction, that measures the 
fraction of tumor area at a distance of 150 micron or more from the nearest blood vessel 
IdUrd, an extrinsic proliferation marker was used to measure the fraction perfused blood 
vessels Lack of labeling around individual vessels is hypothesized to be due to lack of 
perfusion in that vessel Finally we addressed the question whether H1F-1 alpha, an 
endogenous marker known to be up regulated under hypoxia, could be used as an hypoxia 
marker in human tumors 
While using pimonidazole as an exogenous bioreductive marker for hypoxia, we 
observed pimonidazole staining in strongly keratinizing areas This prompted us to next 
investigate whether this staining was hypoxia-specific (chapter 4) To do this, we also 
studied the possible role of reductases in creating artificially high pimonidazole staining in 
these keratinized areas and incubated frozen tumor sections with pimonidazole under oxic 
and hypoxic conditions 
In chapter 5, we further validated the use of IdUrd to estimate microperfusion 
variations by using a human tumor xenograft model where Hoechst 33342 and IdUrd were 
administered simultaneously This allowed a direct comparison between a standard 
perfusion marker and our proposed new parameter, leading to its potential use as an 
estimate of acute hypoxia 
A disadvantage of the immunohistochemical approach is the relatively small 
fraction of tumor area assessed, especially when pre-treatment material comes from tumor 
biopsies We therefore also tested an external scanning approach using a technetium-
labeled 2-nitroimadazole (similar to pimonidazole) employing SPECT scanning (chapter 
6) External scanning techniques allow evaluation of the entire tumor We made a direct 
comparison with pimonidazole staining in the same patients 
In chapter 7, we studied the causes of hypoxic radioresistance We could show that 
some aspects of DNA repair, rather than radiochemical mechanisms alone, can influence 
the oxygen enhancement ratio, with potential implications for targeting hypoxic cells 
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Abstract: Background Hypoxia develops in tumors be­
cause o( a less ordered, ollen chaotic and leaky vascular sup­
ply compared with that in normal tissues In preclinical models 
hypoxia has been shown lo be associated with treatment resis­
tance and increased malignant potential In the clinic, several 
reporls show Ihe presence and extent ol tumor hypoxia as a 
negative prognostic indicator This article reviews the biology 
and importance ol hypoxia in head and neck cancer 
Methods A review of literature was carried out and 
combined with our own experience on hypoxia measurements 
using exogenous and endogenous markers 
Results Hypoxia can increase resislance to radiation and 
cytotoxic drugs and lead to malignant progression alleclmg all 
treatment modalities including surgery Hypoxia measurements 
using electrodes, exogenous bioreductive markers, or endoge­
nous markers show the presence ol hypoxia in most head and 
neck cancers and correlations with outcome although limited, 
consistently indicate hypoxia as an important negative factor 
Each hypoxia measurement method has disadvantages and no 
'gold standard" yet exists Dislmclions among chronic acute 
and intermediate hypoxia need to be made because their 
biology and relevance to treatment resislance differ Reliable 
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methods for measuring these different lorms in the clinic are still 
lacking Several methods to overcome hypoxia have been tested 
clinically with radiosensilizers (mmorazole) hypoxic cytoloxms 
(tirapazamme) and carbogen showing some success New 
treatments such as hypoxia-mediated gene therapy await 
proper clinical testing 
Conclusions The hypoxia problem in head and neck cancer 
needs to be addressed if improvements m current ireatments 
are to be made Increased knowledge of the molecular biology 
of intermediate severe and intermittent hypoxia is needed to 
assess their relevance and indicate strategies for overcoming 
their negative influence © 2005 Wiley Periodicals, Ine Head 
Neck 27:622-638, 2005 
Keywords: hypoxia, radiotherapy, radiation sensitivity, biore­
ductive drugs 
Hypoxia, or lack of oxygen, is rare in normal 
tissues but is a common, if not characteristic, 
feature of tumors. It anses principally from a less 
ordered vasculature in malignant tumors, often 
described as chaotic. Even a small proportion of 
hypoxic tumor cells can have important conse­
quences. The existence of hypoxia in head and 
neck cancer has long been suspected from his­
tologic observations of necrosis and disordered 
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vasculature, later confirmed by direct electrode 
and bioreductive drug measurements and from 
results of treatments designed to overcome hyp-
oxia (see following for details). This review dis-
cusses hypoxia in head and neck cancer, why it 
matters, the types of hypoxia, how extensive it is, 
how it is measured, and what can be done to 
overcome or exploit it. 
WHY HYPOXIA MATTERS 
Hypoxia is frequently found in tumors at the 
time of diagnosis. Tumors with low oxygena-
tion have a poor prognosis, and there is strong 
evidence to suggest that this is because of the 
effects of hypoxia on therapy resistance and ma-
lignant progression. 
Radioresistance. As surrounding oxygen levels 
fall below 5 mmHg, cells become progressively 
more resistant to radiotherapy. The difference in 
radiation sensitivity between aerobic and se-
verely hypoxic cells (oxygen enhancement ratio) 
is typically in the range of 2.5 to 3 for both rodent 
and human tumors.1 In the absence of oxygen, 
radiation-induced radicals in DNA may be re-
versed by donation of hydrogen mainly from non-
protein sulfhydryls, therefore leading to less net 
DNA damage for the same dose. This translates 
into less cell kill. Even a small fraction of hyp-
oxic, and thus radioresistant, cells can dominate 
the response of the tumor, because the radiosensi-
tive cells will be rapidly eliminated, leaving these 
radioresistant cells. 
Chemoraslstance. Hypoxia also contributes to 
resistance against chemotherapeutic agents Be-
cause hypoxic cells are often at a distance from 
blood vessels, drug concentrations are often insuf-
ficient for effective killing because of diffusion 
limitations and drug uptake by intervening well-
oxygenated cells. In addition, prolonged hypoxia 
can lead to cell cycle inhibition and decreases in 
the growth fraction. Because most current chemo-
therapeutic agents are more effective on prolifer-
ating cells, this can lead to therapy resistance.2 _ 4 
Malignant Progression. Hypoxia exerts a strong 
selection pressure such that tumor cells harbor-
ing mutations allowing survival and proliferation 
under hypoxic conditions are likely to predom-
inate (eg, see ref 5). Hypoxia thus promotes 
genomic instability, which may in turn increase 
the number of genetic variants in a tumor. These 
processes contribute to the malignant phenotype 
and to aggressive tumor behavior, including a 
greater propensity for metastasis, angiogenesis, 
and escape from apoptosis.(> ^ Hypoxia can also 
induce major changes in gene expression, thereby 
enhancing the metastatic ability of tumor cells. 
Growth factors, proteolytic enzymes, and adhe-
sion molecules (eg, vascular endothelial growth 
factor [VEGF], interleukin (IL]8, plasminogen 
activator inhibitor [PAI]-1, matrix metallopro-
teinase [MMP]9, urokinase-type plasminogin ac-
tivator receptor [uPAR]) have been known to be 
upregulated by hypoxia and could, therefore, be 
responsible for an increase in metastatic abil-
ity of cells after exposure to hypoxia. The role of 
hypoxia and malignant progression has been sup-
ported by several clinical studies For example, 
Fyles et al1 0 have shown that low oxygen levels 
in cervical tumors are associated with increased 
metastasis and poorer survival. In soft tissue sar-
comas, Brizel et a l n showed that low pretreat-
ment oxygenation is predictive for distant relapse. 
Hypoxia also adversely affected outcome in a 
series of patients with cervical cancer treated pri-
marily with surgery,12 suggesting that factors 
other than hypoxia-mediated radioresistance or 
chemoresistance are operational. 
TYPES OF HYPOXIA 
Hypoxia can be broadly categorized into two 
classes: chronic and acute.1'1 The distinction is 
primarily how long the cells are hypoxic but also 
reflects their different causes. Chronic hypoxia 
applies to cells at a distance from blood vessels 
where they occur because of proliferation pres-
sure forcing them away from perivascular areas 
(Figure 1A, left). It is caused primarily by an 
insufficient number of blood vessels, reflecting 
insufficient angiogenesis. The oxygen supply to 
these cells is limited by diffusion and by oxygen 
use by intervening cells. Chronic hypoxia is often 
called diffusion-limited hypoxia. Because oxygen 
concentration decreases progressively with dis-
tance from a blood vessel (Figure IB), categoriza-
tion into two types (oxic and hypoxic) is somewhat 
artificial. More realistic is a three-compartment 
model (Figure 1A, middle), also including in-
termediate hypoxic cells. From a radiobiology 
standpoint, oxic, fully hypoxic, and intermediate 
hypoxic cells would be maximally radiosensitive, 
maximally radioresistant, and have intermedi-
ate radiosensitivity, respectively. Cells may adapt 
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FIGURE 1. Schematic of hypoxia categories. (A) Geographic location of hypoxic cells relative to blood vessel. Cells can be categorized 
into two or three compartments with varying oxygen concentrations. Darkest blue represents full radlobiologic hypoxia. If blood vessel 
closes (right), all cells become hypoxic. (B) Oxygen concentration as a function of distance from blood vessel, decreasing through use/ 
metabolism of intervening cells, and diffusion limitations. (C) Schematic Illustrating changes In relative proportions of the three 
compartments with different oxygen levels as blood flow in the vessel changes. (D) Schematic showing that as the flow changes, the major 
changes In oxygen concentration occur In the Intermediately oxygenated cells. (Color figure can be viewed in the online issue, which is 
available at www.intersclence.wlley.com.] 
slowly and change their phcnotype as they 
become chronically hypoxic. The oxygon concen­
tration in vessels will determines the extent 
of chronic hypoxia, and thus low hemoglobin 
(Hb) levels can result in increased diffusion lim­
ited hypoxia. 
Acute hypoxia has another cause. Severe 
structural abnormalities of tumor vessels lead to 
leaky vessels and increased intratumoral pres­
sure, which can lead to sudden changes in blood 
flow and thus acute lack of oxygen and nutrients. 
This deprives all cells around the vessel of oxy­
gen (Figure 1A, right). This is often temporary, 
because flow can subsequently increase again. 
Low flow is a more common situation than the 
extreme situation of total cessation in flow de­
picted in Figure 1A (right). As flow changes from 
high to low, the proportions of oxic, intermedi­
ate, and hypoxic cells also change (Figure 1C). 
The result of intermittent flow changes is most 
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evident in cells at an intermediate distance 
from a vessel; those close to the vessel will re-
main oxic, those near necrosis will remain fully 
hypoxic, but the intermediate cells will vary most 
in their oxygen concentration (Figure ID). Such 
flow changes are readily seen in animal tumor 
models and also implicated in human tumors.1 4"1 B 
Rapid reoxygenation by restoration of flow, or in-
creased flow, can have biologic consequences. Re-
perfusion can lead to release of free radicals, with 
mutagenic consequences. Hypoxia may, therefore, 
function as a mutagen by elevating oxygen radical 
levels after repeated cycles of hypoxia and reox-
ygenation. This can lead to chromosomal breaks 
and/or chromosomal rear rangements through 
gene amplification or reoxygenation-induced DNA 
over-replication. In support of the mutagenic ef-
fects of hypoxia/reoxygenation, Reynolds et al19 
found increased levels of point mutations in cells 
cultured under hypoxia, whereas repeated epi-
sodes of hypoxia followed by reoxygenation gave 
rise to even higher levels of mutations. 
HYPOXIA IN HUMAN TUMORS 
Several methods to measure hypoxia have been 
developed; their findings are summarized briefly 
in the following. 
Oxygen Electrodes. The most direct measure-
ment of tumor oxygenation is with Polarograph-
ie electrodes, the most widely used being the 
Eppendorf electrodes. Fine-needle electrodes are 
inserted into the tumor, and measurements are 
made in various positions usually by stepwise 
movement along a track.20 Several tracks are 
made per tumor, resulting in multiple measure-
ments, allowing a histogram, or distribution of 
oxygenation, to be made per tumor. Measure-
ments are typically heterogeneous between pa-
tients and also within individual tumors. Such 
direct measurements of oxygen tension in human 
tumors show a range of median oxygen tensions 
from 1.3% to 3.9% (10-30 mmHg), whereas 
concentrations in normal tissues are significantly 
higher at 3.1% to 8.7% 0 2 (24-66 mmHg).21 
Endogenous Markers. An entire range of proteins 
is now known to be upregulated under hypoxia. 
Some estimate that up to 1.5% of all genes are 
hypoxia responsive.22 Many of these proteins can 
be detected with standard immunohistochemical 
methods and could, therefore, serve as potential 
hypoxia markers, avoiding the need for an in-
vasive method or drug administration. Several 
questions can be asked of such markers. Are they 
dependent only on hypoxia for their expression, or 
do other factors play a modulating role? Are they 
expressed (under hypoxia) in all tumor types? Do 
they have a similar oxygen dependence of ex-
pression as tha t for the parameter of interest; 
for example, for radiotherapy, one would want a 
marker matching the oxygen dependence of ra-
dioresistance. This may be different for chemo-
resistance, which in turn may be different for 
each drug. Is the marker protein expressed under 
acute and chronic hypoxia, in other words, what is 
the time scale for upregulation after hypoxia 
induction? Information on these questions re-
mains sketchy for several markers under current 
investigation The usual approach is first to 
correlate marker expression with another known 
hypoxia marker or method and/or to correlate 
expression with outcome after a particular ther-
apy. Despite lack of mechanistic detail, such data 
can provide useful information for the clinic. 
H/Fi The archetypal hypoxia-regulated protein 
is hypoxia inducible factor la ( H I F - l a ) . 2 3 2 5 This 
is one partner of a dimer, the other partner being 
HIF-lß (not hypoxia inducible). The dimer is a 
transcription factor that binds to a specific DNA 
sequence called hypoxia responsive element 
(HRE) in the promoter of target genes, thus acti-
vating transenption. Under normoxic conditions, 
HIF-la is hydroxylated by specific hydroxylases, 
a reaction dependent on oxygen. Hydroxylation 
renders HIF- la a substrate for the von Hippel-
Lindau protein tha t targets HIF-la for destruc-
tion by means of ubiquitination, thus keeping 
levels low. Lack of oxygen prevents hydroxyla-
tion and thus destruction, allowing levels to rise. 
In addition to HIF- la itself, hypoxia upregulated 
genes can, therefore, be split into two general 
classes, those tha t are HIF-la dependent (con-
taining promotor HREs) and those that are not 
(or not known to be). There are also two other 
related oxygen-regulated proteins, HIF-2a26 '27 
andHIF-Sa . 2 " 2 9 
H/F) Target Genes More than 50 genes are known 
to be transcriptionally regulated by HIF- la . 
Many are involved in adaptive responses to hyp-
oxia, including activation of genes such as those 
encoding for glycolytic enzymes, growth factors 
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and vasoactive peptides, angiogenesis factors, 
and genes involved in apoptosis and invasion. 
Some of the most well known are erythropoietin 
(EPO), CA9, the glucose transporters Gluti and 
Glut3, and VEGF, all having HREs in their pro-
motors. In head and neck cancer, CA9 has been 
reported to be expressed in most tumors ' ' 0 - 3 3 and 
to be spatially and quantitatively related to ne-
crosis and vessel density.30 31 
Non-HIF1 Target Genes Hypoxia also induces a 
number of genes apparently independently of 
HIF-1, usually demonstrated in HIF-la-deficient 
cells.34 Such genes include those involved in fibro-
genesis such as t ransforming growth factor 
[TGF]-(4 and collagens 1 and 3; cell cycle check-
point genes such as p27, GADD153, and p53'15·36; 
and others such as e-NOS, IL8, and metallothio-
nein.37 40 Almost none of these genes has been 
tested as endogenous hypoxia markers in human 
tumors, apart from metallothionein, where ex-
pression was found to colocalize poorly with 
pimonidazole staining in cervix tumors, probably 
resulting from additional regulation than hyp-
oxia alone. 
Exogenous Markers. 
Bioreductive Markers Most hypoxia marker drugs 
evolved from hypoxic cell radiosensitizer programs 
initiated up to 30 years ago. They are usually 2-
or 5-nitroiimdazoles that are reduced by nitro-
reductases to reactive products that rapidly bind 
various cellular constituents, including proteins 
and DNA.'n~4 , Their hypoxia dependence arises 
from the fact that the first one-electron reduc-
tion step is rapidly and efficiently reversed in the 
presence of oxygen. Two of these compounds 
have been approved for clinical use: pimonidazole 
(l-[(2-hydroxy-3-piperdinyl)propyl]-2-nitroim-
idazole) and EF5 (2-(2-nitro-l//-imidazol-l-yl)-
iV-(2,2,3,3,3-pentafluoropropyl)acetamide).44"47 
Reduced, bound products of both these com-
pounds can be detected by specific antibodies, al-
lowing detection by standard immunochemical, 
immunofluorescence, or flow cytometric methods. 
Hypoxia can be quantified in sections by esti-
mating the fractions of stained cells (visual semi-
quantitative scoring or image analysis) ' ^ " 4 8 · 4 9 
or on the basis of fluorescence intensity with ref-
erence to calibration of in vitro binding of hyp-
oxic tlssue.4e ' ' ,7 Many examples of pimonidazole 
and EF5 staining in both animal and human 
tumors have been published, usually showing 
staining at a distance from blood vessels and also 
perinecrotic, when necrosis is present. Because 
hypoxic cells are expected at precisely these lo-
cations, they are convincing markers of chronic 
hypoxia. In head and neck cancer, such staining 
is seen in most tumors when biopsies or surgi-
cal resection specimens are taken between 2 and 
48 hours after intravenous (TV) administration of 
pimonidazole or EFS.18"11'4''·50 Hypoxic fractions 
from such staining were estimated to range from 
close to zero to up to 30%, with mean values be-
tween 5% and 10%. Theoretical calculations and 
preclinical studies on rodent tumors show that 
this fraction of hypoxic cells is sufficient to sub-
stantially reduce radiocurabihty with single ra-
diation doses. Cure reductions would also be 
expected with fractionated schedules, depending 
on the degree of reoxygenation between fractions, 
which varies between tumors. 
Pimonidazole fractions did not correlate with 
Eppendorf probe measurements of hypoxia in 
cervical tumors,01 whereas the latter did correlate 
with outcome.' '2 ' '3 Why this is and whether 
pimonidazole has prognostic significance in this 
site remains to be clarified. 
Nuclear Medicine Assays A number of poten-
tial exogenous hypoxic cell markers, labeled with 
positron-emitting radionuclides, have been stud-
ied, including fluoromisonidazole (FMISO), '4 
fluoro-erythronitroimidazole (FETNIM),'r'r' fluoro-
etamdazole,56 and EFS,57 iodoazomycin galacto-
pyranoside (IAZGP), and Cu(II)-diacetyl-bis (N4-
methylthiosemicarbazone) (Cu-ATSM). Some of 
these agents are now being tested in the clin-
j c 55.58 62 p r o m (hg comparison with fluorode-
oxyglucose (FDG), it is clear that hypoxia is a 
general factor affecting glucose metabolism, but 
the correlation between overall maximum stan-
dardized uptake value for FDG and hypoxic vol-
ume is poor.61 
Single photon emission computed tomogra-
phy (SPECT) and positron emission tomography 
(PET) images of radiolabeled markers can provide 
sensitive, noninvasive assays. Such images are 
much affected by the pharmacokinetics of these 
compounds. IV administration of radiolabeled 
agents is followed by rapid distribution to all 
tissues in relation to their blood volume and flow 
rate and subsequent penetration into tissue by 
both diffusion and active transport mechanisms. 
This early distribution phase is followed by 
excretion of the tracer itself and its metabolites, 
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some of which retain the radioactive signal. In 
general, hydrophilic tracers are excreted pref-
erentially by the kidneys, whereas lipophilic trac-
ers are excreted by the hepatobiliary system.b1 
Quantification of the hypoxia-specific signal 
from SPECT and PET images will be optimal 
at those times when the background is minimal. 
For this reason, it is unlikely that 18F tracers 
will produce high-resolution maps because of 
their short half-life. lodinated markers have 
the advantage of a much longer half-life. Metal-
labeled compounds have much higher specific 
activities and distribute rapidly in the tissues, 
as a consequence, representative images can be 
acquired at short times after administration. Re-
cent data, however, suggest that these markers 
are not hypoxia specific (presentations at the 
Annual Radiation Research Society Meeting, St 
Louis, 2004). 
Nuclear markers labeled with """Tc have also 
been described. In a series of nine patients with 
squamous head and neck carcinoma, """Tc HL91 
visualized three of five local recurrences detected 
on CT Two of three sites of CT-positive nodes 
were also 99mTc HL91 positive.64 Koh et alfir· eval-
uated 1HF-misonidazole tumor uptake in five pa-
tients with head and neck cancer before the start 
of radiation. All tumors showed F-misonidazole 
retention. In three patients, repeat studies were 
performed. The scans showed no tumor accumu-
lation anymore, suggesting that reoxygenation 
had occurred. In a phase I trial studying radia-
tion combined with tirapazamine and cisplatin 
in head and neck cancer, 14 of the 15 tumors 
showed 18F-misonidazole uptake at baseline, 
with only one patient having detectable hypoxia 
at the end of treatment.** This patient subse-
quently had a locoregional failure. These studies 
demonstrate the advantages of using noninva-
sive PET imaging of hypoxia; namely, patients 
can be selected for hypoxia-modifying treatments 
depending on a pretreatment assessment of hyp-
oxia, and early response assessment with treat-
ment modification is possible on the basis of the 
results of the PET scan taken after 3 or 4 weeks 
of treatment. 
A common deficiency of much recent hypoxia 
marker research, both in animal models and on 
patients, is the absence of independent measure-
ments of hypoxia. This relates to the current lack 
of a "gold standard" to measure tumor oxygen-
ation. In general, no strong correlation has been 
found between microelectrode measurements and 
hypoxia marker uptake in animal tumors. ( , , l 
However, when tumor oxygenation is modulated 
within the same tumor model, significant corre-
lations between the different oxygen-measuring 
techniques have been observed.h7 We performed 
a study in patients with head and neck tumors 
in which we compared uptake of <,l)mTc BRU 
59-21, a radioactively labeled 2-nitro-imidazole, 
on SPECT scans with pimonidazole staining on 
sections from the surgical specimen. A significant 
correlation between 99mTc BRU 59-21 uptake and 
pimonidazole staining was found,1'8 indicating the 
feasibility of such external scanning methods for 
tumor hypoxia. 
lododeoxyundme Endogenous markers, such as 
CA9, and exogenous markers, such as pimonid-
azole and EF5 (see following), often show staining 
patterns consistent with chronic hypoxia (ie, at 
a distance from vessels and perinecrotic). How-
ever, rodent tumors often show acute and tem-
porary hypoxia, demonstrated by a variety of 
techniques usually involving double labeling with 
two vascular or hypoxia probes separated in 
time.14 Staining mismatches between the probes 
indicates that in the time interval between ad-
ministrations, some tumor cells have become hyp-
oxic, or vessels become nonfunctional, whereas 
others have reoxygenated. It is plausible that hu-
man tumors also exhibit intermittent hypoxia, 
supported by blood flow measurements in human 
tumors showing marked temporal variations.10 
Acute hypoxia may be at least as dangerous 
as chronic hypoxia, because of the shorter time 
hypoxic, resulting in less decrease in viability 
while retaining full resistance to radiation and 
probably partial resistance to drugs (depending 
on drug clearance rates and reduction of prolifer-
ation in acutely hypoxic cells). With exogenous 
hypoxia markers, staining is sometimes seen 
close to vessels, indicating a nonperfused vessel 
and, therefore, perfusion-limited hypoxia.69 En-
dogenous markers often are regulated by factors 
other than hypoxia, so expression near vessels 
may not have resulted from hypoxia, compli-
cating interpretation. Present exogenous markers 
suffer from the time required for their reduc-
tion and binding, rendering them potentially in-
sensitive for detecting short-term intermittent 
hypoxia. Double-labeling techniques as used in 
animal models cannot or have not been applied 
in humans. 
An indirect measure of local perfusion limi-
tation has been developed using the cell kinetic 
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marker iododeoxyuridine (IdUrd). 7 0 A lack of 
IdUrd-labeled tumor cells in the vicinity of a 
blood vessel, while being positive for the endog­
enous proliferation marker ki67, suggests that 
the vessel was nonperfused, preventing delivery 
of the IdUrd. With this technique, fractions of 
IdUrd-negative vessels in the head and neck 
between 0% and 30% were found. 1 8 It is not 
known whether these vessels subsequently be­
come perfused again. However, the data are 
consistent with a significant fraction of acutely 
hypoxic cells in head and neck tumors. Ideally, 
one would want an endogenous marker that 
was dependent solely on hypoxia, was rapidly in­
duced on hypoxia induction, and rapidly degraded 
on reoxygenation. The search for such a marker 
is still ongoing, and it may require a combination 
of markers. 
EVIDENCE THAT HYPOXIA IS IMPORTANT 
Evidence that hypoxia is important comes mostly 
from studies in which a Polarographie ρθ2 histo-
graph (Eppendorf electrode) was used to mea­
sure tumor hypoxia. In patients with head and 
neck cancer, the prognostic significance of low pre­
treatment ρθ2 was first reported by Nordsmark 
et al in 1996.^2 They studied locoregional con­
trol in patients with advanced head and neck 
cancer treated primarily by radiotherapy. Pa­
tients with a hypoxic fraction (defined as the 
fraction of p02 values <2.5 mmHg) <15% had 
significantly higher rates of locoregional control 
than those with a hypoxic fraction >15% (p = 
.013). A subsequent repeat trial confirmed their 
results 0 ' )(Figure 2, top panel). Bnzel et a l ' 1 
showed that in patients with head and neck can­
cer treated by primary radiotherapy or chemora-
diation, hypoxia (tumor median ρθ2 <10 mmHg) 
adversely affected not only 2-year locoregional 
control (p = .01) but also disease-free survival (p = 
.005) and survival (p = .02). These and other 
studies are uniformly consistent in demonstrating 
the adverse prognostic influence of p02 values 
below 2.5 to 10 mmHg on local tumor control, 
disease-free survival, and overall survival among 
patients with cancer of the head and neck, 
whether treated by radiation therapy, surgery 
and radiation, or chemotherapy and radiation 
(Table 1). 
One should keep in mind that hypoxia mea­
surements in these studies are mostly done in the 
metastatic lymph nodes because of a better ac­
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FIGURE 2. Influence ol tumor oxygenation on outcome after 
radiotherapy for head and neck cancer (A) Oxygen tension was 
measured in tumors in multiple positions with Eppendorf elec­
trodes 5 3 Reprinted with permission from Nordsmark M, Over-
gaard J, "Tumor hypoxia is independent of hemoglobin and 
prognostic for loco-regional tumor control after primary radio­
therapy in advanced head and neck cancer " Acta Oncol 
2004,43(4) 396-403 (B) Tumor hypoxia was measured by 
administering pimonidazole followed by immunohistochemical 
staining. In both cases, high hypoxia (low oxygen tension) was 
associated with a significantly worse outcome Reprinted with 
permission from Kaanders, el al, "Pimonidazole Binding and 
Tumor Vascularity Predict for Treatment Outcome in Head and 
Neck Cancer " Cancer Research 2002,62 7066-7074 [Color 
figure can be viewed in the online issue, which is available at 
www interscience wiley com ] 
compared measurements in the primary tumor 
with metastatic lymph nodes and found compa­
rable patterns of oxygenation in terms of the 
median p02 and the proportion of hypoxic mea­
surements. 7 7 This suggests that the oxygenation 
data obtained at one site are related to tumor 
oxygenation at other sites, so that measurements 
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Table 1. Summary ol trials in head and neck cancer sludying Ihe prognostic significance ol pretreatment hypoxia as measured by 
needle oxygen electrodes 
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2-year LRC 33% vs 77% in patients 01 
with % p 0 2 values <2 5 mmHg 
>15% and <15%, respectively 
Hypoxic Iraction prognostic 018 
indicator (or LRC in multivariate 
analysis 
DFS 78% vs 22% in patients with 009 
median pO? >10 mmHg and 
<10 mmHg 
Median ρθ2 >10 mmHg significantly 
related lo longer survival, longer 
DFS and longer duration ol local 
conlrol in mullivanate analysis 
Median p O j <10 mmHg adversely 01 (LRC) 
affected 2-year LRC (30% vs 73%) 005 (DFS) 
DFS (26% vs 73%), and OS 02 (OS) 
(35% vs 63%) 
Univariate analyses pO? <5 mmHg < 05 
PO2 <2 5 mmHg, and hypoxic < 01 
subvolume were of prognoslic 
significance 
Multivariate analysis only hypoxic 01 
subvolume sigmlicanl 
Actuarial 3-year survival sigmlicanlly 05 
higher in patients with %p02 
values <2 5 mmHg less than Ihe 
median (26 8%) versus > median 
Hypoxic fraction only significant 05 
predictor of OS in multivariate 
analysis 
2-year LRC 90% vs 45% for lumors 04 
wilh %pO s <2 5 mmHg < or > 
median (15%) 
% p 0 2 values <2 5 mmHg significant 004 
predictor of survival in multivariate 
analysis 
Mullivanate analysis hypoxic tumor 001 
volume (lotal tumor volume χ 
relative frequency of p02 readings 
<5 mmHg) was independent 
prognostic factor for survival 
Abbreviations LRC locoregional control DFS disease-tree survival OS. overall survival RT radiotherapy FU fluorouracil 
in any anatomic site would be sufficient to 
estimate a tumor's oxygenation status. 
Data on changes in oxygenation status during 
therapy and prognostic significance of reoxygena-
tion are more rare. Brizel et a l 7 2 performed repeat 
assessments of tumor oxygenation in their study 
after 10 to 15 Gy and found that the values were 
unchanged compared with pretreatment base­
lines. Dietz et a l 7 8 repeated hypoxia measure­
ments 1 week after induction chemoradiation and 
found that more reoxygenation was correlated 
with worse treatment outcome. 
The only data so far on the ability of exogenous 
markers of hypoxia to predict outcome is that of 
Kaanders et al . 3 1 They showed that the fraction of 
pimonidazole-stained cells in pretreatment biopsy 
specimens correlated with local control in pa­
tients with head and neck treated primarily by 
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FIGURE 3. Pimomdazole staining correlates with outcome, most 
significantly in the group where no attempt was made to 
overcome hypoxia during treatment (the non-ARCON group) 
Reprinted with permission from Kaanders, el al, "Pimomdazole 
Binding and Tumor Vascularity Predict for Treatment Outcome in 
Head and Neck Cancer " Cancer Research 2002,62 7066-7074 
[Color figure can be viewed in the online issue, which is available 
at www interscience wiley com ] 
radiotherapy (Figure 2, lower panel). They fur­
ther showed that this applied only for those pa­
tients who did not receive additional therapy 
aimed at tackling the hypoxia problem, whereas in 
those patients treated with accelerated radiother­
apy with carbogen and nicotinamide (ARCON), 
designed to overcome both hypoxia and rapid 
proliferation, pimonidazole was not predictive 
(Figure 3). This indicates the value of pimo­
mdazole, the negative role of hypoxia, and the 
effectiveness of ARCON The study is at present 
small, so updates are awaited with interest. 
HIF-la expression has been shown to corre­
late with outcome in several studies. In head and 
neck cancer, two studies have been reported, one 
showing that high HIF- la and HIF-2a were both 
significantly associated with incomplete response 
to chemoradiation, a poor local relapse-free sur­
vival, and poor overall survival, whereas in a 
multivariate analysis, only HIF-2a expression 
was an independent prognostic factor.3 3 In the 
second study, H I F - l a expression in surgically 
treated patients was significantly associated 
with improved disease-free survival and overall 
survival.7 9 Of note is that high HIF-la was prog-
nostically bad in one study (chemoradiation), 
and was good in another (surgery) (Figure 4). It 
is also not clear whether this is strictly related 
to hypoxia, because poor correlations between 
HIF-la and the exogenous hypoxic marker pimo­
nidazole have been reported. 1 8 Further preclini­
cal and clinical studies are needed to sort out 
these issues. 
In one study of chemoradiotherapy, CA9 
expression significantly correlated with poorer 
relapse-free and overall survival,8 0 whereas in 
two other studies in which radiotherapy was also 
the primary treatment, no correlation with out­
come was found.3 1 3 2 Glut i overexpression was 
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FIGURE 4. The related intrinsic hypoxia markers HIF-Ια (A) and 
HIF-2a (B) significantly correlate with outcome for head and neck 
tumors Treatments were by surgery (HIF-1a79) or by combined 
chemotherapy-radiotherapy (HIF-2a33) Figure 4A reprinted 
with permission from Beasley, et al, "Hypoxia-inducible Factors 
HIF-1a and HIF-2a in Head and Neck Cancer " Cancer Research 
2002,62 2493-2497 Figure 4B reprinted with permission from 
International Journal of Radiation Oncology Biology Physics, 
53 1192-1202, Koukourakis et al, copyright 2002 Elsevier Ine 
[Color figure can be viewed in the online issue, which is available 
at www interscience wiley com ] 
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relapse-free survival in hypopharyngeal tu-
mors,81 although no such correlation was found 
for a series of laryngeal tumors.82 In this latter 
study, however, glut-3 positivity was associated 
with poorer survival. Many studies have looked at 
the prognostic significance of VEGF expression, 
usually with immunohistochemistry. Results 
have been variable, probably reflecting the differ-
ent sites and t rea tment modalities in these 
studies In 15 publications reporting on clinical 
series in head and neck cancer between 1997 and 
2003, VEGF in tumor sections correlated signifi-
cantly with outcome (local control, survival, or 
lymph node metastases) in nine (60%). High 
VEGF levels were generally bad, consistent with 
the idea that they could reflect hypoxia. However, 
the only two (small) studies comparing VEGF 
directly with a recognized exogenous hypoxic 
marker showed that colocalization and/or quanti-
tative comparisons were either weak (EF583) or 
absent (pimonidazole84). 
among patients with cancer has been estimated 
to be up to 40% to 60% and is often increasing 
during therapy. In routine clinical practice, 
however, interventions to correct for anemia are 
only done in patients who are severely symp-
tomatic. Some studies showed that correction of 
anemia by blood transfusion was beneficial, 
whereas others showed no significant positive 
effect. To avoid multiple transfusions, recombi-
nant erythropoietin (EPO) has been tested to 
increase Hb levels and thereby improve tumor 
control rates by reducing hypoxia. EPO stimu-
lates red blood cell (RBC) production in bone 
marrow and is normally produced in the kidneys 
in response to hypoxia. Several studies showed an 
increase in Hb levels when EPO was given 
concurrently with radiotherapy. However, correc-
tion of anemia with EPO did not result in better 
cancer control or survival in a large randomized 
study on patients with head and neck cancer 
treated with curative radiotherapy.92 
TREATMENTS TO OVERCOME OR EXPLOIT HYPOXIA 
Several treatment modifications have been intro-
duced in the clinic to either overcome hypoxia or 
to use hypoxic cells for targeting therapeutics to 
the tumor (Table 2). 
Correction of Anemia. Low hemoglobin levels 
have been correlated with worse prognosis in pa-
tients with head and neck cancer treated with 
both radiotherapy and/or surgery.M5~H0 A correla-
tion was found between anemia and increased 
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• Hypoxic cell 
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expression 
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Abbreviations EPO erythropoietin HRE hypoxia responsive element 
Hyperbaric Oxygen/ARCON. A straightforward 
approach to overcome tumor hypoxia is the 
administration of oxygen at pressures higher 
than 1 atm. This should increase blood oxygen 
levels, both bound to Hb and in plasma, leading 
to greater oxygen diffusion distances, thus re-
oxygenating previously hypoxic cells. In a meta-
analysis, the improvement in local control of 
solid tumors with hyperbaric oxygen therapy in 
addition to radiotherapy was found to be ap-
proximately 10%.^ Administration of hyperbaric 
oxygen, however, is a rather difficult and poten-
tially dangerous procedure to implement in stan-
dard radiotherapy clinics. 
A more feasible alternative is inhalation of 
carbogen, a gas mixture of 95% O2 and 5% CO2, 
which will also increase blood oxygen levels and 
thus reduce diffusion-limited hypoxia. It has been 
used with or without nicotinamide, which can 
increase vascular perfusion. The ARGON protocol 
is currently being evaluated in the clinic and has 
been demonstrated to increase oxygenation and 
local control in these patients.94 Nonrandomized 
clinical studies showed promising results using 
the ARGON protocol. The Nijmegen radiotherapy 
group reported a significant beneficial effect for 
the treatment of stage T3-T4 squamous cell 
carcinoma laryngeal tumors on local control and 
survival compared with historical conventional 
radiation therapy ')r>~<!' However, a phase I/II 
study of the European Organization for Research 
and Treatment of Cancer (EORTC) that involved 
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head and neck squamous cell carcinoma tumors of 
various localizations could not confirm these 
results.98 A randomized phase III clinical trial is 
now underway aiming at inclusion of 344 patients 
with stage II to IV laryngeal cancer to determine 
the benefits of ARCON. 
Hypoxic Cell Radlosensltlzers. Hypoxic radiosen-
sitzers are characterized by a high affinity for 
electrons that enables them to mimic the effect of 
oxygen in rendering cells radiosensitive. The 
nitroimidazole compounds misonidazole, nimora-
dazole, and etanidazole have been evaluated in 
combination with radiation therapy in carcino-
mas of the head and neck. Some studies reported 
disappointing local control and survival.<)<)~,01 
However, more recently, nimorazole was reported 
to significantly improve the effect of radiotherapy 
of supraglottic and pharyngeal tumors in a large 
phase III randomized trial (Danish Head and 
Neck Cancer Study [DAHANCA] 5-85) ' 0 2 Locore-
gional control (49% vs 33% with placebo) and 
disease-free survival (52% vs 41% with placebo) 
were significantly improved (p = .002) Toxicity 
was reported to be mild, and nimorazole is now 
part of the standard treatment of most patients 
with head and neck cancer in Denmark. Although 
nimorazole is not the most effective radiosen-
sitizer in terms of electron affinity, its relative 
lack of toxicity makes it a more clinically use-
ful and effective compound than other more effi-
cient radiosensitizers. 
Hypoxic Coll Selective Agents. In general, bio-
reductive drugs become preferentially reduced to 
their toxic metabolite in the absence of oxygen, 
thereby selectively targeting hypoxic cells. Hyp-
oxic cell cytotoxins, therefore, differ from ra-
diosensitizers in that their cytotoxic effect is 
independent of the administration of radiother-
apy. It has also been calculated that killing hyp-
oxic cells is a more effective approach than 
radiosensitizing them.1 0 3 Tirapazamine (TPZ) is 
the lead compound in this class of agents and has 
been shown to have a marked increased toxicity 
under hypoxic conditions compared with normoxia 
in different cell lines.104 A one-electron reduction 
of TPZ results in a highly reactive radical capable 
of producing lethal DNA lesions In the presence 
of oxygen, this TPZ radical is rapidly oxidized back 
to the nontoxic original compound, resulting in 
lower toxicity to well-oxygenated cells, explaining 
the differential sensitivity toward oxic and hyp-
oxic cells 10S 
TPZ has been tested in a number of clinical 
trials in different tumor sites including in pa-
tients with advanced head and neck tumors. In 
a phase II study performed by the Radiation 
Therapy Oncology Group [RTOG], TPZ was ad-
ministered concurrently with radiation in pa-
t ients with stage III or IV head and neck 
cancer.106 Encouraging results were reported, and 
there was no apparent worsening of radiation-
associated side effects. A subsequent phase I trial 
studied the combination of TPZ with cisplatin 
and radiation in patients with T3/4 and/or N2/3 
squamous cell carcinoma of the head and neck.66 
Treatment was generally well tolerated, and 
3-year local progression-free survival and overall 
survival were 88% and 69%, respectively. 
Another promising bioreductive drug is AQ4N, 
a prodrug that is activated by reduction in hyp-
oxic cells, producing a stable product that interca-
lates in DNA and blocks topoisomerase II action. 
AQ4N is not effective when given alone but shows 
substantial antitumor activity when combined 
with methods to increase the hypoxic fraction 
with radiation or with other anticancer drugs. '" ' 
This compound has just entered clinical testing, 
and no reports in patients with head and neck 
cancer have yet appeared. Whether it will be 
equal to or better than TPZ remains to be seen 
Gene Therapy. Hypoxia can be exploited for 
tumor-specific gene targeting, because very little 
hypoxia occurs in normal tissues. The delivery of 
foreign genes into the tumor can, therefore, be 
achieved by addition of hypoxia response promo-
tors to the therapeutic gene of interest to achieve 
high specificity to hypoxic cells. Most hypoxia-
inducible genes have an hypoxia responsive 
element (HRE) in their promotor region, contain-
ing a binding site for HIF- la . Under hypoxic con-
ditions, HIF- la will be upregulated and induce 
the gene of interest. An example of such an ap-
proach would be administration of HRE-driven 
herpes simplex virus thymidine kinase, followed 
by ganciclovir, which would only be converted to 
its toxic product in tumors containing hypoxic 
cells and thus expressing the converting enzyme. 
The herpes simplex virus thymidine kinase/gan-
ciclovir (HSVtk/GCV) system is used in a number 
of clinical trials also in combination with radia-
t ion.1 0 8 1 0 9 Viruses (adenoviruses, retroviruses), 
naked DNA, and liposomes were the first vehicles 
used for the delivery of the foreign gene to the 
target cell. Unfortunately, they are limited by 
poor gene transfer and patient toxicity. 
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Another more recent approach is the use of 
anaerobic bacteria. For example, Clostridium re-
quires strictly anaerobic conditions to survive. 
Intravenously injected spores of a nonpathogenic 
clostridial species have been shown to localize to 
and germinate in the hypoxic/necrotic regions of 
solid tumors.1 1 0"1 1 2 By genetic engineering of 
Clostridium bacteria, it is possible to express 
proteins with specific antitumor activities. It has 
also been shown that the immune response does 
not hinder repeated administration of clostridial 
spores and that gene expression can be stopped at 
any time with suitable antibiotics.11 '1 Macro-
phages can also be genetically engineered and 
have been shown to migrate to hypoxic areas in 
xenografts, where they can upregulate genes in a 
hypoxia-dependent manner.114 No large-scale hu-
man trials have yet been done with these prom-
ising approaches. 
Others. HIF-1 is an important transcription fac-
tor in the response of cells to hypoxia. It has, 
therefore, been studied as a tumor-specific tar-
get for anticancer therapy. Chen et a l 1 1 ' have 
demonstrated that dominant negative HIF- la 
rendered pancreatic cancer cells sensitive to 
apoptosis and growth inhibition. Regulators of 
HIF-la could also be tumor-specific targets (eg, 
PI3K inhibitors, mitogen-activated protein kinase 
inhibitors, and the FRAP/mTOR inhibitor rapa-
mycin are all able to block HIF-la function). The 
clinical usefulness of such approaches has yet to 
be ascertained. 
DISCUSSION 
It is clear that hypoxia is a negative factor in 
the treatment of head and neck cancer, reducing 
the chance of cure. This is apparent from a 
meta-analysis showing the benefit of hypoxia-
modulating therapies in radiotherapy91; from 
studies with Eppendorf electrodes, showing al-
most universally a significant correlation with 
outcome for several different treatment modal-
ities (high hypoxia is bad); from some of the 
exogenous and endogenous marker studies, de-
spite their inherent problems, showing that high 
hypoxia is bad; and indirectly from blood vessel 
studies showing that low vascular densities, and 
by inference high hypoxia, are associated with 
worse outcome. 
Measurements of hypoxia have been shown to 
be prognostic for outcome in several studies but 
may not necessarily predict success or failure 
after a specific modifying treatment. For exam-
ple, an endogenous marker may predict outcome 
after radiotherapy, but in a subsequent trial of 
a hypoxic cytotoxin with radiotherapy, one may 
find that the marker predicts outcome equally 
well in both control and cytotoxin arms. Because 
there should no longer be a hypoxic problem in 
the cytotoxin arm, the marker should not be 
predictive here. Such a result would thus indi-
cate that the marker is not measuring some-
thing relevant to cytotoxin action and could not, 
therefore, be used for future patient selection. 
The relevance of hypoxia measurements will only 
become clear through well-designed and well-
executed clinical studies in which hypoxia specific 
treatment is based on pretreatment measure-
ments of hypoxia. 
This also raises the question: is there a "gold 
standard" method for measuring hypoxia? The 
answer at present is probably no. Electrodes such 
as Eppendorf have given consistent results for 
correlations with outcome, but are invasive, use-
ful for accessible tumors only, and have large 
collecting volumes on a micro-regional scale, being 
influenced by necrosis and stroma. Exogenous 
markers such as pimomdazole and EF5 give 
consistent pat terns reminiscent of chronic hypox-
ia but can also exhibit differentiation-associated 
staining. Pimonidazole fractions have also been 
reported to show no significant correlation with 
hypoxic fractions measured by Eppendorf elec-
trodes in cervical tumors ^ Endogenous mark-
ers such as HIF- la , VEGF, and CA9 have been 
shown to correlate with outcome in several stud-
ies,'"' ' " 7 l ) 11h despite the fact that correlations 
with each other seem to be poor in some studies. 
This is probably explained by the fact that for 
every endogenous marker, there are a number 
of factors regulating expression in addition to 
hypoxia. These include glucose concentration, pH, 
differentiation, p53 status, and PI3 kinase acti-
vation. Each method has been shown to be prog-
nostic in some studies, but whether this strictly 
related to hypoxia is not clear for many of them. 
More detailed knowledge of the methods and 
more intercomparisons are still needed. In the 
future, it is possible, if not probable, that with 
increasing knowledge of the extent and timing of 
gene regulation under hypoxia, a panel of genes, 
and not just one, will provide an accurate reflec-
tion of the hypoxic state of a tumor. 
A few distinctions need to be kept in mind. In 
some studies, hypoxia measurements in the pri-
mary tumor have correlated with local control, 
whereas in others, they have only correlated with 
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metastatic failure (eg, in cervical cancer, Eppen-
dorf predicts local control, whereas CA9 predicts 
metastases) .1 1 7 1 1 8 One could speculate that this 
may reflect chronic versus acute hypoxia, but 
there are too little definitive data as yet to base 
this on. The distinction between chronic and acute 
is likely to be important, because they will differ 
in energy supply, gene expression, and viability, 
and, therefore, most likely in sensitivity to drugs 
and radiation. More attention to the compara-
tive biology of these hypoxia types is necessary, 
including molecular ways to distinguish them. 
Given the rapid developments in expression 
profiling and proteomics, coupled with the con-
tinuously increasing interest in the biology of 
hypoxia, one can expect progress in this area in 
the near future.22'1'' 1 , 9 '1 2 ü On the basis of the 
studies reported to date in cell systems, a hyp-
oxic response expression profile would certainly 
be expected in tumors, which could reasonably 
be expected to contribute to a predictive profile. 
Whether types of hypoxia can be distinguished in 
such profiles remains to be seen. The last im-
portant distinction is that between intermediate 
and severe hypoxia. Intermediate hypoxic cells 
are likely to be the more viable while still being 
partially radioresistant and partially drug resis-
tant. Their relative importance will also depend 
on the viability of severely hypoxic cells, which in 
turn depends on their hypoxia tolerance. Some 
cells have limited tolerance to severe hypoxia, 
which would shift the balance in favor of inter-
mediate hypoxic cells in terms of importance for 
outcome Indeed, some calculations show that in-
termediate hypoxic cells can influence outcome 
after radiotherapy.121 
It should be noted that in almost all studies 
relating hypoxia measurements with outcome, 
measurements have been made before treatment. 
What is important, however, is what happens to 
the extent of hypoxia during therapy, especially 
because studies in animal tumor models show 
marked differences in reoxygenation rates.1 2 2 m 
In other words, pretreatment hypoxic fractions 
are only half the story Unfortunately, there are a 
number of limiting factors for making measure-
ments during treatment. These include burden to 
the patient and the fact that as one progresses 
through therapy, most cells in the tumor are 
doomed (already rendered clonogemcally dead but 
still physically present and metabolizing), raising 
questions as to the relevance of the measurements 
for the surviving cell minority. Very few such 
clinical studies have been done, and the results 
are conflicting (see previously). Ideally, one would 
want to know pretreatment hypoxic fractions, and 
preferably types of hypoxia, and to predict reoxy-
genation rates from pretreatment measurements. 
Expression profiling, reflecting detailed biologic 
properties of the tumor, may provide a way but 
will need extensive testing. 
Although not the place for a detailed discus-
sion of methods, a few remarks should be made. 
External scanning methods are attractive in 
being noninvasive and covering the entire tumor, 
but resolution is generally poor. Immunohisto-
chemical methods have a sampling problem, mea-
suring only a small fraction of the tumor. The 
problem is even more acute with tissue micro-
arrays. On the other hand, the advantage of 
immunohistochemistry, and tissue microarrays 
in particular, is that multiple markers can be 
studied. Given the complexity of the biologic re-
sponse to hypoxia and the different degrees and 
timing of hypoxia, multiple markers may be es-
sential to fully characterize the hypoxic status 
Given these data on the importance of hyp-
oxia, what can one do about the problem? A num-
ber of options are now available, as discussed 
previously. The choice of method will also depend 
on the primary treatment. For example, carbogen 
would not be expected to have a large effect on 
chemoresistance if this is due to drug diffusion 
limitations, although a hypoxic cytotoxin would 
be expected to have beneficial effects on both 
radiotherapy and chemotherapy response. For 
surgery, the negative effect of hypoxia may be due 
to its association with a higher degree of malig-
nancy (increased invasion and metastases), and 
so eliminating hypoxic cells, for example with an 
hypoxic cytotoxin, would not be expected to pro-
vide a benefit, because the selection of a more 
malignant phenotype has already occurred. If 
there is an increased risk of metastases associ-
ated with hypoxia, one option would be to 
combine surgery with early and aggressive che-
motherapy, preferably with molecular targeted 
therapy, to reduce side effects. Such options await 
rigorous clinical testing. 
In conclusion, the hypoxia problem in head 
and neck cancer needs to be addressed if improve-
ments in current treatments are to be made, 
because hypoxia is common in this site, and all 
indications are that it limits treatment efficacy. 
Increased knowledge of the molecular biology of 
intermediate, severe, and intermittent hypoxia 
will contribute to progress in detecting these 
forms, assessing their relevance to treatment, 
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and providing pointers for overcoming their neg 
ative influence 
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Estimates of hypoxia and perfusion 
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Purpose: Tumor hypoxia measured by microelectrodes has been shown to indicate poor patient outcome. Here 
we investigated Tour potentially more widely applicable immunohistochemical parameters (if tumor oxygenation 
and perfusion in human head-and-neck tumors. 
Methods: Twenty patients with squamous cell carcinomas of the head and neck treated with primary surgery 
were injected with pimonidazole and IdUrd the evening before operation. Consecutive paraffin-embedded 
sections were stained for blood vessels, pimonidazole, IdUrd, and HIF-Ια. IdUrd labeling and Ki-67 labeling 
around individual blood vessels were scored. The spatial relationship between HIF-la and pimonidazole was 
studied, as well as the distribution of both markers as a function of distance from the nearest blood vessel. 
Results: Measurement of all four parameters (diffusion-limited fraction, pimonidazole fraction, HIF-la fraction, 
IdUrd-negative vessels) was feasible, and a significant difference between tumors was found for all parameters. 
IdUrd-labclcd cells were absent around some vessels, indicating lack of perfusion, because these regions were 
positive for Ki-67. There was a positive correlation between diffusion-limited fraction and pimonidazole area for 
all images from all tumors, although no correlation for mean values per tumor. Colocalization of pimonidazole 
and HIF-lor was low (0.02%-25%). Most expression profiles showed a more homogenous distribution for HIF-la 
than pimonidazole. There was no significant correlation between the pimonidazole and H I F - l a fractions in the 
10 tumors studied. 
Conclusions: Simultaneous immunohistochemical measurements related to hypoxia and perfusion are feasible 
(and easily applicable) in resected human tumors. The different geographic distributions of HIF- la and 
pimonidazole indicate that H I F - l a might not be suitable as a marker for chronic hypoxia. Each parameter will 
be correlated with outcome in a larger ongoing study on head-and-neck tumors treated with surgery with or 
without postoperative radiotherapy. © 2002 Elsevier Science Inc. 
Hypoxia, Predictive assay. Radiation therapy, HIF-la, Pimonidazole. 
INTRODUCTION 
Tumor hypoxia measured by microelectrodes has proven lo 
be an adverse prognostic factor in a number of human 
tumors, regardless of the type of treatment (1-4) Hypoxia 
renders tumor cells more resistant to radiotherapy and che­
motherapy, and is also thought to enhance local and sys­
temic tumor progression Hypoxia can be broadly catego­
rized into two main types "chronic" or "diftusion-limited" 
hypoxia, which describes cells at a distance from blood 
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vessels (5), and "acute" or "transient" hypoxia, which re­
sults from local fluctuations in blood perfusion and oxygen 
supply (6, 7) Which type of hypoxia contributes most to 
resistance to therapy is not known, but it is possible that 
acute hypoxia is the more dangerous, because these tumor 
cells are closer to blood vessels and more viable Standard­
ized and easily applicable methods to measure pretreatment 
tumor hypoxia are necessary for the selection of patients 
who could beneht from hypoxia-modulaling or hypoxia-
exploiting therapies 
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Chapter 3 
The Polarographie Eppendorf histograph has been widely 
used in the clinic to measure tumor oxygenation in studies 
correlating hypoxia with outcome (1-4) Disadvantages of 
the method include its limitation to accessible tumors, in­
vasiveness, and possible disturbances of blood flow and 
tissue architecture, making it less attractive as a potential 
method for routine use In addition, this method is not able 
to differentiate between acute and chronic hypoxia Other 
techniques include the use of bioreductive drugs, such as 
pimonidazole (8-11) and EF-^ (12), to detect hypoxic ar­
eas, these are also under investigation in the clinic These 
compounds undergo enzymatic reduction and binding to 
macromolecules at low cellular oxygen tensions Antibodies 
raised against the bound products are used to visualize 
hypoxia The method is widely used and validated in pre­
clinical models (13) Expression of proteins that are upregu-
lated under hypoxia offers further possibilities for estimat­
ing hypoxia This is attractive, because no drug needs to be 
administered, and analysis can be done on retrospective 
series HIF-1 plays a key role in upregulation of many genes 
(14, 15) and is a heterodimenc transcription factor com­
posed of the alpha and beta subumts (16) Under normoxic 
conditions, HIF la is rapidly degraded by the proteosome 
after being targeted for ubiquitination, a process that is 
dependent on pVHL (17) Under hypoxic conditions, deg 
radation of HIF-1 α is suppressed, and transcription of hy-
poxically responsive genes results (18-22) 
Acute hypoxia, although possible to measure in animal 
models, is more difficult to measure in human tumors It 
should be possible, however, to assess it indirectly by mea­
suring tumor blood perfusion Although no immunohisto-
chemical methods to measure blood perfusion have been 
described for use in humans, we have previously reported 
the use of IdUrd, an extrinsic proliferation marker, to esti 
mate the fraction of perfused vessels in an animal tumor 
model (23) We have applied this technique here to estimate 
blood perfusion in patients with head and neck tumors 
In this study, we have assessed the feasibility of simul 
taneously estimating chronic and acute hypoxia in human 
head and-neck tumors by administration of tracer doses of 
both pimonidazole and IdUrd This allowed comparison of 
tour techniques and hypoxia-related parameters 
METHODS AND MATERIALS 
Patient characteristics and marker adminntralion 
Twenty patients with squamous cell carcinoma of the 
head and neck treated with primary surgery were entered in 
this study The study was approved separately by the ethical 
committees ot the two participating institutes and by the 
Office for Protection of Research Risks of the National 
Institutes of Health All patients gave written informed 
consent Inclusion cnlena were as follows age over 18 
years, TNM stage T2-4NxM0, planned for primary sur 
gery, and no severe liver or kidney dysfunction The 
evening before operation, patients were injected with IdUrd 
(5-iodo-2' deoxyundine, C H U V , Service de Pharmacie, 
Lausanne, Switzerland) and pimonidazole (Hypoxyprobe-1, 
Natural Pharmacia International, Belmont, MA) In sterile 
water was dissolved 100 mg of IdUrd, which was injected 
ι ν over 5 min Pimonidazole (0 5 g/m2) was diluted in 
stenle 0 9% saline for ι ν administration over 20 mm A 
maximum dose of 1 was given to patients with a body 
surface >2 m2 IdUrd was given before pimonidazole The 
whole resection specimen was studied, including metastatic 
neck nodes, if present 
Immunnhistochemical naming 
Consecutive paraffin-embedded sections were single 
stained for HIF-la and double stained for blood vessels in 
combination with either pimonidazole, IdUrd, or Ki-67 
Formalin-fixed paraffin-embedded 4-μπι sections were pre­
pared from the resection specimens After dewaxing and 
rehydration, endogenous peroxidase activity was blocked 
with 0 3% hydrogen peroxide in methanol (30 mm at room 
temperature) As antigen retrieval method Pronase (0 \ΨΓ) 
treatment was used for the pimonidazole/CD31 staining and 
microwave treatment for the ldUrd/CD31 and Ki-67/CD31 
staining For the HIF-la staining, sections were incubated 
at 950C for 45 mm with target retrieval solution (DAKO) 
Protein Block Serum-Free (ITK, Uithoorn, The Nether 
lands, 30 mm at room temperature) was used to reduce 
nonspecific staining For double staining, samples were 
incubated overnight at 4 0C with either a mouse anti-BrdU 
(CLB, Amsterdam, dilution 1/100), a mouse anti-Ki-67 
(MB-67, Neomarkers, dilution 1/50), or a biotinylated an­
tibody against pimonidazole (supplied by Dr J A Raleigh, 
dilution 1/1000) Sections were subsequently incubated 
with a biotinylated second antibody (goat anti polyvalent. 
Ultra Vision Detection System Laboratory Vision, USA) tor 
IdUrd and Ki 67, followed by a streptavidm-peroxidase 
(UltraVision Detection System, Laboratory Vision, USA, 
10 mm room temperature) Peroxidase activity was detected 
by incubation with DAB (Vector) until suitable staining 
developed 
After IdUrd Ki-67, or pimonidazole detection, the slides 
were washed in phosphate buffered saline and incubated 
with protein block serum-free solution followed by a mouse 
anti-human CD3I antibody (clone JC/70A, ITK, dilution 
1/25, overnight at 4°C) The biolin-streptavidin-peroxidase 
staining method was used as described above, although an 
amplification step (Tyramide Signal Amplification Kit-In­
direct, NEN Life Science, The Netherlands) was used after 
the incubation with the biotinylated second antibody After 
the slides were washed with phosphate-buffered saline per­
oxidase activity was detected with a DAB/mckel solution in 
distilled water until suitable staining developed 
HIF Ι α staining was performed in the laboratory of G L 
Semenza, as described previously (24) Briefly, the anli-
HIF-la MAb (HI67, 1 mg/mL) was used al a dilution of 
I 1000 tor 1 h at room temperature A Catalyzed Signal 
Amplification System (DAKO) based on slreptavidin-bi-
olin-horseradish peroxidase complex formation was used 
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according to the manufacturer's instructions. Nuclei were 
lightly counterstained with hematoxylin. 
Image analysis 
Images of the serial sections stained for pimonidazole and 
HIF-la were made at a magnification of 5X with a Zeiss 
Axiovert 135 TV inverted microscope mounted to a single-
chip, black-and-white Photometries (CE200A) cooled CCD 
camera A computer-controlled motorized stepping stage 
and IPLab image analysis software (IPLab 2.5) were used 
for capturing the images. Software developed within SCIL-
Image and ImageProPlus was used to analyze the data 
Tumor areas were delineated in the individual images 
under supervision of a pathologist (M van Velthuysen); 
stromal tissue and areas of necrosis were excluded The 
diffusion-limited fraction (DLF), defined as the proportion 
of total tumor tissue greater than a fixed distance (80-150 
μ) from the nearest stained blood vessel, was calculated as 
described previously (25). A region around the edge of each 
image equal to the chosen diffusion distance was excluded 
from the calculations, so that edge regions would not be 
falsely regarded as "hypoxic" if there was a blood vessel 
just out of the image. 
The tumor area stained for pimonidazole and HIF-la was 
measured by thresholding on the specific antibody staining 
Thresholding involved varying the pixel intensity value 
(threshold) above which objects were selected for analysis, 
until the highlighted objects showed good agreement with 
staining patterns seen for the same area under the micro­
scope. Artifacts were removed manually, and the patterns of 
pixels above the threshold were saved as binary images. 
Images of whole tumor sections (mosaics) were then recon­
structed trom the separate images using a macro in Im­
ageProPlus. Image sizes were compressed by a factor of 5. 
Mosaics were made for the gray value images ol pimonida­
zole- and HIF-1 α-stained sections, as well as for the binary 
images of the tumor selections, the pimonidazole and 
HIF-1 α staining patterns, and for blood vessel staining. 
All mosaics were stacked as layers in Adobe Photoshop 
to match the pimomdazole-stained section with the HIF-1 a-
stamed section Matching was done on external contours 
and internal features (e.g., boundaries between tumor and 
stroma or necrosis) using translation, rotation, and stretch­
ing operations Mismatches larger than 20 μ were not ac­
cepted, and only tumor regions where matching was satis­
factory were further analyzed. In some tumors, good 
matching was obtained in one region, but required a sepa­
rate set of operations to obtain satisfactory matching in 
other regions These regions were therefore analyzed sepa­
rately and labeled a, b, c, etc. 
Colocalization of HIF-la and pimonidazole staining was 
measured by performing a logical AND operation between 
the binary images of the respective staining patterns. The 
overlapping area was expressed as traction of the total 
HIF-la area 
To analyze the dislnbulion of pimonidazole and HIF-la, 
a distance map was generated with respect to blood vessels. 
Binanzed blood vessel images were therefore used to gen­
erate a distance transform image, on which each pixel 
received a gray value according to its distance from the 
nearest blood vessel The distance map was then used to 
generate histograms for total tumor area, pimonidazole-
stamed area, and HIF-la-.slained area. These histograms 
were made by counting the number of pixels at a certain 
distance from the nearest blood vessel for distances between 
0 and 200 μ and represent stained area vs. distance. Nor­
malized histograms were then obtained by dividing the 
pimonidazole- and HIF-la-stained areas by the tumor area 
at the corresponding distance. 
Using the distance map, local profiles of pimonidazole 
and HIF-la staining (optical densities [ODs|) as a function 
of distance from the nearest blood vessel also were made for 
selected areas of interest (tumor cords) in two tumors. These 
comprised the average OD for pixels situated at each dis­
tance and are thus a measure of local average staining 
intensity vs distance The ODs were calculated from the 
gray value in each pixel using the light transmission for­
mula· OD = In(background) - ln(gray value), where back­
ground is an area selected as having no specific antibody 
staining. 
IdUrd and Ki-67 labeling around individual blood vessels 
was scored visually as "yes" (labeling) or "no" (no label­
ing). The percentages of IdUrd-negative vessels and of 
Ki-67-negative vessels were then calculated 
Statistics 
To lest for differences between intratumoral and intcrtu-
moral variations, a one-way analysis of variance was per­
formed using SPSS software (SPSS Ine , Chicago, IL). 
Linear regression analyses were carried out lo lest associa­




We earned out this feasibility study in 20 patients. Esti­
mation of the parameters (See below) was successful in 14 
of these 20 In three samples, reasons for failure included 
decalcification of the resection specimen, which was per-
tormed because there was cartilage in the larynx tumor 
specimens. This procedure, involving use of mine acid, 
destroyed the epitopes for vessels (CD31), IdUrd, and pi­
monidazole One sample had no tumor tissue m the biopsy. 
The remaining two samples were taken within 2 h of injec­
tion. In these there was high background staining and little 
obvious hypoxia-specific staining with pimonidazole. A 
possible explanation is that 2 h was too short an interval for 
surgery patients who receive anesthesia concurrently with 
the markers, possibly reducing tumor blood perfusion (Only 
2 patients received pimonidazole shortly before the opera­
tion). These problems are in large part avoidable for future 
studies. 
No IdUrd-related toxicity was observed. After pimomda-
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zole administration, 1 of the 20 patients experienced an 
epileptic-type attack, followed by a temporary coma. The 
patient had a history of alcohol abuse: after reviews by a 
pharmacologist, a psychiatrist, and an FDA committee, it 
was concluded that the cause of the attack could not be 
ascribed to the pimonidazole. 
Estimates of hypoxia by DLF and pimonidazole 
The first parameter studied was DLF, which is based on 
vascular staining and was defined as the proportion of tumor 
tissue farther than 120 μ from the nearest vessel (25). This 
yields an estimate of the fraction of chronically hypoxic 
tumor cells. Second, we measured the proportion of tumor 
tissue staining positively for pimonida/ole, a more direct 
estimate of hypoxia. For each tumor, multiple consecutive 
images of the stained histologic sections were captured and 
analyzed separately (mean 16 images per tumor). Consid­
erable variation between these images was observed for 
both pimonidazole-stained area and DLF from one tumor. A 
5X microscope objective was used for the capture, resulting 
in an image size of approximately 2.5 mm". Variation in 
vasculature and degree of hypoxia between these relatively 
small areas was therefore not unexpected. The mean coef­
ficients of variation for DLF and pimonidazole for the 14 
analyzable tumors were 0.34 and 0.92, respectively. Despite 
this intratumoral variability, there was a significant differ­
ence between tumors for both parameters (one-way analysis 
of variance: ρ = Ι.2.1(Γ13 and ρ = 5.10 l 0 for DLF and 
pimonidazole, respectively). The wide range of mean values 
between the tumors for each parameter is shown in Fig. 1. 
Mean values for the 14 tumors were 30.0% (DLF) and 8.6% 
(pimonidazole). The main probable cause of the consis­
tently larger DLF values is missing out-of-plane vessels, a 
factor that may not necessarily affect ranking (Haustermans 
et al., 2000). 
The correlation between DLF and pimonidazole for each 
tumor separately is shown in Fig. 2, in which each point 
represents one image, with multiple images analyzed per 
tumor. Correlations were significant in 7 of the 14 tumors. 
When all data were combined, there was a highly significant 
correlation between DLF and pimonidazole area {p < 10 , 
r = 0.25, η = 240). In some tumors, pimonidazole-positive 
areas close to blood vessels were seen, possibly indicating 
reduced flow and/or oxygen supply in these vessels. In 
well-differentiated tumors, pimonidazole staining was often 
seen around areas of keratinization. Whether this staining is 
related or unrelated to hypoxia is not known. 
Estimates of perfusion by IdUrd and Ki-67 
We estimated perfusion in individual blood vessels from 
the presence of IdUrd-labeled tumor cells in the vicinity 
(23). The percentage of blood vessels without IdUrd label­
ing varied from 0.7% to 32.5% (Fig. 3). To check whether 
this was a perfusion problem and not absence of prolifera­
tion, we also stained for the endogenous proliferation 
marker Ki-67 in adjacent sections. Ki-67 was found to be 
expressed around almost all vessels in all tumors, such that 
1 2 3 4 5 6 7 8 9 10 11 12 1314a14b 
Individual patient 
Fig. 1. (Top panel) Histogram showing the mean DLFs al a 
distance of 120 μ from the nearest blood vessel for 14 different 
head-and-neck tumors (individual patients). (Bottom panel) Mean 
pimonidazole area (percent of tumor tissue) for the same tumors. 
Error bars are standard errors of the mean. Despite a large intra­
tumoral variation, a significant intcrtumoral variation was seen for 
both parameters. For Patient 14. two different tumor blocks were 
analyzed 
the fraction with no labeling was very low (0%-7%)(Fig. 3). 
Lack of IdUrd labeling was apparently not because of 
absence of proliferating cells. 
Correlations between DLF. pimonidazole. and IdUrd 
No significant correlations were found between the mean 
values per tumor for DLF and pimonidazole (r = 0.09, ρ = 
0.74). There was no correlation between the percent IdUrd-
negative vessels and pimonidazole fraction (r = 0.09, ρ = 
0.75). or between the percent IdUrd-negative vessels and 
DLF (r = 0.37, ρ = 0.20). 
Η IF-la and pimonidazole colocalization 
The last parameter studied was the expression of HIF-la, 
a possible intrinsic marker for tumor hypoxia. Tumor sec­
tions from 10 patients were analyzed for the percentage of 
tumor tissue staining positively for this protein. HIF-la 
staining was localized mainly in the nucleus and varied 
from 0% to 18% of total tumor tissue (Table 1 ). Two tumors 
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Fig 2 Correlation between DLF ultuldled from vascular staining and pimonidazole area in 14 tumors Each pomi 
represents one image double slained lor pimonidazole and vasculature A signihcant correlation was seen m 7 out of 14 
tumori and when all data were taken together (See text) 
showed no HIF-la staining, despite the presence of pi­
monidazole staining in a pattern typical of chronic hypoxia 
These tumors were not analyzed further There was no 
correlation between the quantitative measurements of 
HIF-la and pimonidazole fractions (r = 0 24, ρ = 0 51) 
(Fig 4) The HIF la fraction was almost always lower than 
the pimonidazole fraction, partly because of the nuclear 
rather than whole-cell staining seen with pimonidazole The 
reconstructed images for HIF-la and pimonidazole were 
matched for the remaining tumors In two cases, accurate 
matching could not been achieved probably because of 
differences in section deformation during cutting and pro­
cessing 
The colocalization of markers was calculated as a fraction 
of the total HIF-la staining The percentages of colocaliza­
tion for the 6 tumors analyzed are shown in Table 1 and 
vaned between 0 02% and 25% As can also be seen in 
Table 1, different regions of the same tumor had somewhat 
different extents of HIF-la staining and degree of colocal 
ization with pimonidazole 
HIF la and pimonidazole expremon vi dulance from 
blood vessels 
Oxygen concentration decreases with distance from 
blood vessels, so if HIF-la expression is oxygen dependent, 
upregulation at a distance from blood vessels would be 
expected, similar to the distribution of pimonidazole stain­
ing Profiles of tumor area, pimomdazole-stained area, and 
HIF la-stained area as a function of distance from the 
nearest blood vessel were therefore generated for the 6 
tumors described above Two such profiles are shown in 
Fig 5 (left panels) The peaks for HIF-la and pimonidazole 
occurred at different distances However, total tumor area 



















Fig. 3. Histogram showing the percentage of vessels scored as 
negative (no labeling in surrounding cells) for IdUrd (striped) and 
Ki-67 (full) in 14 different head-and-neck tumors. Large differ­
ences are seen in the fraction of IdUrd-negative vessels between 
tumors. In contrast, labeling of Ki-67 was present around almost 
all vessels in all tumors. 
for tumor NKI-HN008 (lower left), is simply because there 
was more tumor at this distance. Normalised profiles were 
therefore calculated by dividing by the total tumor area, 
giving the percentage of tumor area stained by pimonida­
zole or HIF-la at each distance. Such profiles (right panels) 
showed a peak for pimonidazole. but a more homogeneous 
distribution for HIF-la (For all histograms, the HIF-la-
stained area was multiplied by a factor equal to the mean 
cclLnucleus ratio of the tumor, because HIF-la staining is 















Pig. 4. Fraction of tumor area positive for HIP-1 α vs. fraction of 
tumor area positive for pimonida/ole. There was no significant 
correlation between the two parameters. 
Normalized distributions for 8 of these 10 tumors or 
tumor regions are shown in Fig. 6. Clear peaks for pi­
monidazole are seen in almost all panels, with staining 
increasing at around 80 μ from the nearest vessel. More 
variation was seen in the HIF-1 α profiles, although all were 
generally flatter with no sharply demarcated peaks. More 
variation in expression was also seen, varying from almost 
none (top right) to very high (right, second row). The last 
two rows show examples of separately matched areas of the 





























































Abbreviations: l.N-lymph node: C/N —cell/nucleus ratio. 
* 1. Results for 6/1U tumors: 2 had no HIF-1 α staining, and 2 had insufficient matching (See text). Letters 
a. b. and c represent regions of one tumor that required separate matching. 
* 2. Percent of tumor tissue (stroma and necrosis excluded). 
*3.(HIF-la + PIMO)/HIF-la. where HlF-la + PIMO represents area of colocali/.ed signals, and HIF-la 
the total area for HIF-la alone. 
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Fig 5 (A and C) Area profiles showing tumor area pimonidazole area and HII la area as a funi-lion of dislance from 
ihe nearest blood vessel Tumor areas (number of pixels) have been divided by 'i to facilitate visual comparison wiih 
the markers (B and D) Normalized area profiles showing the percent ol lumor area positive tor pimonidazole and 
HII la lor Ihe same tumors as A and C respectively Correcting for tumor area revealed a more homogeneous 
distribution ot H1F la expression whereas the peak of pimomda/ole expression remained 
same tumor illuslrating similar patlerns in different regions 
Assuming pimonidazole is a good marker tor chronic hyp­
oxia, these dala suggest thai HIF-la is not such a good 
marker In one tumor (HN014), an increase of HIF la 
expression was seen at a distance from blood vessels, al­
though the peak was situated closer to vessels lhan the 
pimonidazole peak The pattern was consistent with a 
chronic hypoxia distribution However, HIF-la staining 
close to blood vessels was also seen in other areas in this 
tumor Staining patterns for this lumor and one showing a 
more homogeneous pattern are shown in Fig 7 
To confirm (he data from these area profiles, which are 
averages over a large tumor area and do not incorporate 
intensity changes, we generated intensity profiles on indi­
vidual tumor cords from two different tumors, one charac-
lenzed under the microscope as showing a pattern typical of 
chronic hypoxia (Fig 8 upper panels) and one showing a 
pattern of homogeneous distribution (lower panel) Two 
different areas are shown for each lumor One tumor cord 
(upper left) shows upregulation of HIF-la and pimonida­
zole at a distance, although again HIF la was expressed 
closer to the blood vessels In the same tumor, a second 
tumor cord (upper right) showed no upregulation of HIF-
l a, indicating variation in staining ot HIF-1 a, as seen in the 
area profiles In the second tumor, neither area showed 
evidence of HIF-la upregulation at a distance from vessels 
Including signal intensity as well as area therefore did not 
change the conclusions about different HIF-la and pi­
monidazole distributions 
DISCUSSION 
This study shows the feasibility of measuring multiple 
hypoxia-relatcd parameters simultaneously in human tu­
mors using immunohistochemical detection methods on 
paraffin material, combined with image analysis The pa­
rameters described here were chosen so that both chronic 
hypoxia and acute hypoxia could be estimated in the same 
tumors Two of the parameters required administration of a 
drug (pimonidazole, IdUrd), whereas the other two required 
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Distance from blood vessels (μ) 
Fig 6 Normalized area profiles of pimomdazole and HIF-1 α as a function of distance from blood vessels for 6 different 
head-and-neck tumors For tumors NKI-HN(K)8 and NKI-HNO 16, two areas were analyzed separately to obtain accurate 
matching 
DLF) The lalter two have the added advantage that they can 
be carried out also on archival material 
Vasculature 
Previous studies have shown a relationship between vas­
culature and outcome (26-30) Such studies have assessed 
intervessel distances, vascular density, or "hot spots " The 
novel parameter DLF used here was specifically designed to 
estimate chronic hypoxia based on radiobiologic consider­
ations and to assess hypoxia only in tumor areas, excluding 
stroma and necrosis Disadvantages of the method are that it 
is indirect and assumes a constant oxygen tension in all 
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Fig. 7. Hxamplcs of imniunohistocheniical staining for HlF-la in 
head-and-neck tumors. A peak of expression of HlF-la is seen at 
a distance from blood vessels {upper image; tumor NKI-HN014) 
or diffusely throughout the whole tumor tissue (lower image; 
tumor NKI-HNÜ1Ü). Arrow in upper panel indicates a blood ves-
sel; NT in lower panel indicates non-tumor tissue. 
vessels. However, for ranking tumors, variations in oxygen-
ation within vessels should be similar between tumors, 
which is not implausible but needs further study. The fact 
that out-of-plane vessels are not taken into account will 
result In overestimates of hypoxia, consistent with the find-
ing that DLF values are always larger than pimonidazole 
fractions. If this factor does not vary significantly between 
tumors, it should not disturb ranking. Despite its drawbacks, 
however, it seems to correlate significantly but weakly with 
pimonidazole fraction. The lack of correlation in 7 tumors 
could be caused by either a differentiation-related artifact or 
a high fraction of permanently or temporarily closed blood 
vessels. Of interest is that the tumors not showing a signif-
icant DLF-pimonidazole correlation had a significantly 
higher fraction of IdUrd-negative vessels (p = 0.05). In 
these tumors, closed vessels may have more pimonidazole 
in their vicinity than perfused vessels, and more than pre-
dicted by the DLF calculation. The usefulness of DLF will 
become apparent only when correlations with outcome are 
made. 
Pimonidazole 
The oxygen dependence for reduction of pimonidazole is 
very similar to that for development of radiation resistance. 
Extensive preclinical data correlating pimonidazole with 
Eppendorf electrode measurements (31) or with the comet 
assay (32) support the idea that pimonidazole detects radio-
biologically relevant hypoxia. In our study, pimonidazole 
staining occurred in cells primarily at a distance from the 
blood vessel, consistent with chronic hypoxia. Occasional 
binding close to vessels could be caused by temporary or 
permanent closure of the vessels or by longitudinally de-
creasing POT values along tumor vessels. Pimonidazole has 
been reported also to colocalize to a large extent with the 
differentiation marker involucrin. and it has been suggested 
that hypoxia might affect differentiation-regulated gene ex-
pression in squamous cell carcinomas (33). We have found 
pimonidazole staining also close to regions of keratinization 
in some tumors, but whether these cells are hypoxic or 
represent nonhypoxic immunostaining is not yet clear. This 
deserves attention and clarification to use this and other 
bioreductives reliably as quantitative hypoxic markers. The 
staining patterns seen in the majority of tumors studied here, 
however, suggest that it indeed monitors mainly diffusion-
limited hypoxia. 
The intratumoral variation of pimonidazole and DLF 
raises a question of accuracy if only small biopsies are 
available instead of large resection specimens. The issue of 
sampling errors was addressed by Cline et al. (34). who 
studied the quantification of hypoxia by the bioreductive 
CCI-103F. They found that 4 random biopsies give a good 
representation of the whole tumor. 
IdUrd 
Measurement of perfusion-limited hypoxia is difficult in 
man. because no perfusion markers equivalent to the 
Hoechst dyes used in animal models are available (35). We 
therefore attempted to exploit the observed heterogeneity of 
labeling by the thymidine analog iododeoxyuridine. a drug 
often used in the clinic, as indicating microregional varia-
tions in perfusion. Our preclinical studies support this hy-
pothesis, although further validation is needed (23). One 
cause of lack of IdUrd labeling is the absence of prolifer-
ating cells. However. MIB1 labeling (Ki-67) was seen in 
IdUrd-negative regions in almost all cases, so the lack of 
IdUrd labeling is unlikely to be from lack of proliferating 
cells but rather from lack of perfusion, leading to lack of 
delivery of the tracer. This interpretation depends on the 
extent to which endogenous markers persist after hypoxia 
induction and cell cycle cessation, and more work in this 
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hg S Inlensity profiles of HIF-la expression and pimonida/ole binding vs distance to the nearest blood vessels for 
4 individual tumor cords in two separate tumors (Upper graphs tumor NKI HN0I4 lower graphs NK1-HN008) 
of pimomdazole and the percentage of IdUrd-negattve ves­
sels is nol loo surprising, because they measure differenl 
types ot hypoxia, and there is no a prion reason to expect 
a correlalion between the fractions ot acute and chronic 
hypoxia 
HIF-la 
Because degradation ot HIF-la is oxygen dependent 
( 19-22) and accumulation occurs under hypoxic conditions 
(18, 36), HIF-la could be a potential marker to estimate 
tumor hypoxia We evaluated here the use of HIF-1 α as an 
endogenous hypoxia marker mainly by comparing HIF-la 
expression with pimomdazole binding on adjacent sections 
The low percentage of colocalizalion and the marked dif­
ferences in the distance profiles for both area and intensity 
indicale lhat HIF-la may not be a reliable marker of chronic 
hypoxia The number of patients analyzed here is low 
although sufficienl to determine colocalizalion patterns 
In areas where HIF-la upregulalion was seen the obser­
vation of a peak closer to blood vessels than pimomdazole 
could be explained by differenl oxygen dependencies tor 
upregulalion and bioreduction, respectively Half-maximal 
expression of HIF-la occurs at an oxygen concentration 
1 5%-2 0% 06), whereas that for pimomdazole is closer lo 
that for radiosensitivity, around 0 15% (37, 38) It should be 
noted that a different geographic distribution would nol 
prevent HIF-la from being a good hypoxia marker How­
ever, although some individual tumor cords showed an 
upregulalion of HIF-la al a distance from blood vessels 
this was not a general or common finding HIF la staining 
was usually distributed more diffusely in the tumor lhan 
pimomdazole In addition, no correlalion between HIF-la-
stained area and pimomdazole stained area could be found 
in this study 
Several factors could confound the use of HIF-la as a 
hypoxia marker Aberrant HIF-la expression could be 
caused by mutations in the HIF-la gene ilself or its regu 
lating pathways Several proteins, including pVHL (17) 
p53 (39), RAS (40), ΡΠΚ (41, 42), v-SRC (43), and others 
(44, 45) have been described as playing a role in the 
slabilization and upregulalion of HIF-la Altered regulation 
or mutation in one of these genes, which occurs frequently 
in human tumors, could lead to hypoxia independent ex 
pression of HIF la and could partly explain the homoge­
nous distribution for HIF 1 α patterns found in some tumors 
For example pVHL normally ensures HIF la degradation 
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via ubiquitination under oxic conditions Mutations in this 
gene lead to HIF-la overexpression, as has been described 
in renal cell carcinomas (46). Other studies have showed 
that PI3K is frequently mutated in head-and-neck tumors, 
and this pathway has also been implicated in HIF-la up-
regulation (41, 42). In addition to altered gene expression, 
HIF-la activity can also be regulated by nonhypoxic sig-
nals, including nitric oxide (47, 48), cytokines, and growth 
factors such as TGF-ß (49), insulin, and EGFR (47) 
Despite these potential confounding factors, Vukovic et 
al. recently reported significant colocaluation of HIF-la 
with EF-5 binding (a bioreductive hypoxia marker similar to 
pimonidazole) in two different human tumor xenografts of 
the cervix (50). They described comparable distribution 
patterns for both markers with respect to blood vessels, 
although HIF-la was situated closer to the vessels than 
pimonidazole Furthermore, CA-9, which is regulated by 
HIF-la, has been reported to correlate quantitatively with 
pimonidazole binding in cervix tumors (51). Recent in vitro 
studies by Landò et al. (52) showed that not only upregu-
lation but also transactivation of HIF-la is oxygen depen-
dent (53). The ability of HIF to recruit transcriptional co-
factors to its target genes is apparently regulated by an oxygen-
dependent hydroxylation It is thus possible that two different 
oxygen-dependenl mechanisms regulate the expression of 
CA-9, and therefore a better correlation between pimonidazole 
and CA-9 is consistent with these new findings. Direct com-
panson of HIF-la and CA-9 is ongoing 
Other recent studies have shown that high expression of 
HIF-la is associated with poor prognosis and resistance to 
therapy in various human tumors, including head-and-neck 
tumors (54, 55). In the study by Aebersold et al. on oro-
pharyngeal cancer (54), it was notable that HIF-la expres-
sion in two-thirds of cases was seen primarily in viable cells 
surrounding necrosis, consistent with chronic hypoxia, 
whereas one-third showed a more homogeneous distribu-
tion, as seen here In both studies, one can conclude that it 
is not a reliable marker for chronic hypoxia. However, it is 
also apparent that HIF-la may still be valuable as a prog-
nostic indicator It is possible that HIF-la expression re-
flects or influences other important factors determining 
clinical outcome, such as proliferation, intrinsic radiosensi-
tivity, or invasion. This requires further study. 
SUMMARY AND CONCLUSIONS 
Estimation of the four hypoxia-related parameters can be 
made in the majonty of cases. Almost all technical problems 
encountered are potentially avoidable, leading to high pre-
dicted success rates for larger studies. Estimates of chronic 
hypoxia by pimonidazole staining and by the vascular-based 
DLF parameter both have potential artifacts. However, al-
though some pimonidazole staining areas (e.g., related to 
keratmization) raised questions as to their hypoxia depen-
dence, patterns in the majority of tumors were consistent 
with those of chronic hypoxia, making it likely that pi-
monidazole provides a reasonable estimate for this type of 
hypoxia. DLF avoids drug administration, but has poten-
tially more artifacts, and correlations with pimonidazole 
staining reveal a large scatter 
Estimating acute hypoxia has not been possible in human 
tumors to date The IdUrd distribution data here suggest it 
may be useful in this regard, as supported by animal data 
However, although the assumption is reasonable that IdUrd-
negative regions are acutely hypoxic, further information 
and validation are needed. 
HIF-1 α expression did not colocalize well or correlate quan­
titatively with pimonidazole staining in this small senes, indi­
cating that it may not be a good marker, at least for chronic 
hypoxia This is likely because of several factors other than 
hypoxia regulating its expression. This study does not exclude 
other hypoxia-rcgulatcd genes, even partly HIF-1-dependent 
ones, as being useful as endogenous hypoxia markers 
The clinical value of each parameter is now being tested 
in a larger study aiming at an accrual of 150 patients with a 
head-and-neck tumor treated by surgery with or without 
postoperative radiotherapy If significant correlations with 
outcome are observed, these parameters could best be fur­
ther tested in a randomized trial evaluating the effect of 
adding a hypoxia-modulating therapy. The expectation 
would then be that in the group receiving the additional 
therapy, those with high levels of hypoxia would benefit 
most, providing good evidence for the relevance of the 
hypoxia parameter. 
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Abstract 
Background and purpose Hypoxia is a strong negative prognostic factor for all three major treatment modalities lor cancer The 
bioreductive drug pimonida7olc is currently under clinical investigation as a hypoxia marker In human head and neck tumors in addition to 
staining patterns typical of chronic hypoxia staining was seen specifically around areas of keratimzalion, raising the question of whether this 
is hypoxia related This could influence quantitative hypoxia estimates using this marker We investigated here whether the dilierentiation 
related staining was caused by locally high reductive enzyme levels 
Patients and methods The nilrolelrazolium compound NBT was used which is reduced by nitroreduclases to yield a blue color The assay 
was validated on three genetically related ΜΟΑ2Ή human mammary carcinoma cell lines wildtype ovcrexprcssmg DT diaphorase (DTI) 
and overexpressmg cytochrome p450 reductase (R4) Increased NBT staining under normoxia was indeed seen for both R4 and DTI lines 
Pnnonidazole staining under normoxia was only seen in the R4 line 
Results Frozen tumor sections Irom 20 patients with head and neck cancer injected with pimomdazole were incubated with NBT Parallel 
sections were stained lor pimomdazole Staining patterns were then compared on matched images and areas of keratimzalion scored lor the 
presence or absence oi pimomdazole and NBT Pimomdazole staining was seen in 56% of keratinized areas and ol these 78% showed 
increased NBT staining indicating that high reductase levels are not a necessary requirement for dilTerentiation-associaled pimomdazole 
staining In a second series Irozen sections of tumors from 15 patients not receiving pimomdazole were incubated with NBT and compared 
with staining after incubation with pimonida/ole under both oxic and hypoxic conditions Pimomdazole staining of some keratinizing areas 
under oxic conditions was seen Of these areas only a proportion (70%) showed increased NBT staining conhrming the lack of 
correspondence between keratin associated pimomdazole staining and reductase levels 
Conclusion Hypoxia-independent pimomdazole staining can occur in more dilTerentialed head and neck tumors necessitating caution in 
hypoxia quantification These data argue against a causative role for locally high reductase levels in differentiation-associated staining 
DT diaphorase appears to play no role in pimomdazole reduction 
® 2004 Elsevier Ireland Lid All rights reserved 
KeMiords Hypoxia Pimomdazole Nitroreductase Hum in 
1. Introduction 
2-Nitroimidazoles become reductively activated and 
bind to macromolecules in the presence ot low oxygen 
levels and therefore are widely used as markers of hypoxia 
Pimomdazole has been validated as a hypoxia marker in 
preclinical studies [1,11] and is under current investigation 
in the clinic [7,8 10,14] In addition to the presence of 
staining in areas in the tumor suspected for hypoxia, ι e far 
from blood vessels, and in pen-nccrotic tissue, another 
general finding in most of these studies |6,I2| is the 
presence of pimomdazole staining in highly differentiated or 
keratinized tumor tissue, raising the question of whether 
this staining is hypoxia-specific This could have obvious 
implications for selecting patients with tumors having high 
or low hypoxic fractions for further hypoxia-modulating 
therapies 
The reduction of pimomdazole requires nitro-reductases 
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One electron (1-e) reductases such as NADPH cytochrome 
p450 reductase, xanthine oxidase, and aldehyde dehydro 
genäse are able to reductively activate 2-mlroimidazoles in 
two separate 1-e reaction steps The addition of the first 
electron to form a nitro radical anion is reversible in the 
presence of molecular oxygen This step is believed to be 
the basis of the oxygen dependence of 2-nitroimidazole 
bioreductive activation and binding Only in the presence of 
low oxygen levels can the second reduction step occur 
allowing a cascade of reductive events to proceed giving 
products which have the potential to bind to cellular 
macromolecules In contrast to 1-e reductases, 2-e 
reductases like DT-diaphorase are able to bypass the first 
oxygen-dependent reduction and thus reduce 2-nitroimida-
zoles independently of the oxygenation status of the cell 
Chapman et al [5] were the first to report the binding of 
misomdazolc (a closely related analogue of pimomdazole) 
in normal, presumably normoxic tissues Cobb et al [2 1] 
described misonidazole retention in stratified squamous 
epitheha He also found a correlation between misomda/ole 
retention in normal tissue and elevated oxygen-independent 
reductase levels and concluded that the retention was more 
likely to be due to high levels of these reductases rather than 
to the presence of hypoxia in these normal tissues In 
contrast, Parliament et al [9] studied the high binding of 
misonidazole to esophageal mucosa in more detail and 
concluded that an oxygen-insensitive process was not a 
major cause They suggested that this high binding resulted 
primarily from a high level of oxygen sensitive bioreductive 
activity 
In the present study, we therefore investigated whether 
differentiation-related staining is due to high levels of 1- or 
2-e reductases Clarification of the hypoxia specificity of 
this staining is of importance for the quantification of 
hypoxia by pimomdazole, and possibly other bioreductive 
markers, especially in tumor sites that are known to contain 
considerable amount of keratimzation, such as in head and 
neck tumors Non specific oxygen-independent reductase 
levels using a color reaction on frozen sections were 
therefore compared with pimomdazole binding in areas of 
keratimzation 
2. Materials and methods 
2 I Patiemi 
Twenty patients with squamous cell carcinoma of the 
head and neck treated with primary surgery, were injected 
with pimomdazole (0 5 g/m", ι ν ) the evening before the 
operation to remove the tumor Pimomdazole hydrochloride 
(Hypoxyprobe"'-l, Natural Pharmacia International, 
Belmont, USA) was diluted in stenle 0 9% saline for 
intravenous injection The study was approved by our 
Institute Review Board and written informed consent was 
obtained from all patients A further IS patients, also with 
squamous cell carcinomas of the head and neck but who 
were not given pimomdazole, were used in a second series 
For both series, a biopsy was taken from the resection 
specimen and frozen in liquid nitrogen For sectioning, the 
tissues were mounted on the freeze microtome head with 
OCT embedding medium and 7 μηι sections were cut at 
- 2 0 o C 
2 2 Immunohisloihemistry 
Sections were fixed in 4% formaldehyde for 10 mm 
After blocking with 0 3% hydrogen peroxide in methanol, 
the slides were incubated with serum free protein block, 
followed by incubation with a biotinylated antibody against 
pimomdazole (supplied by Dr J A Raleigh, 1/1000, over 
night, 4 0C) Sections were subsequently incubated with 
streptavidin-peroxidase (UltraVision Detection System Lab 
Vision USA) for 10 mm at room temperature Finally, 
peroxidase activity was detected with DAB substrate in 
distilled water 
2 3 Reductase aitnit\ a\sa\ 
Frozen sections were fixed in lormaldehyde vapor tor 
30 s to minimize diffusion of enzyme They were then 
incubated at 37 °C for 5 min in phosphate buffer (pH 7 2), 
NBT (3,3'-(3,3'-dimethoxy-4,4'-biphenylcne)bis[2-4-mtro-
phenyl-5-phenyl-2H-tctra7()lium chloride]) 1 2 mM, MgCI 
0 05 M, NADPH 2 4 mM and menadione (vitamin K) 
Sections were terminally fixed in 10% tormaldehyde and 
washed in water Finally, they were rinsed in acetone, 
dehydrated in alcohol, cleared in xylene and mounted in 
Depex 
NBT staining density was estimated semi-quantitatively 
For the cell lines, we used an arbitrary scale of 0 to + + + 
The absence of any except minimal blue staining was 
recorded as 0, a clearly positive blue stain + , a strong blue 
+ + and very strong blue verging on black + + + On the 
tumor sections areas of keratimzation were scored for the 
presence or absence (+ or - ) of increased NBT staining 
(strong blue staining) Scoring was done independently by 
two or more different observers 
2 4 Tissue culture 
The human mammary carcinoma cell line MDA 231 
(wild type) and MDA 231 overexpressing cytochrome p450 
reductase (clone R4) or DT-diaphorase (clone DTI) have 
been described [15,16] DT diaphorasc activity was 
10,000 nmol cyt c reduced/mm per mg protein tor the 
DT-1 clone and 12 for the wild type Cytochrome p450 
reductase activity was determined to be 300 nmol cyt c 
reduced/mm per mg protein for the R4 clone and 6 lor 
the wild type Overexpression ol DT-diaphorase in com 
panson with wildtype cells was confirmed by western 
blotting All cell lines were maintained in exponential 
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growth phase in Dulbecco's modified Eagle s medium 
supplemented with 2 mM glutamme 10% fetal calf serum 
and puromycin (5 μg/ml) They were cultured at M °C in 
water-saturated atmosphere of 95% air and 5% COT 
After trypsimzation, wildtype and transfected cells were 
grown on covershps for 2 days and washed with PBS before 
incubation with pimomdazole or fixation in formaldehyde 
vapor for the NBT assay 
2 5 Incubation with pimomdazole under OXIL versus 
h\poxii conditions 
Fresh frozen tissue sections or cells grown on covershps 
were incubated tor 4 h at 37 "C in 95% air and 5% CO2 or 
under hypoxic conditions in a sealed chamber Incubation 
medium contained DMEM 10% FCS, Hepes (25 mM), 
NADHP (2 4 mM) and 0 or 3 mM pimomdazole Tissue 
sections from 15 different tumors were studied For each 
tumor parallel sections incubated without pimomdazole 
were used as a negative control To creale a hypoxic 
environment a GasPak 100" anaerobic system (Becton 
Dickinson Microbiology Systems Sparks USA) was used 
In this system hydrogen generated from a sodium 
borohydnde tablet combines in the presence of a palladium 
catalyst with the oxygen in the jar to form water thus 
exhausting the oxygen Evans [Π] previously reported that 
the oxygen concentration in these jars was reduced to less 
than 0 4% in 100 mm A clonogenic assay for radio-
scnsitivity was used to evaluate the level of oxygen 
achieved by this system after 3 h, showing an oxygen 
enhancement ratio ol approximately 2 9 tor Chinese 
Hamster CHO cells (data not shown), indicating a high 
degree of hypoxia After incubation, slides were imme 
diately fixed in 4% formaldehyde tor 10 mm followed by 
washes with PBS 
To assess pimomdazole staining intensity, we scored 
keratinized and non-keratimzed areas according to an 
arbitrary five point scale (0, no staining 5 maximum 
staining) Non keratinized areas were chosen next to 
keratinized areas in differentiated tumors whereas in tumors 
showing little or no keratimzation, the tumor as a whole was 
scored 
2 6 FloH cytomilrs 
Cells were trypsmized and fixed in 70% ethanol Fixed 
cells were stained with pimomdazole using a non-
conjugated mouse anti-pimomdazole antibody (supplied 
by Dr J A Raleigh dilution 1/1000, I h, RT) tollowed by an 
FITC-conjugated goal anli-mousc antibody (Sigma, USA), 
according lo standard procedures Cells were assessed for 
fluorescence using a FACScan flow cytometer (Becton 
Dickinson USA) calibrated with fluorescent beads, again 
according to standard procedures Debris was gated out 
from forward versus side scatter plots and the mean green 
fluorescence of the gated cells measured using WinMDI 
software (htlp //facs senpps edu/soflware html) 
3. Results 
II Validation of NBT assav 
MDA 231 human breast carcinoma cell lines over-
expressing either p450 reductase (R4) or DT diaphorase 
(DTI) were used to validate the reductase assay The 
intensity of the blue staining was scored visually Both DT 
and p450 overexprcssmg cell lines showed more intense 
NBT staining compared with wildtype cells indicating that 
NBT detected increased activity of both reductase types 
(Table 1) No significant staining difference could be 
detected between these 1 or 2 electron reductases In the 
majority of the R4 cells, NBT staining was predominanlly 
located in the cytoplasm while in ihe DT-1 cells staining 
was mainly localized in the nucleus 
In addition, we incubated the same cell lines with 
pimomdazole under cither 0x1c or hypoxic conditions 
Pimomdazole reduction and binding was quanlified by flow 
cytometry using an anti-pimomdazole antibody and a 
fluorescent second antibody Two separate experiments 
showed essentially comparable results (Fig 1) All three 
lines showed high staining afler hypoxic incubation which 
was pimomdazole concentration-dependenl Two of the cell 
lines showed little staining after 0x1c incubalion In Ihe R4 
cell line however staining was considerably higher than in 
the other two, although not as high as after hypoxic 
incubation These data indicate that p450 reductase is 
capable of reducing pimomdazole past the 1-c reduction 
step under oxic conditions if expressed at high levels They 
also indicate that DT diaphorase is incapable of reducing 
this mtroimidazoles under normoxia despite its capability 
of 2-e reduction Moreover, in neither experiment was the 
DTI curve significantly higher lhan for wildtype cells under 
hypoxia, indicating that DT diaphorase plays a negligible 
role in pimomdazole reduction under either condition of 
oxygenation 
Tabic 1 
Pimomdazole and NBT staining ol wildlype and transfected MDA211 cells 
NBT staining Pimomdazole staining 
normoxia 
Hypoxia Normoxia 
WT + + + + 0 
R4 + + + + + + + + + 
DTI + + + + + + Ü 
WT wildtype R4 overexprcssmg tylochrome p4S0 rcductast DTI 
ovcrcxprcssing DT diaphorase visual score 0 to + + + intensity ol NBT 
staining visual score 0 to + + + + intensity of pimomdazole binding 
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Exp 1 Exp 2 
0 00 0 20 0 40 0 60 0 Θ0 1 00 1 20 0 00 0 20 0 40 0 60 
Pimomdazole concentration (mM) 
Fig. 1. Pimonida/olc staining in MDA23I human manimary carcinoma cell lines detected by flow cytometry. WT. wildtype (circles): DTI, overexpressing DT 
diaphorase (triangles); R4. overexpressing cytochrome p450 reductase (squares) Oxis incubations, clashed curves; hypoxic incubalions, lull curves. 
3.2. Pimnnidazole staining versus reductase activity 
Reductase activity was measured on frozen tumor 
sections of patients previously injected with pimonidazole. 
A mouse liver was used as a positive control while NADPH 
was omitted as a negative control. Blue staining varied from 
almost none to very high and was often heterogeneous 
throughout the tumor. Areas of keratinization were scored 
for the presence of increased reductase activity. Corre­
sponding areas in adjacent sections were scored for the 
presence of pimonidazole. Examples of the four possible 
outcomes are shown in Fig. 2. illustrating areas positive for 
both markers, one marker or neither marker. Scoring results 
are shown in Table 2. Areas of keratinization were present 
in 10 of the 20 tumors and a total of 64 areas were scored 
after matching pimonidazole and NBT sections. Pimonida­
zole staining was seen in 36 of the 64 areas (56%: Table 2, 
second and fourth data columns). In addition, in these 64 
differentiated areas, reductase levels correlated with pimo­
nidazole staining in only 56% (43% both positive. 13% both 
negative: Table 2. first and fourth data columns). The 
remaining 44% of the areas showed a mismatch: 13% 
pimonidazole positive/NBT negative. 31% pimonidazole 
ncgative/NBT positive. These data show that keratinizing 
NBT + Plmo + 




NBT Pimo + 
NBT- Pimo -
Fig. 2. Staining in fro/en sections of head and neck tumors from patients given pimonidazole. Adjacent sections were incubated with NBT. Photos show four 
matched keratinizing tumor areas stained for pimonida/ole and NBT (right and left in each pair), illustrating the four possible outcomes: + / + . - / + . +/— and 
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Areas ol keralimzalion were scored for ihe presence or absence ol 
pimomda/ole staining ( + or - ) The same areas on consecutive 
scellons were scored for ihe presence or absence of increased NBT 
staining (+ or - ) 
areas are sometimes but not always associated with 
pimonidazole staining, and that high reductase levels are 
not correlated with this staining. 
3.3. Pimonidazole binding under oxit venus hypoxic 
conditions 
To try and clarify whether the pimonidazole staining 
could occur under oxic conditions, we studied a second 
series of patients not given pimonidazole. This allowed us to 
study pimonidazole staining under different conditions of 
oxygenation by incubating frozen sections with the hypoxic 
marker compound. Adjacent sections were again incubated 
with NBT (under normoxia) to measure reductase activity. 
Sections of head and neck tumors with different degrees of 
differentiation and keratmization were studied Staining 
intensity was scored on an arbitrary five-point scale. When 
scoring individual keratinized and adjacent non-keratimzed 
areas, pimonidazole staining was more intense under 
hypoxia than under oxic conditions tor both states of 
differentiation (Table 3). It was also clear that staining was 
more intense in keratinized areas (columns 1 versus 3, 2 
versus 4) However, although both hypoxia and differen­
tiation state affected staining intensity, the influence of 
hypoxia was the more dominant, such that hypoxia-non-
kcratimzed areas still showed more intense staining than 
oxic-keratimzed areas (columns 3 versus 2) 
It was apparent that strongly keratinizing tumors showed 
a more heterogeneous pimonidazole staining than non-
keratimzing tumors (see Fig 3). Not all tumors showed 
pimonidazole staining around areas of keralimzation under 
oxic conditions (Tabic 3, column 2). Of 86 areas that stained 
positively in air, 70% were associated with increased 
reductase activity (high NBT staining; data not shown) The 
remaining 30% had basal NBT staining, again indicating a 
lack of correlation between keratin-associated staining and 
reductase levels 
4. Discussion 
This study tested the hypothesis that the differentiation-
associated staining seen with anti-pimomdazole antibodies 
is, at least in part, not hypoxia-related but due to other 
Table 3 
Intensity of slaimng aller pimonidazole incubation ol fro/en tumor sections 
























































































































A fivc-poml intensity scale was used (visual scoring) and both 
diffcrcnlialed (keratinized) and adjacent non dillerentiated areas were 
scored separately SD. standard deviation. N, number of areas scored 
factors, specifically high levels of non-specific oxygen-
independent nitroreductases. These areas are visually 
different from the classic chronic hypoxia patterns seen 
with pimonidazole in many tumors such as those less well 
differentiated. The classic pattern shows a gradual increase 
of staining intensity and proportion of cells stained with 
increasing distance from blood vessels. In contrast, areas of 
differentiation-associated staining often have very sharp 
boundaries and exist at variable distances from blood 
vessels This raises the obvious question of whether this is 
indeed hypoxia-related staining 
The fact that pimonidazole staining can occur in these 
areas was illustrated in both patient series. The finding that 
pimonidazole incubation of frozen sections under normoxia 
showed staining m some of these areas was particularly 
informative, demonstrating that non-hypoxia-related pimo­
nidazole staining can occur. This only occurred in 
keratinizing areas. There are therefore clearly other factors 
than oxygen concentration that will influence pimonidazole 
staining in histological sections However, the lack of 
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Pimonidazole hypoxia NBT 
Tumor 1 
Tumor 2 
Fig. 3. Staining in adjacent frozen sections of head and neck tumors incubated in vitro with pimonida/ole or NBT. Left panels, pimonidazolc staining after 
hypoxic incubation; right panels. NBT staining of matched areas in adjacent sections after oxic incubation to monitor reductase levels. Top panels show a 
poorly differentiated tumor; lower panels show a well dilicrcntiatcd keratinizing tumor, showing heterogeneous pimonidazole staining and high NBT staining 
m tumor areas. Stromal areas (s) are lighter stained and separate the darker staining tumor areas. 
correlation with NBT staining did not support our 
hypothesis that a major factor could be high reductase 
levels. 
Pimonidazole concentrations used in the in vitro 
incubation experiments were higher than those reached in 
human tumors and this could possibly have influenced the 
non-hypoxic binding. However, we had previously tested a 
range of concentrations of pimonidazole (data not shown) 
and found that a high concentration (3 mM) was necessary 
to obtain a good hypoxia-specitic signal. These high 
concentrations may have been necessitated by non-optimal 
incubation conditions, or loss of enzyme or co-factors 
resulting from freezing and cutting. 
The assay chosen, reduction of the nitrotetrazolium NBT 
to a blue product, was tested by staining-related cell lines 
with different levels of reductase expression. The results 
showed that both reductases investigated, cytochrome p450 
reductase and DT-diaphorase, were capable of reducing 
NBT under oxic conditions. Both enzymes have been shown 
to reduce nitroimadazoles. It therefore appeared to be a 
satisfactory assay to test for variable enzyme levels in 
tumors as potential mediators of non-hypoxic reduction. 
The pimonidazole data on these cell lines showed 
additionally that DT-diaphorase appeared to be incapable 
of reducing pimonidazole under air, and also possibly under 
hypoxia. Increased NBT staining in tissue sections therefore 
could reflect either higher p45ü reductase or DT-diaphorase 
concentrations, but only p450 reductase levels will be 
relevant to pimonidazole staining. Whether there are other 
reductases occurring in human tumors which can be 
detected by NBT is not known. 
If high reductase levels are not the cause of the 
differentiation-associated pimonidazole staining, what then 
is? One possibility is that the antibody cross reacts with 
another protein or cellular constituent. This is unlikely, 
since staining of control sections not containing pimonida-
zole (from patients not given pimonidazole and not 
incubated with pimonidazole in vitro) show low background 
staining and no specific differentiation-associated staining. 
It is possible thai unreduced pimonidazole binds or is 
trapped in keratinizing areas and is subsequently detected by 
the antibody. We have nothing to prove or disprove this 
possibility. Interestingly, oxygen-independent binding of 
pimonidazole to melanin in melanoma cell lines has been 
reported [4] and so by analogy, it is possible that 
pimonidazole may bind to other cellular constituents such 
as keratin. 
Raleigh and colleagues |12| showed a large overlap 
between pimonidazole and the differentiation marker 
involucrin in human cervix tumors. This co-localization 
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supports a relationship between differentiation and pimoni-
dazole staining, and is not inconsistent with the idea that the 
differentiating cells are also hypoxic. They are also not 
inconsistent with the notion that some of these areas may 
not be hypoxic. This still needs further investigation. 
Another perhaps more important question is whether the 
cells in well differentiated areas and which stain with 
pimonidazole are also clonogenic For patients treated with 
radiotherapy, the radioresistance of hypoxic cells is likely to 
be a major problem, and was the primary reason for 
originally stimulating the development ot bioreductive 
hypoxia markers. For chemotherapy, a similar reasoning 
applies, although the chemoresistance of hypoxic cells is 
likely to be caused by lower drug concentrations reaching 
these cells, and the fact that a higher proportion will be out 
of cycle. The requirement for clonogemcity remains, 
however It would therefore be very useful to know what 
fraction of pimomdazole-stained cells are clonogenic. At 
present there are no methods to measure this m human 
tumors, although one could speculate that it could be 
addressed by studies correlating gene expression patterns 
under progressive hypoxia and nutrient deprivation with 
loss of clonogemcity. If an expression pattern inconsistent 
with clonogenic ability (e.g. reflecting a particular differ­
entiation and energy status) could be found, this could be 
exploited to investigate the status of pimonidazole stained 
cells in vivo. 
If the differentiation-associated staining is non-hypoxia-
related, the 'hypoxic fraction' measured by pimonidazole 
will be overestimated. How big is this problem? In the 
present study, differentiation-associated staining was seen 
in six of the 20 tumors from patients given pimonidazole. In 
these five patients, we estimated that 30% of the total 
pimonidazole staining appeared to be differentiation-
associated (judgment based on proximity to kcratinization 
and sharpness of borders). This means that in 25% of 
patients (5/20), the hypoxic fraction would be overestimated 
by 30% This is a worst-case scenario since it assumes 
that the cells showing differentiation-associated staining 
are not hypoxic, and some of them are likely to be both 
differentiated and hypoxic 
In conclusion, pimonidazole may give an overestimate of 
the true hypoxic fraction in some head and neck tumors due 
to differentiation-associated staining. High reductase levels 
do not seem to be the cause of this staining, at least not in all 
keratinizing areas, and therefore it cannot be corrected for 
by the NBT. The problem addressed here could also be 
regarded as a question of setting an appropriate intensity 
threshold, which should ideally exclude the light oxic 
staining seen in some differentiated areas This is difficult to 
realize in practice. It is possible that any overestimate is 
Differentiation-associated pimonidazole staining 
further compounded by the fact that a proportion of the 
pimonidazole-stained cells may no longer be clonogenic 
This remains an important question. Correlations of the 
extent of pimonidazole staining with outcome after radio­
therapy should help clarify some of these issues. 
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Thymidine analogues lo asses microperfusion 
T H Y M I D I N E A N A L O G U E S T O A S S E S S M I C R O P E R F U S I O N IN 
H U M A N T U M O R S 
HILDE L. JANSSEN, M.D., P H . D . , * ANNA S. LJUNGKVIST, P H . D . / PAUL F. RIJKEN, + DEBBIE SPRONG,* 
JAN BUSSINK, M.D., P H . D . / ALBERT J. VAN DER KOGEL, P H . D . , + 
KARIN M. HAUSTERMANS, M.D., P H . D . , * AND ADRIAN C. B E G G , P H . D . * 
•Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands. +Department of Radiation 
Oncology, University Medical Center Nijmegen, Nijmegen, The Netherlands, department ot Radiation Oncology, 
University Hospital Gasthuisberg, Leuven. Belgium 
Purpose: To validate the use of the thymidine analogues as local perfusion markers in human tumors (no labeling 
indicates no perfusion) by comparison with the well-characterized perfusion marker Hoechst 33342. 
Methods and Materials: Human tumor xenografts from gliomas and head-and-neck cancers were injected with 
iododeoxyuridine (IdUrd) or bromodeoxyuridine (BrdUrd) and the fluorescent dye Hoechst 33342. In frozen 
sections, each blood vessel was scored for the presence of Idllrd/BrdUrd labeling and Hoechst in surrounding 
cells. The percentage of analogue-negative vessels was compared with the fraction of Hoechst-negative vessels. 
Collocalizalion of the two markers was also scored. 
Results: We found considerable intertumor variation in the fraction of perfused vessels, measured by analogue 
labeling, both in the human tumor xenografts and in a series of tumor biopsies from head-and-neck cancer 
patients. There was a significant correlation between the Hoechst-negative and IdUrd/BrdUrd-negative vessels in 
the xenografts (r = 85, ρ = 0.0004), despite some mismatches on a per-vessel basis. 
Conclusions: Thymidine analogues can be successfully used to rank lumors according to their fraction of 
perfused vessels. Whether this fraction correlates with the extent of acute hypoxia needs further confirmation. 
© 2005 Elsevier Inc. 
Perfusion, Acute hypoxia. Thymidine analogues. 
INTRODUCTION 
Hypoxia in animal and human tumors is thought to occur 
through either diffusion or perfusion hmilalion.s. It is likely that 
these two forms of hypoxia are biologically different and might 
have different consequences for treatment Diffusion-limited 
hypoxia occurs when tumor cells grow faster than the forma­
tion of new blood vessels As cells are pushed away from 
blood vessels they become gradually more hypoxic. They will 
then usually stay hypoxic for a relatively long time and are 
therefore called chronically hypoxic cells. Perfusion-hmited 
hypoxia is caused by transient fluctuations in blood flow, e g., 
sudden shutdown of blood vessels, or slowed or even reversed 
blood flow Such reductions in blood flow can subsequently 
reverse, resulting in reoxygenation of surrounding tumor cells. 
This type of hypoxia is typically more abrupt and shorter in 
duration and is thus termed acute hypoxia Such cells might 
have greater viability because of this transient nature, whereas 
the majority of the chronically hypoxic cells will eventually die 
if the tumor is not treated. 
Reprint requests to Adrian C Begg, Ph.D , The Netherlands 
Cancer Institute. Division of Experimental Therapy, Plcsmanlaan 
121, 1066 CX Amsterdam, The Netherlands Tel ( + 31) 20-512-
2036, Fax ( + 31)20-512-2050 E-mail a.begg@nki nl 
Tumor hypoxia can have important consequences. Mea­
surements ot oxygen tension within tumors by the Eppen-
dorf electrode have been shown in multiple studies to cor­
relate significantly with outcomes, indicating that hypoxia is 
an important negative factor determining treatment out­
comes However, these electrodes have a large collecting 
volume, and the data might therefore represent an unknown 
mixture of both acute and chronic hypoxia, as well as 
necrosis. Few data are available on the relative importance 
of acute vs chronic hypoxia on treatment outcomes Chron­
ically hypoxic cells are energy deficient for a longer time, 
resulting in an adapted energy metabolism and, depending 
on the severity of hypoxia, reduced deoxyribonucleic acid 
(DNA) repair (1, 2). This could reduce their impact in 
determining the outcomes of therapy Acutely hypoxic cells, 
on the other hand, have not been adapted yet to a low-
energy situation and thus might well be capable of repair 
and resistant to therapy 
Acute hypoxia can be measured indirectly by studying 
This work was financed by the Dutch Cancer Society, grant ΝΚ1 
2000-2202 
Received Dec 16, 2004, and in revised form Mar 15, 2005 
Accepted for publication Mar 29, 2005 
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vascular perfusion or changes in blood flow in tumors. 
Several markers are available for measuring perfusion in 
animal tumors, including labeled dcxtrans, albumins, and 
fluorescent dyes, such as Hoechst 33342 and DÌOC7 (3). 
Typically, the marker is injected intravenously (i v.), and a 
tumor sample is taken within minutes or visualized directly 
in the undisturbed tumor with the "sandwich tumor" tech-
nique (4). Hoechst dyes diffuse quickly out of vessels and 
bind to DNA of cells surrounding a vessel, thereby delin-
eating areas of perfusion. Unfortunately, most of these 
markers are not suitable for human use for reasons of 
toxicity and so other markers have been and are being 
sought that are suitable for clinical application. 
We have previously reported the use of iododeoxyuridine 
(IdUrd), an extnnsically administered proliferation marker, 
to estimate the fraction of perfused vessels in an animal 
tumor model and in cancer patients (5). Iododeoxyuridine is 
a thymidine analogue approved for clinical use, originally in 
high doses as a radiosensitizer and subsequently at tracer 
doses as a cell kinetic marker. Both in mice and in humans, 
we and others have observed significant variations in label-
ing index around individual vessels. We hypothesized that 
the labeling of tumor cells in the vicinity of a blood vessel 
depends on the perfusion of that particular blood vessel. In 
a mouse model, we showed that changes in tumor perfusion 
induced by nicotinamide and hydralazine were successfully 
detected with this technique (5). In human tumors, wide 
variations between tumors was observed in the fraction of 
blood vessels with no surrounding IdUrd labeling, implying 
considerable variations in acute hypoxia (6) 
Although the results obtained to date suggest that lack of 
IdUrd labeling reflects lack of perfusion, this was indirect 
evidence only. The purpose of this study was to further 
validate the use of IdUrd as a perfusion marker by perform-
ing a direct comparison with the well-characterized perfu-
sion marker Hoechst 33342. Using xenografts with different 
levels of perfusion, we show that tumors with low and high 
perfusion can be successfully distinguished with IdUrd. 
METHODS AND MATERIALS 
Tumors 
Human tumor xenografts from glioma and head-and-neck can-
cer were used for this study The protocols for production and 
maintenance have been described previously (7. 8) Briefly, tumor 
specimens were obtained from primary human gliomas or squa-
mous cell carcinomas of the head and neck (larynx, hypopharynx, 
oropharynx, or oral cavity). The tumors were immediately trans-
planted subcutaneously on the flank of a group of five aneslhelized 
Balb/c nu/nu mice Mice were kept in a specific pathogen-free unii 
in accordance with institulional guidelines Approval of Ihe local 
ethics committee for animal use was obtained for all expenmenls 
The overall take rale was 60%. Tumors were passaged when they 
reached a diameter of approximately 8-10 mm Representative 
whole-tumor cross-sections of 16 tumors originating from 11 
different patients were used in this study 
Markers 
The S-phase marker bromodeoxyundinc (BrdUrd) (Sigma. Si 
Louis. MO) was given inlrapenloncally al 500 mg/kg in a volume 
of 0 5 mL saline Iododeoxyuridine was given inlrapemoneally at 
30 mg/kg in a volume of 0 5 mL saline The fluorescent dye 
Hoechst 33342 (Sigma) was dissolved in saline and given ι ν in a 
lail vein al a dose of 15 mg/kg Bromodeoxyundine or IdUrd was 
injected 15 mm and Hoechst 33342 either 1 or 15 mm before the 
animals were killed (see "Results" for individual protocols) Tu­
mors were excised and immediately slored in liquid nitrogen unni 
ihey were cut into 5-mm frozen sections, which were stored at 
-80 o C until stained. Sections were cut through ihe largest circum­
ference of the tumor for analysis 
Immunohistochemical staining 
Atler thawing, the sections were hxed in cold acetone (40C) for 
10 mm. and the slides were rinsed and mounted in phosphate-
buffered saline (PBS) (0 1 mol/L, pH 7 4) The Hoechst 33342 
signal was recorded before immunohistochemical staining (see 
below) Between all the conseculive steps of the staining proce­
dure, sections were rinsed three limes for 2 min in PBS. Antibodies 
were diluted in PBS with 0 1% bovine serum albumin and 0 1% 
Tween-20 Tissue sections were incubated overnight al 4°C wnh 
undiluted 9FI (endothelial marker), followed by 60 min al 370C with 
letramethylrhodamine isothiocyanale (TRITC)-conjugated goat anti-
rat antibody (Fab,) I 100 This was followed by 60-mm incubalion 
of Alexa 546-conjugated donkey ami-goal antibody 1 100. After 
scanning of the vascular signal, the DNA in the tissue sections was 
denatured with 2 Ν hydrochloric acid for 10 mm To neutralize ihe 
pH, the sections were immediately rinsed in 0 1 mol/L borax for 10 
mm Then ihe sections were incubaled al 37°C tor 45 mm with 
Br-3, a mouse monoclonal to BrdUrd 1 50 (Callag Laboratories, 
San Francisco, CA) Finally, the sections were incubated for 1 h at 
room temperalure wuh goat anti-mouse Alexa 488 conjugate 1 100 
(Molecular Probes, Eugene, OR) 
Scanning of tumor sections and image processing 
The tumor sections were analyzed wnh a semiauiomalic method 
based on a tomputenzed digilal image-analysis system, as de­
scribed previously (8) Briefly, a high-resolution, intensified solid-
state camera on a fluorescence microscope (Axioskop, Zeiss. 
Oberkochen, Germany) with a computer-comrolled molonzcd 
stepping stage was used The images were recorded and processed 
with the digital imaging application TCL image (TNO, Delft, The 
Netherlands) 
Each tumor cross-section was sequentially scanned for each 
marker The scans were performed ai I00X magmhcalion. Differ-
enl fillers were used for Hoechsl 33342 (ullraviolel), IdUrd/BdUrd 
(Alexa 488), and vasculature (TRITC and Alexa 546). Each scan 
consisted of 25-100 microscopic fields, depending on the size of 
the tumor sections, and resulted in one binary image reconstrucled 
from ihe individual fields Three images were obtained displaying 
(/) perfused areas (Hoechst 33342), (2) endothelial struclures 
(9FI), and (.1) proliferation (BrdUrd or IdUrd). In addition, a 
fourth image was made of nuclei to better see tumor morphology, 
wnh propidium iodide staining 
Analysis of perfusion 
The goal was lo compare Hoechsl and BrdUrd/ldUrd on a 
per-vessel basis Each vessel was therefore scored for Hoechst 
positivity and BrdUrd/ldUrd posmvity m surrounding lumor cells. 
70 
Thymidine analogues ίο asses microperfusion 
To achieve this, the three separate images of vasculature. Hoechst, 
and BrdUrd/ldUrd needed to be overlaid and matched. Each gray­
scale image was first thresholded lo separate signal from back­
ground, carried out interactively, from which a binary image was 
made. For practical reasons, thresholding for Experiments 1 (head 
and neck) and 2 (gliomas) was performed by one person (P.F.R.. 
Nijmegen). For the third experiment {extended series of head-and-
neck tumors and gliomas), thresholding was performed by a dif­
ferent person (A.C.B.. Amsterdam). Test images thresholded by 
both people showed little visual difference. Despite this, because 
interobserver difference might have played some role, data for the 
first two experiments and the third experiment were plotted sepa­
rately (see "Results"). Images were then matched pairwise with the 
Image Overlay function (Image-Pro Plus; Media Cybernetics. Sil­
ver Spring. MD). Because the images were all taken from the same 
tumor section (rather than parallel/different sections), adjustments 
were generally small and involved translation rather than rotation. 
Matching was done on external contours and internal features (e.g., 
holes, large blood vessels) and was in almost all cases straightfor­
ward and unambiguous. This procedure positioned the images so 
that they could be merged. Each binary image was then given a 
pseudocolor (blue for Hoechst, red for vessels, green for BrdUrd/ 
IdUrd) and then merged, with the Process/ColorChannel/Merge 
facility within Image-Pro Plus. The merged images were subse­
quently scored in Photoshop (Adobe Systems, San Jose, CA), 
searching for a vessel, scoring Hoechst and BrdUrd/ldUrd posi-
tivity, marking the vessel as scored, and repeating for subsequent 
vessels. 
Fig. 2. Examples of all four possible combinations of iodode-
oxyuridine (S) and Hoechst (H) labeling around individual blood 
vessels. Arrows indicate the appropriate vessel in each panel. 
Magnifications from low-resolution, composite multifield image. 
Statistics 
Linear regression and the Student's Mest (Excel; Microsoft, 
Redmond, WA) were used to check significance of correlations 
between the two parameters of Hoechst-negative and IdUrd-neg-
ative vessels. 
Human tumor scoring 
The preparation of slides of human tumor biopsies, the staining 
for IdUrd and blood vessels, and the scoring of IdUrd-positive 
tumor cells around individual blood vessels was performed as 
described previously (6). 
(^* 
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Fig, 1, Example image of a human glioma xenograft stained for 
blood vessels (red), bromodeoxyuridine (green), and perfusion 
(blue). The large areas of blue represent well-perfused regions, 
whereas the blood vessels at bottom left show no perfusion. 
Vessels positive for both iododeoxyuridine (S) and Hoechst (Η) 
(S + H + ) and negative for both (S —H—) are indicated by the 
arrows. High-resolution, individual-field image. 
RESULTS 
Individual blood vessels in merged images of Hoechst 
(H), Brd/IdUrd (S. for S-phase marker), and vasculature 
were scored for the presence or absence of BrdUrd/ldUrd 
labeling and Hoechst staining. Blood vessels were scored 
positive for BrdUrd/ldUrd when labeling was present within 
a radius of three to four cell layers from the blood vessel. 
They could then be divided into four groups, namely, 
S + H + . S + H - , S - H + . and S - H - , Examples of scoring 
are shown in Figs, 1 and 2, If BrdUrd/ldUrd were a good 
perfusion marker, most blood vessels would be expected to 
be either positive or negative for both markers ( S + H + , 
S - H - ) , A large fraction of mismatches (i,e.. blood vessels 
that are positive for only one marker [S + H - . S - H + j ) 
would not support our hypothesis. 
In the first experiment a protocol standardly used in 
previous studies was used, in which BrdUrd was adminis­
tered 15 min and Hoechst 1 min before the animals were 
killed. Four different xenograft tumors were used, all de­
rived from squamous cell carcinoma of the head and neck. 
Results of the scoring are presented in Table 1, With this 
protocol, a substantial amount of mismatches were seen, 
S + H - mismatches were seen in 17,7% (average over four 
tumors) and S - H + mismatches in 10% of the blood vessels 
(average over four tumors). The 14-min difference in time 
between injection of the two markers could contribute to 
mismatches, if within that time some vessels had opened 
and others closed, resulting in single rather than double 
labeling. We therefore changed the protocol for subsequent 
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Abhrevialions S = bromodeoxyundine (BrdUrd); H 
negative 
Hoechst 3142; + = positive. 
experiments, injecting both BrdUrd and Hoechst at the same 
time, 15 min before killing In addition, some vessels scored 
as S —H+ could have resulted from an absence of tumor 
cells around the vessels, because blood vessels in head-and-
neck tumors are often surrounded by an extensive amount of 
stroma. Despite the mismatches, the total fraction of 
BrdUrd-negative vessels (S-H + , S - H - ) showed a trend 
with the total fraction of Hoechst-negative vessels ( S - H - , 
S + H - ) (Fig. 3, closed symbols; r = 0.87, ρ = 0.13). 
In the second experiment, four different glioma xeno­
grafts were chosen because of their relatively low amount of 
stroma. Scoring results for the four glioma cell lines are 
shown in Table 2. Mismatches were significantly reduced 
compared with the previous experiment (mean of 2-4% for 
both S + H - and S-H + ) There was a trend for higher 
BrdUrd-negative vessels with high Hoechst-negative ves­
sels, although not significant (Fig. 3, open symbols; r = 
0.86, ρ = 0.14). Combining the data from these two exper­
iments showed a significant correlation between the two 
parameters (Fig 3, r = 0.94, ρ < 0 0005). All four gliomas 
were relatively well perfused, with a low fraction of 
Hoechst-negative vessels, compared with the head-and-
neck xenografts 
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% Hoechst-negative vessels 
Fig 3 Correlation between bromodeoxyundine (BrdUrd)-negative 
vessels and Hoechst-negative vessels for four different head-and-
neck xenografts (closed symbols) and four different glioma xeno­
grafts (open symbols) 
more tumor cell lines, both gliomas and head-and-neck 
squamous cell carcinomas, to obtain a larger variation in 
perfusion, using the simultaneous injection protocol In this 
experiment, we also used IdUrd instead of BrdUrd, to allow 
a more direct comparison with our clinical studies in which 
we used IdUrd as the S-phase marker (see below). S-H + 
mismatches were found in 6 9% of vessels (mean value of 
I2 tumors) and S + H in 7 4% (Table 3). Both types of 
mismatches were again smaller than in the first expenment, 
probably owing to the simultaneous administration of the 
two markers. A larger vanation was seen than in the second 
expenment, probably owing to the increased number of 
tumors with varying histologies. To test whether IdUrd 
could replace Hoechst as a perfusion marker, we again 
calculated the total percentage of Hoechst-negative vessels 
(non- or low-perfused vessels) and compared this with the 
fraction of vessels negative for IdUrd. In this senes of 12 
tumors, there was a significant correlation (r = 0.85, ρ = 
0 0004; η = 12; Fig. 4), indicating that IdUrd seems able to 
distinguish between tumors with high- and low-perfused 
fractions. There were also significant correlations for the 
head-and-neck xenografts alone (r = 0.93, ρ = 0 008; η = 
6) and for the glioma xenografts alone (r = 0 86, ρ = 0 03; 
η = 6). 
To further study the feasibility of the technique in hu­
mans, we analyzed a series of tumors from head-and-neck 
cancer patients who were given IdUrd i.v. 12-16 h before a 
biopsy was taken Tumor sections were double-stained for 
blood vessels and IdUrd labeling. Images from individual 
microscope fields were then reconstructed into a mosaic 
representing whole-tumor cross-sections, as described pre­
viously (6). Individual vessels were scored for the presence 
or absence of surrounding IdUrd-labeled tumor cells. As 
with the xenograft studies, the parameter of interest was the 
fraction of IdUrd-negative vessels, a proposed indicator of 
the extent of acute hypoxia. For this study we analyzed 
tumors from 31 patients and combined the results with those 
from 15 tumors previously published (6). A wide variation 
in percentage IdUrd-negative vessels was observed between 
tumors, ranging from < 1 % to >40%, with a median of 19% 
(Fig 5) These data suggest that the fraction of nonperfused 
vessels in human head-and-neck cancer can be considerable 
but also show considerable variability. 
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Table 2 Companson of labeling around individual vessels in glioma xenografts 





































Abbreviations as in Table I 
DISCUSSION 
The use of thymidine analogues (IdUdr/BrdUrd) to mea-
sure perfusion is based on the hypothesis that the labeling of 
tumor cells in the vicinity of a blood vessel depends on the 
perfusion of that particular blood vessel. Blood vessels were 
individually scored under the microscope for the presence 
or absence of IdUrd-labeled tumor cells surrounding them. 
Vessels without labeling are considered nonperfused. We 
showed in a previous study, using a similar protocol, that 
the fraction of IdUrd-negative blood vessels was increased 
or decreased when tumor perfusion was manipulated by 
nicotinamide or hydralazine, respectively In this study, we 
further validated the technique by comparing it with the 
commonly used perfusion marker Hoechst 33342 in a series 
of xenografts having different levels of vascular perfusion. 
The simultaneous use of both markers allowed us not only 
to study the overall correlation of the fractions of vessels 
negative for each marker, but also to study the colocahza-
tion of the markers on a vessel-to-vessel basis. 
The extent of matching between the two probes (thymi-
dine analogues and Hoechst 33342) will be partly influ-
enced by their pharmacologic properties In humans, IdUdr 
has been shown to have a half-life in plasma of <5 mm and 
probably nearer 2 mm (9, 10). This would mean an approx-
imately 90% decrease within approximately 6 mm (3 half-
lives). Hoechst 33342 has a similar plasma half-life of 
approximately 2 min (11). The effective labeling time for 
both these probes is therefore similar and short, and they 
both enter cells rapidly. Any difference in uptake or usage 
might result in different availability of one probe vs the 
other at the end of long vessels, favoring mismatches in one 
direction. However, we found equal amounts of S + H— and 
S - H + mismatches (both 7%). These considerations sup-
port the use of the two probes in the present study 
In the series of xenografts used here, nonperfusion mea-
sured by IdUrd/BrdUrd (i.e., fraction ot vessels negative for 
the analogue) correlated well with nonperfusion measured 
by Hoechst (fraction of vessels negative for Hoechst). We 
therefore conclude that IdUrd/BrdUrd can be used to dis-
tinguish between tumors with high or low fractions of 
nonperfused vessels Despite this correlation, there was not 
always a match of IdUrd/BrdUrd labeling and Hoechst 
staining on a per-vessel basis. There are several possible 
explanations. First, mismatches were higher in the initial 
protocol, in which BrdUrd was administered 15 mm and 
Hoechst 1 min before killing of the animals. Vessels that 
opened or closed during this interval could give rise to 
single instead of double labeling. Changing the protocol to 




























































































Abbrevmtwm SCCNij = squamous carcinoma head and neck (all others = glioma) Other 
abbreviations as m Table 1 
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40 
Fig. 4. Correlation between iododeoxyuridine (IdUrd)-negative 
vessels and Hoccsht-negative vessels for 12 human tumor xeno­
grafts. Closed symbols = head-and-neck tumors; open symbols = 
gliomas. 
simultaneous administration of both markers reduced these 
mismatches but did not completely eliminate them, support­
ing this as a possible cause. Second, diffusion of BrdUrd/ 
IdUrd from neighboring blood vessels could give rise to 
blood vessels positive for BrdUrd/IdUrd and negative for 
Hoechst, because the thymidine analogues diffuse further 
than Hoechst, the latter being rapidly bound to DNA in the 
first cells it reaches. Such mismatches might not be mis­
leading, however, because oxygen might also be supplied 
from surrounding vessels, thus preventing local hypoxia. If 
so, analogue positivity might correctly reflect oxygen status, 
although this needs to be proved. 
Lack of IdUrd labeling in a perfused vessel (Hoechst posi­
tive) could occur if there were no tumor cells in the vicinity of 
the vessels, for instance when blood vessels are surrounded by 
an extensive amount of stroma. With the immunofluorescence 
ledinit|ue used here, without counterstaining. It was impossible 
to evaluate whether tissue surrounding a blood vessel was 
tumor or stroma. In our series of tumor biopsies from patients, 
immunohistochemical staining allowed selection of blood ves­
sels with sufficient surrounding tumor cells, thus reducing this 
artifact. Finally, a lack of IdUrd labeling around a perfused 
vessel could also be caused by lack of proliferating tumor cells 
in the vicinity of that vessel. However, in a previous series of 
human head-and-neck tumors, we scored vessels for the pres­
ence of Ki-67 and found that almost all blood vessels were 
surrounded by Ki-67-positive tumor cells, despite significant 
fractions being IdUrd-negative, showing that a lack of IdUrd is 
unlikely to be due to a lack of proliferating cells. The theoret­
ical possibility that there are proliferating cells but no S-phase 
cells is statistically highly unlikely. We scored tens to hundreds 
of tumor cells around each vessel, and the chance that they 
were all in other phases than S, when the average labeling 
index is approximately 10%, is almost zero. A perfusion lack 
therefore remains the most plausible explanation. 
Our human data set, showing a considerable variation in 
fraction of IdUrd-negative vessels, strengthens the conclusion 
that IdUrd can be used to measure nonperfused vessels in 
human tumors. In this study, IdUrd was injected 12-16 h 
before sampling. Because the half-life of IdUrd in patients is 
on the order of 2 min (9, 10), resulting in a short labeling time, 
the data represent a snapshot at the time of injection. There is 
no reason to believe this mean fraction will change over time, 
although perfusion in individual vessels might change, so 
administration-sampling time should not affect the results. 
Some questions remain unanswered, however. Is perfusion, 
measured by IdUrd or Hoechst, a good indicator of acute 
hypoxia'? Blood vessels that are closed at the time of injection 
can reopen, thus being acutely hypoxic. Alternatively, they 
could remain closed for a longer period after injection of the 
marker, then being more chronically hypoxic. Because we 
have no information regarding how long a blood vessel re­
mains closed, it is difficult to distinguish with the current 
method between nonperfused vessels causing acute hypoxia 
and nonperfused vessels causing chronic hypoxia of a com­
plete tumor chord (in contrast to chronic hypoxia occurring at 
the periphery of perfused chords). So at present we cannot say 
that the IdUrd-negative fraction correlates with the extent of 
acute hypoxia. It is likely that no IdUrd means hypoxia 
(through perfusion lack), but how long this lasts cannot be 
determined with this method. One additional possibility is that 
plasma flow could occur without erythrocyte flow, resulting in 
IdUrd labeling in a somewhat or largely hypoxic area (al­
though plasma can also carry a certain amount of dissolved 
oxygen). This would result in IdUrd labeling underestimating 
hypoxia, but to what extent is unknown. 
A combination of two hypoxia markers separated in time 
would be useful in clarifying this issue, as has been used in 
animal studies (12), although whether this could be applied to 
humans is doubtful. The double-dye method with Hoechst and 
DiOC (3), also successful in animal models for quantifying 
perfusion changes, again cannot be applied to humans. Non-
46 tumors median 18.9% 
0 4 8 12 16 20 24 28 32 36 40 44 
% IdUrd-negative vessels 
Fig. 5. Histogram of percentage iododeoxyuridine {ldUrd)-nega-
tive blood vessels in biopsies from 46 lumors of the head and neck 
taken directly from patients 12-16 h after iododeoxyuridine ad­
ministration. Data from 15 tumors have been published previ­
ously (6). 
74 
invasive ways to measure perfusion in human tumors have 
been described including the use of dynamic contrast MRI 
blood oxygen level-dependent (BOLD) MRI, and perfusion 
CT (13-16) However, these will measure total perfusion, not 
perfusion on a microlevel and not the fraction of perfused 
vessels as measured here Such techniques, though useful, are 
therefore less likely to quantitatively reflect the level of acute 
hypoxia 
Whether perfusion variations play an important role in 
determining therapy response is another remaining ques 
lion which can only be answered in a large clinical trial We 
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Abstract. The aim of this study was to assess the safety 
and biodistribution of technetium-99m BRU 59-21, a 
novel radioactively labelled 2-nitro-imidazole hypoxic 
marker, in head and neck cancer patients and to correlate 
uptake with pimomdazole staining. "'"Tc-BRU 59-21 
was administered intravenously (mean dose 824 MBq, 
range 780-857 MBq) to ten head and neck cancer pa­
tients scheduled for primary surgery, and whole-body 
images and SPET scans were then obtained. Uptake of 
radioactivity in the regions of interest was determined 
and tumour to normal tissue ratios were calculated after 
correlative evaluation with MRI/CT. Twelve to 16 h be­
fore surgery (up to 2 weeks after the scan), patients re­
ceived pimomdazole intravenously. Tumour sections 
were stained immunohistochemically for pimomdazole 
binding. No serious adverse events were reported. In five 
patients there were ten adverse events, which were mild 
in intensity and resolved completely without interven­
tion. Uptake of 9 9 mTc-BRU 59-21 was observed in eight 
of the ten primary tumours. Tumour to normal tissue ra­
tios on the SPET scans for primary tumour and lymph 
nodes increased from 1.8 (range 0.9-2 7) to 2.1 (range 
0.8-3.7) between 30 mm and 3 h post injection. Tumour 
to normal tissue ratios in the primary tumour were sig­
nificantly correlated with pimomdazole staining for 
SPET scans performed 30 mm and 3 h post injection 
(ZMXOló and P=0.037, respectively). When primary tu-
mour and involved lymph nodes were considered in con-
junction, correlation between the tumour to normal tissue 
ratio and pimonidazole staining was observed for early 
Kann M G Haustermans ( S ) 
Department of Experimental Therapy, 
Nelherlands Cancer Institute, Plesmanlaan 121, 1066 CX, 
Amsterdam, The Nelherlands 
e-mail Kann Hauslermans@uz kuleuven ac.be 
Tel +32-16-346900, Fax +32-16-346901 
(P<0.001) but not for late SPET scans (P=0.076). How-
ever, late scans showed better tumour delineation than 
early scans. Administration of 99mTc-BRU 59-21 in head 
and neck cancer patients appears to be safe and feasible 
Uptake and retention in tumour tissue was observed, 
suggestive of tumour hypoxia, and this was supported by 
correlations with staining for the hypoxic marker pi-
momdazole. 
Keywords' Head and neck cancer - Hypoxia - Pimomd-
azole - SPET 
Eur J Nucl Med (2002) 29:1206-1211 
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Introduction 
Tumour hypoxia is an important negative prognostic fac-
tor for outcome after treatment of malignant tumours by 
both radiotherapy and surgery [1, 2, 3, 4, 5]. If a reliable 
and easily applicable method to measure tumour hypoxia 
before treatment were available, patients could be select-
ed for additional treatment aimed at modifying or ex-
ploiting hypoxia. 
Tumour oxygenation is frequently measured with an 
Eppendorf electrode This is an invasive procedure, lim-
iting its application in clinical practice. Measuring tu-
mour hypoxia by non-invasive methods includes the use 
of bioreductive markers, such as the 2-nitro-imidazole 
derivatives. Clinically approved hypoxic markers include 
pimomdazole [6] and EF5 [7] and can be visualised by 
immunohistochemical staining in tissue sections. In a 
previous study, we have shown that pimomdazole stain-




9 9 mTc-BRU 59-21, a novel 2-nitro-iniidazole agent, 
has been shown to selectively localise in tissues with a 
low oxygen concentration due to tschaemia [9, 10], in 
tumour cells incubated under hypoxic conditions and 
following intravenous injection in animal models repre­
sentative of poorly perfused tumours [11]. Preliminary 
results from a phase I study indicated that 9 9 mTc-BRU 
59-21 has an acceptable safety profile in healthy volun­
teers [unpublished data from Bracco Research]. Given 
the selective uptake of 9 9 mTc-BRU 59-21 in hypoxic tis­
sues and the non-invasive method of assessment by ex­
ternal nuclear scanning, 9 9 mTc-BRU 59-21 could be an 
attractive agent for determination of the oxygen status 
of malignant tumours in vivo. The objective of this 
phase I study was therefore to assess the safety and bio-
distribution of 9 9 mTc-BRU 59-21 in head and neck can­
cer patients and to correlate uptake of the agent in vivo 
with staining by pimonidazole, a recognised hypoxic 
marker. 
Materials and methods 
This was a single-centre phase I sludy, approved by the ethics 
committee ot the Netherlands Cancer Institute It involved ten pa­
tients with primary squamous cell carcinoma of the head and neck, 
classified as stage T2-4NxM0 according to the TNM system [12] 
and scheduled for primary surgery After written informed consent 
had been obtained, a single intravenous (ι ν ) injection of 
, , mTc-BRU 59-21 was administered and imaging was performed 
in order to study the biodistribution of the agent Safety was moni­
tored by pre- and post-dose evaluation by means of medical histo­
ry, clinical examination, laboratory evaluations and ECG Before 
surgery (performed within 2 weeks after the scans), pimonidazole 
was administered by ι ν infusion After resection, tumour sections 
were made for immunohistochemical staining Three female pa­
tients and seven males were included. The mean age of patients at 
the time of scintigraphy was 63 years (range 51-78) Further pa­
tient data are given in Table I. 
The ""Tc-BRU 59-21 used in this study was prepared using a 
kit containing two vials [13]. Reconstitution of vial A, containing 
2 mg BRU59-21, the 2-nitro-imidazole derivative, was performed 
by adding 9ymTc-pertechnetate solution and saline Vial B, contain­
ing penletate pentasodium and stannous chloride, was reconstitut­
ed with saline to form stannous penletate solution. The stannous 
pentetate solution of vial Β was added to vial A to form " " T c 
BRU 59-21 Before administration, the radiochemical purity 
(RCP) of the agent was calculated using a combined high-perfor­
mance liquid chromatography (HPLC) and paper-liquid chroma­
tography method for each patient The RCP obtained in all ten in­
jected patients had a mean value of 93 5% (range 90 5%-95 5%), 
well above the required 90% level A mean dose of 824 MBq 
(range 780-857 MBq) was administered ι ν 
Planar and single-photon emission tomography (SPET) images 
were obtained over a 3- to 4-h period following intravenous injec­
tion At 30 mm and 3-3.5 h post-injection, SPFT images were ob­
tained. Whole-body planar images were obtained at 1, 2 and 3 h 
post injection 
The presence of localised "'"Tc-BRU 59-21 radioactivity on 
the dynamic, SPET and static nuclear images was determined by 
visual analysis and analysis of regions of interest (ROIs) on the 
SPET images ROIs included the primary tumour, clinically in­
volved lymph nodes (>l cm) and normal tissue (deep neck muscu­
lature with low-intensity uptake) For each ROl, the number of 
pixels, the number of counts and the counts/pixel were calculated 
The data were expressed as counts/pixel in (he ROl, and as the ra­
tio between counts/pixel in tumour and normal tissue 
Twelve to 16 h before surgery, 0 5 mg/m: pimonidazole (Hyp-
oxyprobe-1; Natural Pharmacia Inlemalional, Belmont USA) was 
administered by ι ν infusion After surgery, sections from primary 
tumour and/or lymph node metastases were obtained from the De­
partment of Pathology and stained with a biotinylated antibody 
against pimomda/ole (kindly supplied by Dr J A Raleigh, Uni­
versity of North Carolina, Chapel Hill, USA), according lo our 
previously reported protocol [8] Image analysis was done on digi­
tal microscopic images using image analysis software (IPLab 2 5 
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SPECT imaging of hypoxia 
Fig. 1. Anterior " T c - B R U 59-21 planar images displayed with 
dual intensity showing a normal distribution of the tracer (A) and 
abnormal myocardial uptake (arrow on B) 
and SCIL-Image); pimonida^ole-positive areas were measured by 
thresholding on the pimonidazole stain in the total tissue section. 
To test for correlations between the uptake of ""'Tc-BRU 
59-21 in the tumour and pimonida/ole staining on tumour sec­
tions, linear regression analysis was performed. 
Results 
No serious adverse events were reported during the study 
period. In five of the ten patients a total of ten adverse 
events were reported. Side-effects were of mild intensity, 
and patients recovered completely without medical inter­
vention. Effects included: pain at the primary tumour site 
and pain in the ear, dizziness, metal taste, dry mouth, er­
ythema on the wrist and headache, all of which occurred 
after injection. The other three adverse events occurred 
in one patient and included an increase in white blood 
count and creatinine and a decrease in haemoglobin. On 
re-testing, laboratory results improved and the patient re­
covered without any sequelae. Four of these adverse 
events were assessed as possibly causally related, two as 
being of unknown cause and four as unrelated. 
After injection of 9 9 mTc-BRU 59-21, whole-body im­
ages showed activity in the liver, gallbladder, intestines 
and urinary bladder. Unexpected cardiac uptake was seen 
in four patients, presumably due to subclinical cardiac 
disease (Fig. 1). Early SPET showed activity in the sali­
vary glands, in the anterior part of the oral cavity (proba­
bly saliva), at the site of the soft palate and in the thy­
roid. 
In three patients, the nuclear scan was visually as­
sessed as negative at the primary tumour site. However, 
in one of those patients (no. 102) the tumour to normal 
tissue ratio was greater than I. In the remaining seven 
patients, uptake at the primary site was observed 
(Figs. 2, 3, 4). In all patients, tumour was better delineat­
ed on the late SPET scans. On static whole-body images. 
Fig. 2. A CT scan showing a 
T4 laryngeal carcinoma {ar­
row). Early (B) and late (C) 
transaxial "mTc-BRU 59-21 
SPET images show intense up­
take at the tumour site 
Fig. 3. A Coronal MR1 STIR 
sequence showing a T3 oropha­
ryngeal carcinoma {arrow). 
Β Early coronal WmTc-BRU 
59-21 SPET showing slightly 
increased uptake at the tumour 
site. By contrast, late coronal 
'»mTc-BRU 59-21 SPET (C) 
shows more intense tumour up­
take 
Chapter 6 
Fig. 4. Λ Transaxial MRI 
showing a T2 tumour in the 
right side of the tongue (ar­
row). Tumour uptake of ""'Tc-
BRU 59-21, not observed on 
early transaxial SPET (Β), is 
intense on late SPET (C) 
Fig. 5. Relationship between 
pimonidazole staining and 
9,imTc-BRU 59-21 uptake in tu­
mour, represented as the tu­
mour to normal tissue ratio of 
counts/pixel. In the left-hand 
panels, data for the primary tu­
mour and lymph nodes are 
shown, and in the right-hand 
panels, data for primary tumour 
only. The upper two panels 
show data for the early SPET 
scans (0.5 h) while the lower 
two panels show data for the 
late SPET scans (3 h). In each 
panel the correlation coefficent 
(r) and the level of significance 
(P value) are indicated 
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the primary tumour could not be identified in any of the 
patients. 
In three patients, four clinically involved lymph nodes 
were present. Only two of these showed increased up­
take on the SPET scan. In one patient, a 2-cm neck node 
showed no increased uptake, while the other patient had 
a I-cm neck node only, which was too small for detec­
tion by SPET. The tumour to normal tissue ratios for pri­
mary tumour and lymph nodes on the SPET scans in­
creased from 1.8 (range 0.9-2.7) for the early scan to 2.1 
(range 0.8-3.7) for the late scan (Table 2). 
No adverse events were reported after pimonidazole 
infusion. Pimonidazole positive staining in the histologi­
cal tumour sections was observed in all ten primary tu­
mours and seven tumour-positive lymph nodes (Table 2). 
Correlations between SPET scan data and the pi-
monidazole-positive fraction are presented graphically in 
Fig. 5. For the early (30 min) SPET scans, considering 
either primary tumour alone or primary tumour in con­
junction with lymph nodes, there were statistically sig­
nificant correlations between the tumour to normal tissue 
ratio for counts/pixel and the pimonidazole fraction (up­
per 2 panels, with »=0.73, P=0.016 and A-0.86, PO.OOl, 
respectively). The same trends were seen with the 3-h 
SPET scan data (lower 2 panels), although only data for 
primary tumour (r=0.67, /3=0.037) showed a significant 
correlation with the pimonidazole-positive fraction. 
Discussion 
Nuclear imaging with intravenously administered ""'Tc-
BRU 59-21 appeared to be safe and feasible, without sig­
nificant adverse effects. The reported events were similar 
to results from a volunteer study [unpublished data from 
Bracco Research]. No adverse events were reported for 
pimonidazole at the dose level used. Uptake on the SPET 
scan was observed in eight of ten primary tumours; the 
X2 
SPECT imaging of hypoxia 







































































































































PT, Primary tumour, LN, lymph node 
uptake was especially evident on the 3-h scan, since the 
delineation of tumour from normal tissue was facilitated 
by decreased background activity. 
To our knowledge, this is the first comparison of tu­
mour hypoxia in cancer patients using in vivo uptake of 
a radioactively labelled 2-nitro-imidazole and immuno-
histochemical staining on tumour sections with a similar 
2-nitro-imidazole bioreductive marker. There are inher­
ent problems in comparing the two methods (external 
scanning and immunohistochemistry). One is an intensi­
ty measurement of radioactivity (SPET) while the other 
is an area measurement (pimomdazole staining). The ef­
fective volume being measured is also different: slice 
thickness is 5 mm for SPET and only 5 μιη for tissue 
sections. In addition, the immunohistochemistry results 
are obtained from only a small fraction of the total tu­
mour. Whether pimonidazole staining data on small ar­
eas is representative for the whole tumour is the subject 
of ongoing study. 
To improve results in future studies with 99mTc-BRU 
59-21, image fusion between SPET data and MRI/CT 
scan [14] should be considered in order to locate tu­
mours on the SPET scan more accurately. In addition, 
the optimum interval between administration and SPET 
scanning must be determined. Scans at least 3 h after in­
jection appear to be necessary in order to obtain better 
tumour delineation and decreased non-specific back­
ground activity. Future studies using 99mTc-BRU 59-21 
should include a larger number of patients to determine 
its prognostic value by correlating uptake with treatment 
outcome. 
In conclusion, in vivo evaluation of tumour hypoxia 
with 99mTc-BRU 59-21 appears to be safe and feasible. 
Uptake and retention in tumour tissue can be assessed 
with SPET, and the observed correlations with pimomd­
azole staining indicate that it has promise as a method to 
assess tumour hypoxia. 
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Resistance of hypoxic cells to ionizing radiation is 
determined by homologous recombination 
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Role of DNA repair in hypoxic radiäres is tance 
R E S I S T A N C E O F H Y P O X I C C E L L S T O IONIZING RADIATION IS 
I N F L U E N C E D BY H O M O L O G O U S R E C O M B I N A T I O N S T A T U S 
DEBBIE SPRONG, M Sc , HILDE L. JANSSEN, M.D., CONCHITA VENS, PH D , AND ADRIAN C. BEGG, PH D 
Division of Experimental Therapy The Netherlands Cancer Institute Amsterdam The Netherlands 
Purpose: To determine the role of DNA repair in hypoxic radioresistance. 
Methods and Materials: Chinese hamster cell lines with mutations in homologous recombination (XRCC2, 
XRCC3, BRAC2, RAD51C) or nonhomologous end-joining (DNA-PKcs) genes were irradiated under normoxic 
(20% oxygen) and hypoxic (<0.1 % oxygen) conditions, and the oxygen enhancement ratio (OER) was calculated. 
In addition, Fanconi anemia fibroblasts (complementation groups C and G) were compared with fibroblasts from 
nonsyndrome patients. RAD51 foci were studied using immunofluorescence. 
Results: All hamster cell lines deficient in homologous recombination showed a decrease in OER (1.5-2.0 vs. 2.6-3.0 
for wild-types). In contrast, the OER for the DNA-PKcs-deficient line was comparable to wild-type controls. The (wo 
Fanconi anemia cell strains also showed a signiheant reduction in OER. The OER for RAD51 foci formation at late 
times after irradiation was considerably lower than that for survival in wild-type cells. 
Conclusion: Homologous recombination plays an important role in determining hypoxic cell radiosensitivity. 
Lower OLRs have also been reported in cells deficient in XPF and ERCC1, which, similar to homologous 
recombination genes, are known to play a role in cross-link repair. Because Fanconi anemia cells are also 
sensitive to cross-linking agents, this strengthens the notion that the capacity to repair cross-links determines 
hypoxic radiosensitivity. © 2006 Elsevier Inc. 
Hypoxia, Radiosensitivity, DNA repair. Homologous recombination. Foci. 
INTRODUCTION 
The degree of hypoxia in tumors has been shown to be a 
negative prognostic indicator in a variety of cancers, par 
licularly when the modality is radiotherapy, but also for 
other modalilies (1-6) For radiotherapy, one obvious con 
tnbuting factor is that hypoxic cells are up to threefold more 
resistant to ionizing radiation than cells irradiated under 
well oxygenated conditions This phenomenon has stimu-
lated considerable effort for several decades to find ways to 
sensitize hypoxic cells specifically to ionizing radiation (7, 8) 
or to develop drugs specifically toxic to hypoxic cells (9) 
These have led to improvements in responses in some 
clinical trials (10 II), confirming the importance of hy-
poxic cells in delermimng treatment outcome, and in partic-
ular, the importance of radioresistance The present hypoxic 
radiosensitizers and hypoxic cytotoxins have associated toxic-
ity and arc not optimal in terms of efficacy (9, 12) The 
search for better methods to attack the hypoxia problem is 
theretorc an important ongoing endeavor 
To design better interventions to overcome hypoxic radio-
Repnnl requests to Adrian C Begg, Ph D Division ot Exper-
imental Therapy The Netherlands Cancer Instilute Plcsmanlaan 
121 Amsterdam 1066 CX The Netherlands Tel ( + 11)20512-
20% Fax ( + 11)20 512 2050 Email abegg@nkinl 
Partly funded by Dutch Cancer Society Grant ΝΚΙ 2000-2202 
H L Janssen is currently at the Department of Radiation On­
cology University Hospital Gasthuisberg l-euven Belgium 
resistance, an understanding of the mechanism ot resistance is 
important Radiochemical mechanisms determining resistance 
have been known for many years to play an important role In 
brief and simplistically, under normoxic conditions, oxygen is 
capable ot reacting with electrons ejected from macromole 
cules by the irradiating photons (ionizations), preventing return 
and recombination on the ionized macromolecule—essentially 
fixing the damage radiochemically Hydrogen donation by 
thiols, particularly glutathione, can "repair' lesions, but such 
thiols compete inefficiently with the counteracting effects of 
oxygen (13-16) The lack of oxygen in hypoxic cells results in 
a greater probability of radiochemical restitution or "repair," 
and thus less induced damage The time scale of this process is 
in milliseconds (17) More recent evidence, however, has sug 
gested that biochemical, as well as radiochemical, mechanisms 
may be affecting the radioresistance of hypoxic cells 
In addition to the more numerous DNA base damages, 
DNA single-strand breaks and DNA double-strand breaks, 
ionizing radiation also induces DNA-protem cross-links 
(18) and DNA-interstrand cross links (19, 20) DNA-protein 
Atknonledgminls—We are grateful for the gift ot FA cell lines 
trom Dr H Joenje Free University Amsterdam and for his 
helpful comments We also thank Ins Groeneveld for helping in 
the initial experiments to set up the hypoxic irradiation system 
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cross-links are one of the few lesions that have been shown 
to be formed in greater numbers under hypoxic than under 
normoxic irradiation conditions (18) Murray and col­
leagues (21, 22) showed a correlation between hypoxic 
radioresistance and the sensitivity of the cells to DNA 
interstrand cross-linking agents in a series of hamster mu­
tant cell lines The implication is that the ability to repair 
cross-links is important for radioresistance under hypoxia 
but less so for normoxic irradiation, because fewer cross­
links are formed The repair of such cross-links takes hours 
rather than fractions of 1 second 
Many aspects of repair pathways involved in removal of 
interstrand cross-links are now known These involve some, 
but not all, proteins central to nucleotide excision repair 
(NER), namely ERCC1 and XPF (23-25) These proteins 
form a dimer, stimulating activity capable of incising DNA 
during NER, 5' of a lesion such as a bulky adduci or 
thymine dimer (26, 27) Cells mutated or lacking either of 
these two genes are highly sensitive to interstrand cross-
linking agents (25, 28, 29) Murray and colleagues (21, 22) 
exclusively studied mutants on the NER pathway In addi 
lion however, homologous recombination (HR) appears lo 
play a central role in cross-link repair because cells lacking 
one of several genes central to HR also exhibit considerably 
enhanced sensitivity to cross-linking agents (23 25 30 31) 
Given the link between cross-link repair and hypoxic 
resistance, we studied a potential role for HR in determining 
hypoxia radioresistance We investigated not only well 
studied hamster mutants but also human fibroblasts, includ­
ing strains from Fanconi anemia (FA) patients known to be 
hypersensitive to cross-linking agents (Miltenyi Biotech 
GmbH, Cologne Germany) to show the relevance of the 
results to humans 
METHODS AND MATERIALS 
Cell lines 
Chinese hamsier mutarli cell lines were provided by Μ Ζ Zdi 
emcka and Β Godthelp (Leiden University Medical Center Lei 
din The Netherlands) These included the wild type lines CHO 9 
AA8 V79 andV79B the HR deficient lines irslSF (XRCC1) irsi 
(XRCC2) CL V4B (RADSIC) and V C8 (BRCA2) and the non 
homologous end joining (NHEJ) deficienl line XR CI (DNA PKcs) 
In addition theCL-V4B RADSIC line was used being the RAD") I 
deficient CL V4B line complemenled with full length RAD51 
cDNA (also obtained from Μ Ζ Zdienicka and Β Godthelp) The 
irslSF line was originally made by R Β Painler (University of 
California San Francisco CA) and irsi by J Thacker (MRC 
Radiobiology Unit Harwell UK) All cell lines were grown and 
passaged under standard conditions at 370C wilh SÇf carbon 
dioxide with Ham FIO medium and 10% felal calf seium 
Human fibroblasts were grown under the same conditions Wild 
type cells were obtained as cell strains derived in our laboratory 
from skin biopsies from cancer palienls (HF^O) or as oulgrowih 
from a squamous cancer biopsy Irom a head and neck tumor 
(HF291) In the latter case hbroblasis were isolated using mag 
netic beads coupled lo a fibroblasi specific anlibody (relerence) 
leaving a pure diploid libroblasl population The BJ cell line 
was the gilt of Roderick Beijersbergcn (our institule) and is an 
hTERT transformed normal human fibroblasi cell line The FA 
complemenlalion groups C and G cell strains were provided by 
H Joenje (Free University Amsterdam The Netherlands) The 
Fanconi cells were cultured under Y/r oxygen and one passage 
before Ihe experiments cultured under ambient oxygen level as 
was done tor the wild type cells 
Irradiation 
Irradiation was performed using a Panlax X ray sel operating al 
l^O kV and 12 m A and a 0 6 mm copper filler For hypoxic 
irradiation an hypoxic chamber was used (BBL GasPak Anaerobic 
System Becton Dickinson San Diego CA) This consisted of a 
cylindrical chamber wiih a sealable lid (2 S L 23 cm tall 12 cm 
diameler) in which a stack of up lo eight tissue culture Petri dishes 
(9 cm diameler) was placed For all experiments glass dishes were 
used to avoid Ihe problem of oxygen dissolved in plastic which 
could reduce ihe degree of hypoxia For hypoxia induction cells 
were cultured in 5 mL instead of the usual 10 mL to reduce the 
time to eliminate oxygen from Ihe medium In addition 25 mM 
4 (2 hydroxyelhyl) 1 piperazineelhanesulfonic acid was added to 
the culture media to reduce pH fluctuations After irradiation the 
culture medium was broughl back to ihe normal volume Hypoxia 
was created by a chemical reaclion in which hydrogen generated 
from a sodium borohydnde tablet after the addition of waier 
combined in ihe presence of (he palladium catalyst with Ihe oxy 
gen in the jar lo form waler A color indicator strip (Anaerotest 
Merck Whitehouse Station NJ) showed that hypoxia developmem 
usually occurred approximately ΑΊ mm afler initialing Ihe chem 
ical reaction The cells were kepi m ihe chamber for a total of 3 h 
lo ensure full hypoxia It was not possible to make independent 
measurements of the extent of hypoxia with this system However 
a reproducible oxygen enhancemem raiio (OER) for wild type 
hamster cells of around 2 5-2 8 (see Results ) showed that ra 
diobiologic hypoxia was routinely achieved indicating oxygen 
levels of < 0 \c/c During the induction of hypoxia Ihe chamber 
housing ihe dishes containing the cells was kept in a 370C incu 
balor Afler 3 h the chamber was taken lo the X ray set and Ihe 
stack of plates irradiated vemcally from above Each dish was 
approximately 2 cm tall giving a stack of approximately 16 cm 
The dislance Irom the X ray source to the bottom dish was 50 cm 
so that the dose varied by a facior of aboul 1 9 with the lop dish 
gelling ihe highesi dose because of closer proximity to the source 
A dose-response curve could thus be generated with one irradia 
lion exposure Cells irradiated in air were also incubated for 1 h 
under hypoxia bul were reoxygenated jusi belore irradiation 
Cell sun η al 
Cell survival was assessed by colony formation For the hamster 
cells a forward assay was performed m which cells were pl.iled 
the day before hypoxic Irealmem and irradiation and incubated for 
1 week for colony formation before staining with a solution of 
crystal violet For the human fibroblasts a reverse (delayed 
plating) assay was used because these cells were more sensitive lo 
Irypsini/alion and lake more time lo recover and begin growth 
Cells were therefore treated 2-3 days after plating when in mid 
log phase Afler normoxic or hypoxic irradialion cells were re 
turned to a 37^C mcubalor lor 16 h belore Irypsimzing plalmg 
and incubating lor 2 weeks for colony formation Colonies were 
counted manually under an inverted microscope Plalmg etficien 
cics were calculated as colonies per plaled cell and surviving 
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fractions as ratios of plating efficiencies for irradiated and unirra­
diated cells. The standard definition of a colony as one containing 
>50 cells was used throughout. 
Cell kinetics 
To assess the effects of hypoxia and irradiation on the cell cycle, 
cells were grown on glass coverslips and placed in the glass dishes 
routinely used for the hypoxia experiments. Each dish contained 
several coverslips. Dishes were then made hypoxic, irradiated, 
reoxygenated, and returned to the incubator. At varying limes after 
irradiation, one coverslip was removed, placed in a second dish, 
and incubated for 15 min with 1 μΜ bromodeoxyuridine, followed 
by washing in phosphate-buffered saline (PBS) and fixing in cold 
70% ethanol. Control groups included hypoxia alone, irradiation 
alone, and no hypoxia or irradiation. 
For immunofluorescence staining, cells were pretreaied with 0.1 
mg/mL pepsin in 0.IN HCl for 5 min at 37°C, washed with PBS, 
followed by 5 min in 2N HO at 370C to denature the DNA. The cells 
were washed thoroughly with PBS before adding antibody. The 
primary antibody, mouse anti-bromodeoxyuridine (clone Bu20a, 
Dako, Glostrup, Denmark), was used in a 1:100 dilution. After a 
30-min incubation at room temperature, the cells were washed with 
PBS, and the fluorescein isothiocyanate-conjugated secondary anti­
body, goat anti-mouse (Sigma Chemical, St. Louis, MO), was added 
in a 1:100 dilution. Incubation of the secondary antibody was per­
formed in the dark for 30 min at room temperature. Primary and 
secondary antibodies were diluted in PBS with 1% bovine serum 
albumin and 0.5% Tween-20. After the last antibody labeling step, the 
cells were countcrstaincd with 1 μg/mL 4'-6' diamidino-2-phenylin-
dole in PBS for 15 min und mounted in Vectashicld mounting 
medium (Vector Laboratories, Burlingame, CA) on a microscope 
slide. The percentage of S-phase cells was measured by counting the 
labeled cells under a fluorescence microscope. More than 2(X) cells 
were counted per time point/treatment. 
Foci formation 
Foci formation alter irradiation was investigated using an anli-
Rud5l antibody (H-92. Santa Cruz Biotechnology, Santa Cruz. CA). 
Cells were grown on coverslips and treated as described above. At 
varying times after irradiation, one coverslip was removed and fixed 
in 4% paraformaldehyde for 15 min. The fixed cells were washed 3 
times with PBS, permeabilized for 15 min in 0.2% Triton X-100, 
followed by 10 min in 50 mM glycine in PBS. After blocking with 
0.5% bovine scrum albumin in 0.1% glycine/PBS for 30 min. the 
primary antibody was added in a 1:50 dilution. The cells were incu­
bated for 2 hours, washed in PBS/0.1 % Tween-20, and incubated for 
2 h in the dark with the fluorescein isothiocyanale-conjugaled sec­
ondary antibody, donkey anti-rabbit (Jackson ImmunoResearch, West 
Grove, PA) at a 1:100 dilution. 
Cells were countcrstaincd with 1 μg/mL 4'-6, diamidino-2-phe-
nylindole in PBS for 15 min and mounted in Vectashield mounting 
medium (Vector Laboratories) on a microscope slide. Scoring was 
performed under a fluorescence microscope using a 100X ob­
jective. More than 150 cells per time point were counted. 
R E S U L T S 
Hamster mutant cells 
Cell survival after irradiation under normoxic and hy­
poxic conditions was determined for four different HR 
deficient cell lines and compared with their corresponding 
wild-type counterparts. In each experiment, mutant cells 
were irradiated in the same chamber as the wild-type cells, 
and each experiment was repeated three times. A similar 
procedure was used for the NHEJ -deficient cell line XRC-1 
and its wild-type parent CHO-9. All cell lines showed 
increased radioresistance when irradiated under hypoxic 
conditions. The difference in dose to give the same cell kill 
under normoxic and hypoxic conditions (OER) varied be­
tween 2.5 and 3.2 for the wild-type cell lines. 
The XRCC3-deficient cell line (irslSF) was more sensi­
tive to ionizing irradiation under normoxic conditions 
than was its wild-type AA8, consistent with previous 
reports (Fig I a). This was also true for hypoxic irradiation, 
to such an extent that the survival of the HR-deficient cell 
line under hypoxia was less than the survival of the wild-
type cells irradiated under normoxia. The doses required to 
attain a given level of survival were calculated from poly­
nomial curve fits through the data for each irradiation con­
dition for each of the three experiments. The OERs were 
then calculated per experiment, and the mean and standard 
deviation for the three experiments per cell line were cal­
culated. The OER of i rs lSF varied between 1.9 and 2.0 
compared with the wild-type AA8, which varied between 
2.5 and 3.1 (Fig. lb). In contrast, the NHEJ-deficient cell 
line, XR-C1, which was also more sensitive to ionizing 
irradiation than the wild-type cells (Fig 1c). showed no 
decrease in the OER, remaining around 2.6-2.7 (Fig. Id). 
To study the involvement of HR in hypoxic radioresis­
tance further, we studied three more mutant cell lines with 
different deficiencies in HR genes and compared these with 
their parental cell lines. All three lines showed results com­
parable to that of the XRCC3 mutant (i.e., all mutants were 
more sensitive to irradiation under both normoxic and hy­
poxic conditions; Fig. 2). The calculated OERs were also 
lower than those for the wild-type cells for all three cell 
lines. The OER for the wild-type V79 was around 2.5 and 
for V79B, varied between 2.5 and 3. The OER for the 
XRCC2-, BRCA2-, and RADSlC-dcficicnt lines was 1.5-
1.8, 1.6, and 1.2-1.5, respectively. To visualize the differ­
ences in OER more clearly, the mean values for all nine cell 
lines are shown in Fig. 3. All HR-deficient lines showed 
lower OERs than all wild-type lines and lower OERs than 
the NHEJ-deficient cell line. The increase in radiosensitiv-
ity, under normoxic conditions, of i r s lSF compared with its 
wild-type (Fig. 1) was greater than for the other three 
HR-deficient lines (Fig. 2). The reason for this is unknown. 
However, the differences in OER appeared to be indepen­
dent of these different effects on normoxic radiosensitivity. 
Because the mutant lines were created by chemical mu­
tagen treatment, it is possible that unknown genetic alter­
ations could have been responsible for the reduced OERs, 
other than the known dysfunctional gene for HR. Although 
a similar genetic change is unlikely to have occurred in all 
four mutant lines, we attempted to exclude this possibility 
formally. We therefore compared one of the cell lines, the 
RAD51C-deficient CL-V4B, with its complemented coun­








Fig 1 Riidiosensmvity and oxygen enhancement ratio of wild-type and mutant Chinese hamster cells (a,b) Irslsf 
(XRCC3 dehcient) with corresponding wild-type (AA8) (cd) XR-C1 (DNA-PKcs deficient) with corresponding 
wild-type (CHO-9) (a.c) Survival curves determined by colony formation Closed symbols indicate normoxic irradi­
ations, open symbols, hypoxic irradiations, circles, wild-type, and tnangles. mutant (b.d) Oxygen enhancement ratios 
derived from these data at different survival levels. Closed symbols indicate wild-type: open symbols, mutant Oxygen 
enhancement ratio for homologous recombination mutant irslSF is less than wild-type (b). and that lor nonhomologous 
end-joining mutant XR-C1 remains unchanged compared with us wild-type (d) Three separate expenments shown (a.c, 
individual points, b.d. means) Errors are standard deviation 
V79B cells that had never undergone genetic or chemical 
alterations. Replacing the defective RAD51C gene resulted 
in increased radioresistance under normoxic and hypoxic 
conditions compared with the noncomplemented CL-V4B 
line (Fig. 4), such that the data for the complemented line 
(CL-C) were indistinguishable from those for wild-type V79B 
cells (Fig. 4) These dam strongly support the idea that the 
changes observed in OER were dependent on HR status 
Human cells 
To determine whether the effects on hypoxic radioresis­
tance could be observed in human cells, we studied several 
human wild-type fibroblasts and compared these with two FA 
cell strains, with deficiencies in complementation groups C and 
G, respectively Such cells are known to be sensitive to 
cross-linking agents, such as the hamster cells described 
above. As with the hamster cell lines, we looked at cell 
survival after normoxic and hypoxic irradiation and com­
pared the OERs. 
The FA cells showed no significant increase in radiosen-
sitivity compared with the wild-type cell lines under normoxic 
conditions, in contrast to the hamster mutant cells, although 
significant variation was observed in the radiosensitivity be­
tween the different non-FA cell lines This variation was 
greater after hypoxic irradiation, but it was still clear that the 
FA cells were more sensitive after irradiation under hypoxic 
conditions than were the wild-type cells (Fig. 5a). 
The calculated OERs for the wild-type lines varied be­
tween 1 8 and 2.2, and the OER for the FA cells was around 
1 4-1.5 (Fig. 5b). For the human, as for the hamster, cells, 
a significant difference in OER was found for the HR-
dehcient cells compared with the wild-type cells, although 
the OERs for the human fibroblasts were, in general, lower 
than those for the hamster cells. The OERs for all hamster 
and human lines are summarized in Table 1. All mutant 
cells showed lower OERs than their corresponding wild-
types. 
Damage-indue ed foc ι formation 
To examine further the role of HR in hypoxic radioresis­
tance, the induction of RAD51 focus formation in wild-type 
hamster AA8 cells after normoxic and hypoxic irradiation 
was investigated For these studies, cells were fixed at 
various points after hypoxic and normoxic irradiation and 
stained for RAD51, and the experiment was repealed three 
times. Four doses were given under each oxygenation con-
dmon, with the mean dose two times greater under hypoxia 
The range of doses allowed a companson at an equal dose 
or equal survival levels. 
The number of foci per positive cell (Fig 6a,b) peaked at 
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Fig 2 Radiosensilivity and oxygen enhancement ratio of three more homologous recombination mutant lines and their 
wild-type counterparts (a,d) irsi (XRCC2 deficient) and V79B, (b.e) CL-V4B (RAD51C deficient) and V79B: (c,f) 
V-C8 (BRCA2 deficient) and V79 All three homologous recombination-mutants had lower oxygen enhancement ratios 
than their corresponding wild-types Symbols as in Fig 1 
1 h, the earliest point studied, and increased with dose for 
both normoxic and hypoxic cells A slower decline appeared 
to occur thereafter for the hypoxic cells, with more foci 
remaining at the late points The percentage of RAD51-
posttive cells showed a broadly similar pattern, being low 
before irradiation (around 4%), peaking at 1 h after nor­
moxic irradiation, and decreasing progressively with lime 
up to 24 h to just greater than the background levels (Fig. 
6c). A similar pattern was seen for the hypoxic cells, al­
though the peak was broader and the decline less steep. At 
the later times, around 25% of positive cells were still 
present (Fig. 6d) It appeared that the decrease was less 
rapid alter hypoxic irradiation, which could belter be visu­
alized by comparing normoxic and hypoxic curves at equal 
survival levels. Therefore, we added the dashed curves 
(open squares) in Fig 6a,c, representing the curves for 6.3 
Gy hypoxic irradiation (reproduced from Fig 6b,d). The 
closed squares for normoxic irradiation represent an approx­
imate equally effective dose (2.4 Gy, dose ratio 2 6). It is 
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Fig 3 Summary of oxygen enhancement ratios showing that all 
homologous recombination deficient lines (open symbols) have 
lower oxygen enhancement ratios than all wild-type or nonho­
mologous end-joining cells lines (closed symbols) CHO-9 (black 
circles). V79 (black upward triangles). AA8 (black downward 
mangles). V79B (black squares), V-C8 (while circles). IrslSF 
(white upward triangles). Irsi (white downward mangles), CL-
V4B (white squares), and XR-CI (white diamonds) 
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Fig 4 Radiosensilivity of CL-V4B (CL) and us counterpart com­
plemented wiih RadSIC (CL-C) compared with wild-type V79B 
cells (WT) Closed symbols, normoxic (ox), open symbols, hy­
poxic (hyp) Complemented cell line had same radiosensilivity as 
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Fig 5 Radiosensilivity and oxygen enhancement ratio of human fibroblasts (a) Cell survival under normoxic (closed 
symbols) or hypoxic (open symbols) irradiation Circles indicate normal human hbroblasts triangles Fanconi anemia 
hbroblasts (b) Oxygen enhancement ratios denved at different survival levels for normal (closed) and Fanconi anemia 
complementation group C and G (open) hbroblasts (See Table I for number of strains and repeats ) Fanconi anemia 
cells had lower oxygen enhancement ratios than nonsyndrome hbroblasts 
then apparent that the foci disappearance is less rapid, at 
equal kill levels, after hypoxic irradiation 
A linear increase was found with dose for numbers of foci 
per cell (Fig 7a-c), with progressively shallower slopes for 
the dose-response curves with increasing times For the 
percentage of positive cells (Fig 7d-f) the dose depen 
dence was not linear, with a sharp increase at lower doses 
and flattening at higher doses For foci numbers (Fig 7a-c), 
the OER, as assessed from the ratio of slopes, decreased 
with time (OER 2 69, 1 62, and 0 90 tor 1, 6, and 24 h, 
respectively) The normoxic and hypoxic slopes were sig 
mhcantly different from each other at 1 and 6 h although at 
24 h, they were not indicating that at this late time, the OER 
was not significantly different from 1 0 (p = 0 2 t lest) 
Because HR is cell cycle dependent, we examined bro-
modeoxyuridme incorporation after hypoxic and normoxic 
irradiations to exclude possible differences caused by these 
treatments No differences were found in labeling index 
after the different irradiation treatments The labeling index 
dropped from 55% initially to 35% 24 h after irradiation, 
and the nomrradiated, but hypoxia-trealed control cells 
showed a decrease from 55% to 45% during the same 
penod The lack of effect of either irradiation or hypoxia 
under these conditions excluded cycle distribution changes 
as an explanation for any differences seen in Rad5l foci 
between the normoxic and hypoxic conditions 
DISCUSSION 
The data presented show strong evidence that a defi­
ciency m HR leads to a reduction in the OER The greatest 
contribution to this OER reduction was a larger relative 
increase in the sensitivity of the mutant lines under hypoxia 
than under normoxia Similar effects on the OER were 
previously found in some hamster lines with mutations in 
genes involved in excision repair, particularly XPF and 
ERCC1 (18,21,22) These lines were also more sensitive to 
cross-linking agents The XPF and ERCC1 genes, as well 
Table 1 Summary of oxygen enhancement ratios for wild type and mutant hamster 





















2 7 ± 0 3 
27 ± 0 3 
3 0 ± 0 1 
2 6 ± 0 6 
2 0 ± 01 
I 9 ± 0 2 
1 5 ± 0 3 
1 7 ± 0 2 




















2 0 ± 0 1 
2 1 + 0 5 
2 4 ± 0 1 
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AbbreMulìtm\ OER — oxygen enhancement ratio HR = homologous recombination NHEJ 
non homologous end joining ICLR = mtcrstrand cross link repair 
Errors = standard deviation 
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Fig 6 Time course of RADi l foci formation after normoxic (a e) and hypoxic (b d) irradiation in Chinese hamster AA8 
i-ells (a b) Number of foci per cell (e d) Percentage of cells with foci Each curve represents mean of three experiments 
errors are standard deviation (a c) Open squares and dashed line represent hypoxic curves for 6 ^ Gy reproduced from 
data in b and d tor comparison this dose produced equal survival to normoxic 2 37 Gy (black squares/solid line) 
as the HR genes, have been reported to be important in 
the repair of DNA cross-links (23-2'ϊ) The two sets of 
data, therefore, point toward the repair of cross-links as 
an important factor in determining hypoxic radioresis­
tance 
One possible explanation for the presented data would be 
that DNA interStrand cross-links are induced at greater 
numbers after hypoxic irradiation than after normoxic irra­
diation Under normal circumstances, hypoxic cells would 
be capable of efficiently removing these cross-links and the 
mutants would not A deficiency in this repair process 
would lead to increased sensitivity of hypoxic cells, because 
cross-links are highly likely to be lethal it lett unrepaired 
Whether the yields of interstrand cross-links are indeed 
greater after hypoxic irradiation is not known tor certain 
However, cyclopunne lesions, involving a covalenl bond 
between DNA base and sugar (effectively a cross-link), arc 
formed in greater numbers under hypoxia, because oxygen 
can react with radical intermediates, fixing damage and 
preventing cross-link formation (34) In a similar way, it is 
likely that radiation-induced DNA-mterstrand cross-links 
(between nucleotides rather than within a nucleotide) are 
also formed by the same mechanism, and thus will occur at 
greater numbers under hypoxic conditions (T Lindahl, per­
sonal communication, 2005) Direct evidence in cells is 
lacking although irradiation of DNA produces more cross­
links under vacuum than under oxygen (20 35) indicating 
that the hypothesis is feasible 
A lower OER was also found in the human FA fibro 
blasts All FA-deficient lines (human or rodent) are sensitive 
to cross-linking agents which is in fact, used as a diag­
nostic criterion of FA The demonstration in our study of 
a lower OER for FA strains is therefore consistent with a 
cross-link repair defect affecting hypoxic radiosensitiv-
ity FA was originally thought to result from a detect in 
HR, although more recent data have suggested that FA 
proteins function more generally to stabilize replication 
forks, which encounter nicks gaps or replication block 
ing lesions (36, 37) Its effect on HR events is therefore 
restricted to those occurring as a result of replication fork 
stalling This can affect the repair of cross-links and will 
take time to occur, because it depends on a replication 
fork encountering a lesion Cross-link repair after drugs 
such as cisplatin and melphalan is known to take at least 
24 h, even in fast-growing hamster cells (28) It is likely 
that repair of radiation-induced cross-links will also oc 
cur with similar slow kinetics In addition to FA, we 
would predict that BRCA2 dehcient human cells would 
also have a lower OER, such as we found for hamster 
cells, because such human cells are sensitive to cross­
links (38) and the BRCA2 protein is directly involved in 
the mechanics of HR 
RAD5I foci in wild-type cells declined more slowly 
after hypoxic than after normoxic irradiation This was 
reflected in the OER, which was similar to that for 
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Fig 7 Dose-response curves for production of RAD51 loci alter normoxic (open symbols) or hypoxic (closed symbols) 
irradiation in AA8 cells (a-c) Foci per cell (d-f) Percentage of cells with foci Errors ± standard deviation average 
of 66 cells counted per point Oxygen enhancement ratio for foci formation decreased with time approaching ^ I 0 at 
24 h 
around I 0 al 24 h The slower decline and lower OER 
indicates that HR played a relatively more important role 
after hypoxic irradiation, parlitularly al later limes The 
time dependence is consistent with the hypothesis stated 
above that HR triggered by stalled replication forks is 
involved in repair of cross-links At early times RAD51 
will associate with radiation-induced double-strand 
breaks, but at later times, RAD51 will associale with 
cross-link-stalled replication forks, which we postulate 
are more prevalent after hypoxic irradiation Double-
strand breaks are also formed during repair of cross-links, 
leading lo phosphorylation of histone H2AX at the break 
site (2Ì) which can be detected as γΗ2ΑΧ foci We 
found broadly similar patterns of formation and disap 
pearance of γΗ2ΑΧ foci (data not shown) as for RAD51 
foci, again consistent with our hypothesis 
We initially thought that DNA-protem cross-links were 
the critical lesions, because they are known to form at 
greater yields after hypoxic than after normoxic irradia 
(ion (18), to such an extent that it has been proposed as 
a method to measure hypoxic fractions in tumors (39) 
Less is known about repair of DNA-protein cross links 
It is likely that excision events are necessary, involving 
NER proteins (18, 40-42) and/or proteolytic removal of 
the protein (41) Whether HR is involved is not clear If 
so this would also provide an explanation lor the present 
results although direct evidence is lacking Most such 
DNA-protein cross link studies were performed at high 
doses and with relatively insensitive assays, and more 
recent studies in the dose range used in our study have 
shown little difference in total cross-link yields under 
normoxic and hypoxic irradiation conditions (41) This 
suggests that inlerstrand, rather than DNA-protein, 
cross-links may be the more important lesion 
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Role of DNA repair in hypoxic radioresistcmce 
Most of the HR mutants were also more radiosensitive 
under normoxic conditions. The increased sensitivity after 
normoxic irradiation is probably a consequence of less-
efficient double-strand break repair Such repair can occur 
by nonhomologous end-joining in all phases of the cell 
cycle, and by HR, but restricted to the S and Gj phases 
Because the hamster cells used here have a high proportion 
of cells in the S phase (55-60%), increased sensitivity 
would be expected by knocking out this repair pathway. In 
contrast, the S-phase fraction in our human fibroblast strains 
was considerably lower (16.5% ± 8 9%; error is standard 
deviation, η = 10), and so an effect on the radiosensitivity 
of reducing HR would not be expected, because it would 
only affect a minor fraction of total cells, and the unaffected 
resistant fraction would dominate the response of the pop­
ulation as a whole 
The method used in our study to produce hypoxia did not 
enable accurate monitoring of the oxygen concentration How­
ever, the high OERs for the wild-type hamster lines were 
consistent with an oxygen concentration of <0.1%. Others 
have reported somewhat greater OERs for hamster cell lines 
(22, 44, 45), usually using gassing and vacuum techniques to 
produce a given oxygen concentration It may therefore be that 
the method we used is less efficient at producing concentra­
tions in the extreme hypoxia range. However, most of our 
experiments were done with wild-type and mutants in the same 
chamber, so the relative differences are valid. 
The OERs tor the human fibroblast lines were lower than 
for the hamster cells, as has been reported by others (46, 
47). In initial experiments using a "forward" colony assay 
(plating first and irradiating shortly afterward), we found 
quite low OERs, which appeared to be greater the longer the 
interval between plating and irradiation. Although we did 
not pursue this in depth, it is consistent with a lack of 
proliferation at early times after plating, resulting in less 
S-phase cells and thus less HR. This, in tum, is consistent 
with HR being important for hypoxic radioresistance, al­
though changes in glutathione after trypsinization and plat­
ing could also have contributed This stimulated us to irra­
diate the human fibroblasts in mid-log phase, at which 
OERs >2 0 were obtained. 
The two FA strains tested also had a lower OER than the 
three nonsyndrome fibroblast strains. Because they were 
unrelated strains, the question anses whether the difference 
could have occurred by chance. However, first, the nor­
moxic radiation sensitivity of the three wild-type human 
fibroblast strains (dose to give 10% survival was 3.2 Gy) 
was identical to the average for a series of 79 human 
fibroblast strains from patients studied in our laboratory 
(48) Second, the coefficient of variation for dose to give 
10% survival in that study was 20% These data indicate 
that variations between individuals are only modest and that 
radiation sensitivity can be consistently measured, at least 
within one laboratory The considerable differences found 
between the FA and wild-type strains is therefore highly 
likely to be real. We found that the two FA cell lines were 
not significantly more sensitive to normoxic irradiation than 
our wild-type strains. Kalb and colleagues (49) have re­
ported similar findings, although they cultured their cells 
under 3% oxygen, which they termed "hypoxic " This level 
of hypoxia, however, would make little difference to intrin­
sic radiosensitivity, and so their data are essentially consis­
tent with ours. 
Bindra and colleagues (50) found that hypoxia downregu-
lated RAD51 in a series of human tumor lines They also 
showed that this was accompanied by less HR after hypoxic 
incubation, using a plasmid assay. However, these results 
are not in conflict with the presented data, because their 
hypoxia was 0 01% oxygen for 48 h, and they found little 
effects on RAD51 expression after 24 h Our hypoxia was 
for a maximum of 3 hours, considerably shorter and possi­
bly less extreme, where little effects on RAD51 and HR 
would be expected. 
CONCLUSION 
Homologous recombination plays a greater role in deter­
mining hypoxic radiosensitivity than normoxic radiosensi­
tivity. This is not the case for nonhomologous end-joining. 
The effect is probably mediated by repair of interstrand 
cross-links, although direct evidence of increased cross-link 
yields under hypoxia in mammalian cells is lacking. Effects 
of HR on DNA-protein cross-links, for which good evi­
dence of increased yields under hypoxia exists, remains a 
possibility. These data imply that targeting HR to increase 
radiosensitivity would provide partial tumor selectivity, be­
cause of proliferation and hypoxia dependencies. 
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Summary and discussion 
SUMMARY 
Hypoxia is a common feature in malignant tumors caused by either diffusion or 
perfusion limitations, further exacerbated by an increased consumption rate in 
proliferating cells. Pretreatment measurements of hypoxia in patients with different 
primary tumor sites have shown that the presence of a large amount of hypoxia is a 
negative predictor for outcome. For head and neck carcinomas, these studies were done in 
patients treated with either radiotherapy or surgery. It is a well known phenomenon that 
hypoxia renders tumor cells more resistant to radiotherapy and chemotherapy. Hypoxia is 
also associated with an increased risk of developing distant metastasis and this is thought 
to be a result of the selection of more malignant tumor cells arising under hypoxic stress. 
Easily applicable and reproducible methods to measure the fraction of tumor hypoxia are 
necessary to evaluate the role of hypoxia in tumor progression and treatment response in 
large clinical trials. Ideally these parameters should be designed in a way that they can be 
easily introduced into daily clinical practice. 
In the first part of this thesis we focused on the development of non-invasive 
methods to measure tumor hypoxia and to distinguish between acute and chronic hypoxia. 
We developed four different hypoxia-related parameters based on immunohistochemistry 
and image analysis (chapter 3) and studied these parameters in a group of patients with a 
primary head and neck tumor treated by surgery with or without postoperative 
radiotherapy. 
The first parameter was based on the use of an exogenous marker pimonidazole, 
which becomes reduced upon low cellular oxygen levels and subsequently binds to 
cellular proteins in hypoxic cells only. After intravenous injection of pimonidazole, 
reduced products can be visualized immunohistochemically by the use of an antibody 
against the reduced, bound products. In our study, patients were injected with 
pimonidazole the evening before operation and staining was performed on resection 
specimens. We developed an image analysis system to measure the fraction of tumor 
positive for pimonidazole. Staining patterns of pimonidazole showed increased staining at 
a distance of blood vessels and around areas of necrosis, as expected with the detection of 
mainly chronic hypoxia. Our data, and also those of other preclinical and clinical studies, 
support the use of pimonidazole as a hypoxic marker. We therefore used pimonidazole to 
evaluate other possible hypoxic parameters that might not necessitate the administration 
of a drug. 
We therefore subsequently developed a vascular parameter called the diffusion 
limited fraction that measures the fraction of tumor area at a certain distance from blood 
vessels. This provides by definition a measure of chronic hypoxia. When making a 
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comparison with pimonidazole we found a significant correlation but only in half of the 
tumors studied Variations in perfusion/oxygenation between vessels cannot be taken into 
account by this method In addition, the image analysis is rather laborious and 
measurements are sensitive to possible staining artefacts of blood vessels 
Another attractive method to measure hypoxia without the necessity of drug 
administration is the use of endogenous markers (proteins) that are upregulated under 
hypoxic conditions One candidate protein is hypoxia-inducible factor-la (HIF-la), a 
transcription factor subumt which is stabilized in the nucleus under hypoxic conditions 
and regulates the activation of many hypoxia-responsive genes We analyzed HIF-la 
staining on consecutive tumor sections, allowing a direct comparison with pimonidazole 
We found no correlation with the fraction of tumor stained for pimonidazole, 
colocahzation was sparse, and expression profiles often revealed a homogeneous pattern 
of HIF-la as a function of distance from blood vessels In some tumors, no expression of 
HIF-la was found, while pimonidazole positive, and thus hypoxic cells, were present We 
thus concluded that HIF-la is not useful as a chronic hypoxia marker Discrepancies 
could be explained by the fact that other conditions and pathways can also regulate HIF-
la expression Frequently found genetic alterations in malignant tumors can influence 
HIF-la expression, e g VHL status and PTEN mutations Despite the fact that HIF-la 
expression does not seem to correlate with chronic hypoxia, HIF-la expression has been 
shown to correlate with outcome in two different studies on head and neck cancer and 
could thus potentially be used as a predictive marker The reason is not known at this 
time, although it appears, based on the present studies, to be independent of hypoxia 
The last parameter that we developed arose from an attempt to measure 
microperfusion in human tumors since we hypothesized that perfusion variations in a 
tumor can provide an indirect assessment of acute hypoxia We realize that there will not 
be a perfect correlation However, even if it is not a very accurate measurement of acute 
hypoxia, the role of perfusion variations in determining treatment outcome can have 
important implications for the use of some specific treatments to overcome perfusion 
deficits There are so far no human data on measurements of perfusion variations at a 
microregional level The only studies performed in humans on tumor perfusion have used 
NMR imaging This technique however allows only measurements on perfusion of the 
whole tumor and is less capable of detecting small or local perfusion variations The 
method we describe here makes use of a thymidine analogue (IdUrd) that is injected as a 
bolus the evening before operation We hypothesized that the labeling of tumor cells in 
the vicinity of a blood vessel is dependent on the perfusion ofthat particular blood vessel 
at the time of injection We checked for the presence of proliferating cells by the 
proliferation marker Ki67 Considerable variations were found in the fraction of IdUrd-
104 
Sammarv and discussion 
negative vessels between different head and neck tumors In contrast, almost all blood 
vessels were surrounded by Ki-67-positive tumor cells, showing that a lack of IdUrd is 
unlikely to be due to a lack of proliferating cells, but rather due to temporary perfusion 
fluctuations 
In chapter 5 of this thesis we further studied the use of thymidine analogs to 
measure perfusion This technique was validated in a series of human tumor xenografts in 
mice, allowing a comparison with the commonly used perfusion marker Hoechst 33342 
Perfusion measured by IdUrd/BrdUrd (i e fraction of vessels negative for the analog) 
correlated well with perfusion measured by Hoechst (fraction of vessels negative for 
Hoechst) This study further strengthens our hypothesis that IdUrd/BrdUrd can be used to 
distinguish between tumors with high or low fractions of perfused vessels 
In our studies with pimomdazole, in addition to the typical chronic hypoxia 
patterns of pimomdazole staining, we observed sharp staining around keratinized areas 
Since head and neck squamous cell carcinomas often contain strongly keratinized areas, 
we felt it was necessary to investigate whether this staining was hypoxia specific (chapter 
4) We incubated fresh frozen tumor sections with pimomdazole staining under oxic and 
hypoxic conditions and observed positive staining in keratinized areas in oxic conditions 
However, by scoring the intensity of this staining in keratinized areas, we found that it 
was always less under oxic conditions compared with hypoxic conditions High reductase 
levels or the presence of 2-electron reductases could in theory bypass the oxygen 
dependant reduction of nitro-imidazoles We therefore measured reductase levels by an 
NBT assay to investigate whether these higher reductase levels in keratinized areas could 
explain the observed oxic staining in those areas However, reductase levels were not 
always increased in keratinized areas and are thus less likely to be the cause of this 
pimomdazole staining in keratinized areas Since oxic staining was always less intense 
than hypoxic staining we believe we can address this problem by choosing an appropriate 
intensity threshold, which ideally excludes light oxic staining seen in some differentiated 
areas 
The clinical value of the immunohistochemical parameters (proportion of tumor 
cells positive for pimomdazole staining, HIF-la staining and the fraction of IdUrd-
negative blood vessels) is now being tested in a large group of patients with a head and 
neck squamous cell carcinoma primarily treated by surgery with or without postoperative 
radiotherapy Correlations with outcome are not yet presented since follow-up time was 
not long enough at the time of writing By using pimomdazole as a marker of mainly 
chronic hypoxia and IdUrd as an assessment of microperfusion variations, we hope that 
our study will shed some light on the differential importance of acute versus chronic 
hypoxia If significant correlations with outcome are observed, these parameters should 
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ideally be further tested in a randomised trial evaluating the effect of adding a hypoxia-
modulating therapy 
A disadvantage of the immunohistochemical approach is the relatively small 
fraction of tumor area assessed In addition, biopsy or resection material is always 
required, making repeated measurements during treatment more difficult The use of 
radiolabeled bioreductive markers and subsequently scanning by PET or SPECT could 
bypass these problems We performed a pilot study in ten of our patients with head and 
neck tumors where we compared uptake of Tc-99m BRU 59-21, a radioactively labeled 2-
nitro-imidazole, on SPECT scans with pimonidazole staining on sections from the surgical 
specimen A significant correlation between Tc-99m BRU 59-21 uptake and the fraction 
ot tumor positive for pimonidazole staining was found, indicating the feasibility of such 
external scanning methods for tumor hypoxia (chapter 6) 
In the second part of this thesis (chapter 7) we studied more fundamental aspects of 
hypoxic radioresistance, since this knowledge is necessary to create new hypoxia 
modulating strategies In particular, we studied the role of DNA repair enzymes in 
determining hypoxic radioresistance As outlined in the introduction, different types of 
DNA damages are formed under hypoxic verus oxic conditions, implying that different 
repair pathways might play a role in determining repair and survival In the absence of 
oxygen, more DNA-crosslmks are formed Previous studies had shown a correlation 
between hypoxic radioresistance and the sensitivity of the cells to cross-linking agents in a 
series of hamster mutant cell lines deficient in some NER proteins known to play a role in 
crosslink repair Recent data also show that homologous recombination (HR) also plays 
an important role in the repair of DNA interStrand crosslinks We therefore studied 
different hamster cell lines deficient in HR and found a decrease in oxygen enhancement 
ratio (OER) compared to wild-type cells In contrast, the OER for NHEJ deficient cell line 
(DNA-PKcs deficient) was comparable to wild type controls These data show that 
enzymes involved in homologous recombination play a role in hypoxic radiosensitivity 
A lower OER was also found in human Fanconi Anemia (FA) fibroblasts All FA-
deficient lines (human and rodent) are sensitive to cross-linking agents The lower OER 
found in our study is thus consistent with a cross-link repair defect affecting hypoxic 
radiosensitivity In addition these data indicate that cross-links and their repair are 
important in determining radiosensitivity not only in rodents, but also in humans 
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DISCUSSION 
The study of hypoxia remains an interesting and challenging subject in cancer 
research, since many questions remain about the role and the type of hypoxia in 
determining tumor progression and response to therapy Methods to measure hypoxia are 
absolutely necessary to obtain answers to all these questions and to select patients who 
will benefit from hypoxia modulating therapies In addition, research into hypoxia-
modulating or targeting treatments should remain an important focus of attention 
Methods to measure tumor hypoxia are not only useful for clinical applications, but also 
for basic research purposes 
Most methods to measure hypoxia have advantages, disadvantages and possible 
artefacts By using an immunohistochemical approach we are able to study the relative 
proportion of viable hypoxic tumor cells in relation to blood vessel structures, micro-
environment, perfusion variations, endogenous markers and other prognostic factors like, 
for example, EGFR Pimomdazole staining proved to be a good chronic hypoxia marker, 
although light staining around keratinized areas should be considered as an artefact 
Endogenous markers are very promising and have the advantage that no drug needs to be 
administered and thus retrospective analysis can be performed We found that HIF-a was 
not a good marker for chronic hypoxia, although it still shows promise as marker for 
tumor invasiveness and bad outcome No suitable endogenous hypoxia marker has been 
found so far, mostly since signalling pathways are often controlled by multiple proteins 
and tumor conditions This does not exclude that in the future a combination of 
endogenous markers could identify highly hypoxic tumors and might predict treatment 
outcome More recent and more powerful techniques with micro-arrays and/or proteomics 
are showing promise in finding hypoxic signatures that can identify hypoxic tumors and 
predict outcome after different types of treatment 
Our human and mice studies show that IdUrd can be used to distinguish tumors 
with low and high perfusion The simultaneous use of pimomdazole and IdUrd by 
immonuhistochemical techniques should enable further differentiation between perfusion 
and diffusion limited hypoxia (acute versus chronic) 
The advantage of using non-invasive imaging of tumor hypoxia by SPECT or PET 
scanning is that no biopsy material is required and repeated measurements can be 
performed during treatment, allowing early response evaluation and possible treatment 
modification They also allow visualization of the whole tumor, in contrast to 
immunohistochemical measurements on small tumor biopsies A disadvantage of this 
technique is the cost and availability of appropriate scanning material Moreover, 
microregional information is further lacking, since resolution is less optimal We showed 
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here the feasibility of the use of SPECT scanning as a non-invasive method to study tumor 
hypoxia In a small pilot study we found a correlation with immunohistochemical 
measurements of hypoxia by pimomdazole in the same patients 
Thus, we can state that different methods to measure tumor hypoxia and perfusion 
are not only available, but expanding Based on this and other studies, to get a complete 
picture we should combine different measurements Alternatively, one could choose a 
specific method depending on the question of interest, instead of looking for a single ideal 
way to measure all forms of hypoxia For example, when information on hypoxia is 
required to shape radiation fields with higher doses to the hypoxic regions, whole tumor 
imaging by nuclear scanning methods may be the best choice Immunohistochemical 
methods would be of interest when micro-regional information (e g relation to blood 
vessels or presence of viable proliferating tumor cells) is necessary for answering 
biological questions Such immunohistochemical methods are easy to incorporate into 
routine clinical practice since they are already used in the diagnostic work-up 
In addition, besides research to measure hypoxia, research into hypoxia-
modulating or targeting treatments should remain an important focus of attention We 
therefore studied in our last chapter the potential mechanism of hypoxic radioresistance 
with the aim of finding potential targets to radiosensitize hypoxic tumors Normal hypoxic 
tumor cells need a threefold higher irradiation dose to obtain cell kill In practice, such 
high doses are impossible to deliver due to dose constraints to normal tissues A decrease 
of OER from three to two fold would already be clinically significant We show here in 
our study that DNA repair pathways involved in crosslink repair, such as HR and parts of 
NER, can determine hypoxic radiosensitivity and are thus potential subjects for hypoxia 
targeting strategies 
CONCLUSION 
We developed and validated different methods to measure tumor hypoxia and perfusion in 
both animal models and in cancer patients Most parameters are now being applied on a 
large group of head and neck cancer patients treated primarily with surgery with or 
without postoperative radiotherapy Correlations with outcome (expected within one year 
to allow sufficient follow-up) are expected to give valuable information on the differential 
importance of diffusion versus perfusion limited hypoxia Finally, the roles of repair 
proteins (HR and NER pathways) in determining hypoxic radiosensitivity are of interest 




Zuurstofgebrek in maligne tumoren van het hoofd-halsgebied; metingen en belang 
Alle cellen in ons lichaam hebben zuurstof nodig om te kunnen overleven 
Tumoren bestaan uit delende cellen die extra energie en zuurstof nodig hebben om verder 
te kunnen groeien Zuurstofgebrek of hypoxic is een belangrijk kenmerk van verschillende 
typen kwaadaardige tumoren, die enerzijds veroorzaakt wordt door de groei van de tumor, 
waarbij de cellen langzaam verder van een bloedvat verwijderd worden en dus gradueel 
minder zuurstof krijgen door beperking in de diffusie van zuurstof Dit wordt chronische 
hypoxie genoemd Anderzijds zijn tumoren ook gevoelig voor variaties in de doorbloeding 
van de bloedvaten waardoor tumorcellen plotseling van zuurstof verstoken kunnen 
blijven Onder dergelijke omstandigheden wordt van acute hypoxic gesproken Studies 
van patiënten bij wie de zuurstofspanning in tumoren werd gemeten voorafgaande aan de 
behandeling toonden aan dat de aanwezigheid van hypoxic een negatieve invloed heeft op 
de overleving van patiënten Dit werd zowel voor chirurgisch behandelde als voor enkel 
met radiotherapie behandelde hoofd-halstumorpatienten aangetoond In vitro studies tonen 
aan dat hypoxische cellen tot 3 maal resistenter zijn tegen radiotherapie Bovendien bleek 
hypoxic ook geassocieerd aan een verhoogd risico op de ontwikkeling van metastasen Dit 
wordt verklaard door het feit dat onder hypoxische omstandigheden enkel de meest 
geadapteerde en vaak meest kwaadaardige cellen kunnen overleven Om de rol van 
hypoxic bij de behandeling van maligniteiten goed te kunnen evalueren, zijn eenvoudige 
en reproduceerbare methodes nodig die makkelijk toepasbaar zijn in de dagelijkse 
klinische praktijk 
Dit proefschrift beschrijft in de eerste plaats de ontwikkeling van met-invasieve 
technieken om zuurstofgebrek te meten in kwaadaardige tumoren Het onderscheid tussen 
acute en chronische hypoxic is hiervoor belangrijk Er werden vier hypoxie-gerelateerde 
parameters ontwikkeld op basis van immunohistochemische kleuringen in combinatie met 
gecomputeriseerde beeld analyse technieken in een groep patiënten met een primair 
chirurgisch behandeld plaveiselcelcarcinoom in het hoofd en halsgebied al dan met 
gevolgd door postoperatieve radiotherapie (chapter 3) 
De eerste parameter is gebaseerd op het gebruik van een bioreductieve stof, 
Pimonidazole die 12 uur preoperatief intraveneus wordt toegediend Pimonidazole heeft 
als eigenschap dat het gereduceerd wordt bij lage zuurstofconcentraties en in deze 
gereduceerde vorm covalente en irreversibele bindingen aangaat met eiwitten in de cel 
Door gebruik te maken van een antilichaam tegen het gereduceerde product kunnen 
hypoxische cellen immunohistochemisch in het operatiepreparaat geïdentificeerd worden 
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Met het gecomputeriseerde beeld analyse systeem werd eerst de tumor afgelijnd en 
vervolgens een intensiteits drempel gelegd om de proportie tumor weefsel positief voor 
pimonidazole exact te meten Pimonidazole kleuring werd voornamelijk gezien op een 
zekere afstand van de bloedvaten en rond gebieden met necrose, hetgeen verenigbaar is 
met de aanwezigheid van chronische hypoxw Deze bevindingen ondersteunden evenals 
andere preklinische en klinische studies het gebruik van pimonidazole als chronische 
hypoxic marker 
We ontwikkelden eveneens een parameter enkel gebaseerd op immunohistochemische 
kleuring van bloedvaten, waardoor het gebruik van een extrinsieke marker dus met nodig 
is De diffusie gelimiteerde fractie (DLF, Diffusion limited fraction) werd gedefinieerd als 
de proportie tumor die meer dan 120 μηι verwijderd is van elk nabij gelegen bloedvat We 
veronderstellen hierbij dat de diffusie afstand van zuurstof uit een bloedvat ongeveer 120 
μιτι bedraagt In de 14 bestudeerde tumoren vonden we geen correlatie met de fractie 
pimonidazole Een nadeel van deze methode is het feit dat er geen rekening wordt 
gehouden met variaties in perfusie en oxygenatie van de bloedvaten Bovendien bleek uit 
onze piloot studie dat de analyse tijdrovend is en gevoelig voor eventuele artefacten in de 
bloedvat kleuring 
Een andere mogelijkheid om de toediening van een extrinsieke marker te vermijden is 
gebruik te maken van een endogeen eiwit dat enkel tot expressie komt onder hypoxische 
omstandigheden Een voorbeeld van een dergelijk eiwit is Hypoxia-inducible factor-Ια 
(HIF-Ια) HIF-la is een transcriptiefactor die gestabiliseerd wordt in de celkern bij lage 
zuurstofconcentraties en die de activiteit van vele hypoxie-gevoelige eiwitten regelt Met 
een anti lichaam tegen HIF-la hebben we de expressie van HIF-la vergeleken met de 
pimonidazole kleuring in achtereenvolgende weefselcoupes Dit leverde geen correlatie op 
tussen HIF-la en pimonidazole expressie Na matchen van de coupes was er slechts een 
beperkte overlap van beide markers Bovendien was het expressie profiel van HIF-la in 
relatie tot de bloedvaten homogener Omdat in een aantal tumoren (2/10) geen HIF-la 
expressie werd gevonden, terwijl er wel pimonidazole aankleuring (en dus hypoxic) in 
deze tumoren aanwezig was, kon HIF-la niet langer als een betrouwbare hypoxiemarker 
voor chronische hypoxic worden gehanteerd Waarschijnlijk wordt dit verklaard door het 
feit dat andere omstandigheden en pathways de expressie van HIF-la regelen Zo kunnen 
bijvoorbeeld spontane genetische veranderingen, zoals vb VHL status en PTEN mutaties, 
die regelmatig voorkomen in maligne tumoren, de expressie van HIF-la reguleren 
De laatste hypoxic gerelateerde parameter werd ontwikkeld met de bedoeling variaties in 
de doorbloeding (= perfusie) van tumoren te meten Onze hypothese is immers dat 
variaties in de perfusie een belangrijke oorzaak zijn van acuut zuurstofgebrek in tumoren 
Hoewel dit wellicht geen exacte meting is van de hoeveelheid acute hypoxic kan een 
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betrouwbare meting van de perfusie wel een indirecte meting van acute hypoxic zijn en 
daardoor belangrijke therapeutische implicaties hebben De methode die we hier 
beschrijven maakt gebruik van een extrinsieke proliferatie marker, nl een thymidine 
analoog (IdUrd) die eveneens 12 uur preoperatief werd ingespoten als een bolusmjectie 
Bloedvaten die op het moment van inspuiting geopend zijn kunnen de tumor cellen in hun 
omgeving voorzien van IdUrd Bloedvaten werden vervolgens gescoord aan de hand van 
tumor cellen positief voor IdUrd We veronderstellen dat de labeling van tumorcellen in 
de nabijheid van een bloedvat afhankelijk is van de perfusie van het desbetreffende 
bloedvat op het moment van injectie De aanwezigheid van prolifererende cellen, 
noodzakelijk voor de incorporatie van IdUrd, werd gecontroleerd door een gelijktijdige 
kleuring voor de proliferatie marker Ki67 We vonden belangrijke variaties in de fractie 
IdUrd negatieve bloedvaten in de bestudeerde hoofd en hals maligmteiten Bijna alle 
bloedvaten waren daarentegen omringd door Ki-67 positieve cellen, aangevende dat de 
afwezigheid van IdUrd wellicht geen gevolg is van de afwezigheid van prohferende 
cellen, maar eerder van tijdelijke variaties in perfusie 
In hoofdstuk 5 van dit proefschrift bestudeerden we verder het gebruik van 
thymidine analogen om perfusie variaties te meten De techniek werd gevalideerd in een 
reeks van humane xenograften in naakte muizen door vergelijking met de perfusiemarker 
Hoechst 33342 Perfusie gemeten met behulp van IdUrd/BrdU correleerde goed met 
perfusie gemeten door middel van Hoechst 33342 Deze data bevestigen onze hypothese 
dat IdUrd gebruikt kan worden om een onderscheid te maken tussen tumoren met een 
hoge of lage fractie geperfundeerde bloedvaten 
In onze studies met pimomdazole observeerden we vaak aankleunng rond 
verhoomde gebieden In hoofdstuk 4 hebben we verder onderzocht of deze aankleunng 
mogelijks een artefact is dan wel tengevolge van hypoxic Vnescoupes van verhoomde 
tumoren werden geincubeerd met pimomdazole zowel onder hypoxische condities als in 
aanwezigheid van zuurstof Deze experimenten toonden beperkte aankleunng van de 
verhoomde gebieden in aanwezigheid van zuurstof, maar deze aankleunng was veel 
minder intens dan in de afwezigheid van zuurstof Scherpe en intense aankleunng rond 
verhoomde gebieden lijkt dus hypoxic specifiek Door het kiezen van de juiste intensiteits 
drempel is het mogelijk onderscheid te maken tussen hypoxie-gerelateerde kleuring en 
lichte atypische pimomdazole kleuring in verhoomde gebieden 
De klinische waarde van de verschillende immunohistochemische parameters 
wordt momenteel getest in een groep van 150 patiënten met een primair chirurgisch 
behandeld plaveiselcelcarcinoom van het hoofd-halsgebied al dan met gevolgd door 
postoperatieve radiotherapie Correlaties met het ziekteverloop werden tot op heden nog 
niet gepresenteerd vanwege de nog beperkte follow-up Door gelijktijdig gebruik te 
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maken van pimonidazole (als chronische hypoxiemarker) en IdUrd als perfusiemarker 
hopen we dat onze studie informatie zal verschaffen over het prognostisch belang van 
acute en chronische hypoxie Als significante correlaties met het ziekteverloop gevonden 
worden, kunnen deze parameters verder getest kunnen worden in een gerandomiseerde 
studie die het effect beoordeelt van een aanvullende hypoxie-modulerende behandeling 
Een nadeel van de immunohistochemische aanpak is de relatief kleine proportie 
van tumor die beoordeeld wordt Bovendien blijven biopsies of chirurgisch resectie 
materiaal noodzakelijk, zodat evaluaties tijdens of na de behandeling bemoeilijkt worden 
Het gebruik van gelabelde bioreductieve stoffen die vervolgens gedetecteerd kunnen 
worden met behulp van een PET of SPECT zou dit probleem gedeeltelijk kunnen 
oplossen In een piloot studie tien patiënten met een plaveiselcelcarcinoom in het hoofd 
halsgebied, werd de activiteit van Tc-99m BRU 59-21, (een radioactief 2-nitro-imidazole) 
gemeten met een SPECT scan, vergeleken met een immunohistochemische bepaling van 
hypoxic dmv pimonidazole We vonden een significante correlatie tussen Tc-99m BRU 
59-21 uptake en de fractie tumor positief voor pimonidazole Deze studie bewijst dat 
externe scanning methodes mogelijk kunnen worden toegepast voor het meten van 
hypoxic in vivo (hoofdstuk 6) Intussen zijn reeds vele andere gelabelde stoffen (18F-
misomdazole, Cu-ATSM, Tc-99m metronidazole, etc) geschikt bevonden voor het meten 
van hypoxic Onze studie is echter de enige die de vergelijking maakt met de 
immunohistochemische meting van hypoxic dmv een bioreductieve marker 
In het laatste deel van dit proefschrift (hoofdstuk 7) hebben we meer fundamenteel 
onderzoek gedaan naar de biochemische aspecten van radioresistentie onder hypoxische 
omstandigheden met de bedoeling therapeutische aanknopingspunten te vinden die 
hypoxische cellen radiogevoehger kunnen maken Bestraling geeft verschillende types 
van DNA schade afhankelijk van de aanwezigheid van zuurstof Dit impliceert dat ook 
verschillende DNA herstel pathways een rol spelen in herstel van DNA schade en dus 
mogelijk ook een rol spelen in de bestralingsgevoeligheid In de afwezigheid van zuurstof 
worden meer DNA interstrand crosslinks gevormd Gezien homologe recombinatie (HR) 
een rol speelt in het herstel van DNA interstrand crosslinks bestudeerden WIJ de rol van 
HR in het bepalen van de strahngsgevoeligheid onder hypoxic Hamstercellijnen deficient 
in HR blijken gevoeliger aan radiotherapie onder hypoxic dan hun wild type Ook humane 
Fanconi Anemia fibroblasten tonen een lagere Oxygen Enhancenment Ratio (OER) dan 
normale fibroblasten Deze gegevens tonen aan dat homologe recombinatie een 
belangrijke rol speelt in de gevoeligheid van een cel voor bestraling onder hypoxische 
omstandigheden Het ontrafelen van deze DNA herstel pathways tijdens hypoxic kan 
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uiteraard leiden tot mogelijke aanknopingspunten om tumor cellen die hypoxisch zijn 





Oef, het is af nu kan ik eindelijk alle mensen bedanken die me elk op hun eigen manier 
hebben geholpen bij het tot stand brengen van dit proefschrift 
Eerst en vooral een woordje aandacht voor mijn promotor Prof Dr Adrian Begg, onder 
wiens deskundige begeleiding ik vier jaar lang als OIO heb gewerkt op de afdeling 
experimentele therapie in het NKI 
Beste Adnan, zonder jou had ik hier nooit gestaan Ik ben je ontzettend dankbaar voor 
alles watje voor me gedaan hebt, ook in de afgelopen twee jaar toen ik ondergedompeld 
werd in het drukke klinische leven Je hebt me enthousiasme, vertrouwen en vrijheid 
gegeven om nieuwe dingen te proberen, je hebt me vele dingen geleerd die een bagage 
vormen voor de rest van mijn leven Ik ben nog steeds verbaasd hoe snel JIJ onze data 
telkens in grafieken en tabellen wist te zetten Dank voor de vele interessante discussies, 
werkvergaderingen en vooral voor je hulp bij het herschrijven en corrigeren van 
manuscripten Niet alleen op professioneel maar ook op sociaal vlak heb ik enorm genoten 
van onze samenwerking Bedankt voor je vriendschap en je gastvrijheid Hoop dat we 
contact blijven houden 
Ik wil ook mijn andere promotores, Prof dr Κ Haustermans en Prof dr A Balm 
bedanken voor het opstarten en verder begeleiden van ons hypoxie project 
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Pons Balm, ik ben jou en het hele KNO team van het NKI zeer erkentelijk voor het 
includeren van patiënten in onze studie Je bent echt een onmisbare spil in ons project 
Bedankt voor de fijne contacten, het vertrouwen en je inzet 
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Liefste Debbie, eerst en vooral bedankt voor het vele werk datje voor ons project verricht 
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(ik wist in het begin nauwelijks wat pipetteren was), heb je me dan ook vele labtechnieken 
bijgebracht Het was leuk werken met je op het lab Maar er was natuurlijk ook de 
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plezante tijd naast het labwerk. Bedankt voor je opvang, steun en vriendschap, ik hoop dat 
ze nog lang mag blijven duren. 
Hetzelfde geldt voor jou Ingrid, mijn andere paranimf, bedankt voor je goedheid, je 
bescherming in tijden van nood of kwaad (?), je babbel en steun. Jij had het hypoxic 
project opgestart en hebt ons prima ingewerkt. Alleen jammer datje niet dat jurkje 
gekocht hebt, want het stond je beeldig!! 
Frank Hoebers, met jou heb ik letterlijk mijn eerste stapjes in het lab gezet, weetje nog?? 
Bedankt voor je hulp bij de klinische studies en opzetten van de Ν BT-Assay. 
Gerard Blommestijn, onze beeldverwerking specialist. Ik heb je persoonlijke steun, advies 
en gezelschap zeer geapprecieerd. Ben benieuwd naar je volgende mega fuif?? 
Iris, de tijd datje bij ons als student gewerkt hebt, was echt een toffe periode. Je was erg 
gemotiveerd en hebt veel werk verricht, waarvoor mijn dank. 
Verder wil ik iedereen in het NKI, UZ Leuven, UCL en Nijmegen bedanken die 
meegeholpen heeft aan het includeren van patiënten en verzamelen van materiaal voor 
onze klinische studie. Loes van Velthuizen, bedankt dat we altijd bij je mochten 
aankloppen voor advies en laten snijden van coupes. 
Dank aan Bert Van der Kogel, Hans Kaanders, Jan Bussink, Anna Ljungkvist en Paul 
Rijken van de dienst experimentele radiotherapie in Nijmegen voor de fijne 
samenwerking en de vele interessante discussies. Anna en Paul, heel erg bedankt voor de 
vele muizen proeven, kleuringen en het scannen van beelden. 
Thea, een redder in nood voor iedereen en dus ook heel vaak voor mij. Bedankt, ook voor 
je vriendschap en de vele tussen-de-middag wandelingetjes. 
H6, bedankt voor de relaxte en leuke sfeer, de talrijke vrijdagavond borrels en andere 
uitjes. Een spelletje darten, voetballen of gewoon een biertje of een babbel, jullie maakten 
met zijn allen het werken op H6 heel aangenaam. 
Verder wil ik vrienden en familie bedanken voor de steun en vriendschap in de voorbije 
jaren. Robert, je was er altijd als ik je nodig had, ook al zat je mijlen ver. Je bent altijd in 
mijn doctoraat blijven geloven. Bedankt voor je dagelijkse mails, telefoontjes en gewoon 
de leuke tijd. Onze wegen zijn stilaan uiteen gelopen, maar onze harten kruisen nog 
steeds. Wens je het allerbeste!!! Hendrik, jij hebt ook een bijzonder plekje in mijn hart. 
Bedankt voor je tijdje bezorgdheid en sympathie. Isa, vond het heel leuk dat ik een 
jaartje bij jou mocht wonen; met dank ook aan je moeder die af en toe de ijskast kwam 
vullen. Mark, bedankt voor je morele steun, squashles en je labtop. Sari, we hebben 
mekaar te weinig gezien, maar als ik hulp nodig had, was je er wel en dat apprecieer ik 
enorm. Martijn, mooie en minder mooie momenten, ik onthou het liefst de eerste en ben je 
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